CME: Recent Episodes
ReachMD
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jonathon B. Cohen, MD, MS
As the therapeutic landscape for follicular lymphoma continues to evolve, CAR T-cell therapy is emerging as a transformative option for select patients with relapsed or high-risk disease. But it also comes with a lot of important considerations, like knowing when to refer and how to manage common adverse events. Joining Dr. Charles Turck to explore how CAR T fits into the broader treatment algorithm for follicular lymphoma is Dr. Jonathan Cohen. Not only is he a Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, but he's also the Co-Director of the Lymphoma Program at the Winship Cancer Institute of Emory University in Atlanta.
Faculty: Shikha Wadhwani, MD
Faculty: Dana Rizk, MD
For the second episode of the KDIGO IgA Nephropathy (IgAN) podcast series, Dr. Dana Rizk and Dr. Shikha Wadhwani discuss the IgAN treatment revolution. The conversation explores how a deeper understanding of the disease's pathophysiology has led to new therapeutic options, moving beyond traditional supportive care.
Key topics include:
- The shift in IgAN treatment since the KDIGO 2021 guidelines
- The four-hit hypothesis of IgAN, and how new therapies are being developed to target each step of the disease's pathogenesis
- Factors for clinicians to consider when choosing new treatments
- The evolving role of traditional therapies alongside newer agents
This episode was supported by Travere
Faculty: Marion Munk, MD, Ph.D
Faculty: David Boyer, MD
This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.
Faculty: David Boyer, MD
Faculty: Diana V. Do, MD
This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.
Faculty: Diana V. Do, MD
Faculty: David Boyer, MD
This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.
Faculty: Marion Munk, MD, Ph.D
Faculty: David Boyer, MD
This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.
Faculty: David Boyer, MD
Faculty: Marion Munk, MD, Ph.D
This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.
Faculty: Diana V. Do, MD
Faculty: Marion Munk, MD, Ph.D
This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.
Faculty: Marion Munk, MD, Ph.D
Faculty: Diana V. Do, MD
This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.
Host: Stephen Nicholls, FRACP, FACC, FESC, FAHA
This program is intended for health care professionals only.
Dr. Stephen Nicholls reveals new data on obicetrapib that are showing promise in reducing cardiovascular events.
Faculty: Douglas Adkins, MD
This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.
Host: Douglas Adkins, MD
This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.
Faculty: Douglas Adkins, MD
This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.
Faculty: Douglas Adkins, MD
Faculty: Ravindra Uppaluri, MD, PhD
Faculty: Nancy Lee, MD, FASTRO
This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.
Host: Robert Haddad, MD
Host: Ravindra Uppaluri, MD, PhD
Host: Nancy Lee, MD, FASTRO
Join our expert panel as they explore the evolving treatment landscape of resectable locally advanced head and neck squamous cell carcinoma. Learn how perioperative immune checkpoint inhibitors are improving event-free survival and get practical insights on applying this data to clinical care. The discussion highlights the importance of early multidisciplinary collaboration and offers perspectives on patient selection, treatment timing, and managing adverse events. Don’t miss this opportunity to enhance your approach to reducing recurrence and disease progression in your patients.
Faculty: Ravindra Uppaluri, MD, PhD
This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.
Faculty: Nancy Lee, MD, FASTRO
This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.
Faculty: Ravindra Uppaluri, MD, PhD
This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.
Faculty: Joshua Richter, MD
Faculty: Noopur Raje, MD
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
Faculty: Joshua Richter, MD
Faculty: Sagar Lonial, MD, FACP
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
Host: Brian P. McDonough, MD, FAAFP
Guest: Silvio Inzucchi, MD
Guest: Darren McGuire, MD, MHSc
Subcutaneously-administered GLP-1 RAs have demonstrated cardiovascular and renal risk reduction in individuals with type 2 diabetes at high ASCVD risk; they are recommended in the 2025 ADA Standards of Care as part of the comprehensive approach to cardiovascular and kidney risk reduction. Many individuals with type 2 diabetes are reluctant to initiate or refuse injectable therapy. Oral GLP-1 RA therapy has demonstrated robust reductions in A1C and in body weight; in addition, the cardiovascular safety of oral GLP-1 RA therapy has been established in individuals with T2D and high cardiovascular risk. Until recently, there has been an unmet need to determine the cardiovascular efficacy of this oral therapy in patients at high cardiovascular risk—for example, in those individuals with ASCVD, CKD, or both. Dr. Silvio Inzucchi and Dr. Darren McGuire will review trials with injectable GLP-1 RAs in individuals with T2D and high ASCVD risk, and discuss the recent clinical trial evidence in this population with oral GLP-1 RA therapy and the implications for patient management.
Faculty: Sagar Lonial, MD, FACP
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
Faculty: Noopur Raje, MD
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
Faculty: Joshua Richter, MD
Faculty: Noopur Raje, MD
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
Faculty: Joshua Richter, MD
Faculty: Sagar Lonial, MD, FACP
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
Faculty: Sagar Lonial, MD, FACP
Faculty: Noopur Raje, MD
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
Faculty: Sagar Lonial, MD, FACP
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
Host: Maria Fleseriu, MD, FACE
Acromegaly, a rare endocrine disorder caused by excessive growth hormone (GH) secretion, has a profound impact on affected individuals and healthcare systems. Patients often experience delays in diagnosis, averaging 4 to 6 years, which exacerbates disease progression and leads to irreversible comorbidities. Do you know how to effectively treat acromegaly to increase your patients’ quality of life? Tune in for an overview of the latest data.
Host: Shankara Paneesha, MD FRCP FRCPath
Listen to Dr. Shankara Paneesha and discover the evolving treatment landscape for relapsed CLL. Get insights on BTK resistance, new treatment options including cellular therapy, and the importance of patient-specific factors in treatment decisions.
Guest: Thomas Buttgereit
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
Host: Dr. Danny Cohn
Guest: Thomas Buttgereit
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
Host: Dr. Danny Cohn
Guest: Thomas Buttgereit
Guest: Anna Valerieva
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
Guest: Anna Valerieva
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
Host: Dr. Danny Cohn
Guest: Thomas Buttgereit
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
Guest: Thomas Buttgereit
Guest: Anna Valerieva
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
Guest: Anna Valerieva
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
Host: Dr. Danny Cohn
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
Host: Dr. Danny Cohn
Guest: Thomas Buttgereit
Guest: Anna Valerieva
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
Faculty: Kevin Alexander, MD
This brief clinical discussion examines findings presented at the ESC Heart Failure 2025 meeting in Belgrade, Serbia, on the impact of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM). The analysis highlights a reduction in atrial fibrillation events and an improvement in cardiovascular outcomes among patients treated with acoramidis, including those with both wild-type and variant transthyretin (TTR). Data from the ATTRibute-CM study are reviewed, showing associations between treatment and increased serum TTR levels, delayed time to first cardiovascular hospitalization, reduced NT-proBNP levels, and lower all-cause mortality. These results suggest a clinically meaningful benefit of acoramidis and support its potential role in managing ATTR-CM.
Host: Aristides Maniatis, MD
Guest: Kari Hosack
Guest: Meagan Broeckert
Guest: Sam Watson
Join Dr. Aristides Maniatis for this Patient-Clinician Connection, a case-based activity that explores the full spectrum of care in Growth Hormone Deficiency. Through real patient and caregiver dialogues, this program teaches clinicians how to identify early signs of GHD, make accurate diagnoses, navigate pediatric-to-adult care transitions, and manage the switch from daily to long-acting growth hormone therapy. Grounded in real-life experiences and expert insights, this activity delivers practical strategies for fostering patient-centered care and improving outcomes across every stage of the GHD journey
Host: Stephen Brunton, MD, FAAFP, CDCES
Guest: John Buse, MD, PhD
Guest: Jennifer Goldman, PharmD, CDCES, BC-ADM-FCCP
Guest: Eden Miller, DO, D-ACD, D-ABOM
The diagnosis of hypercortisolism is often delayed or missed, especially in primary care settings, leading to detrimental consequences for patients, such as unnecessary morbidity and mortality. Recent data suggest that the prevalence of hypercortisolism is far higher than previously estimated. Clinicians need to be aware of optimal approaches for identifying, diagnosing, and treating hypercortisolism. New data are emerging for hypercortisolism treatments that can improve outcomes in patients with hypercortisolism and hard-to-control type 2 diabetes.
Guest: Heather Wakelee, MD, FASCO
Perioperative immunotherapy has evolved into a novel therapeutic strategy for early-stage, resectable NSCLC, maximizing the efficacy of immunotherapy when the primary tumor is still present with a high neoantigen burden. Perioperative immunotherapy also allows the use of preoperative pathology as a guide for postoperative care and offers a pathway to potential surgical intervention due to tumor shrinkage for those who are not initially eligible for surgery. Clarifying the rationale behind perioperative immunotherapy in this context is crucial for optimizing treatment strategies and outcomes.
Guest: John M. Kirkwood, MD
Guest: Sapna Patel, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
Guest: Sapna Patel, MD
Guest: John M. Kirkwood, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
Guest: John M. Kirkwood, MD
Guest: Sapna Patel, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
Host: Stephen Liu, MD
Guest: Joshua K. Sabari, MD
Guest: Susan Scott, MD
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
Guest: Paolo A. Ascierto, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
Guest: Hussein Tawbi, MD, PhD
Guest: Sapna Patel, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
Guest: Hussein Tawbi, MD, PhD
Guest: Paolo A. Ascierto, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
Host: Stephen Liu, MD
Guest: Joshua K. Sabari, MD
Guest: Susan Scott, MD
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
Host: Stephen Liu, MD
Guest: Joshua K. Sabari, MD
Guest: Susan Scott, MD
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
Host: Stephen Liu, MD
Guest: Joshua K. Sabari, MD
Guest: Susan Scott, MD
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
Host: Stephen Liu, MD
Guest: Joshua K. Sabari, MD
Guest: Susan Scott, MD
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
Host: Stephen Liu, MD
Guest: Joshua K. Sabari, MD
Guest: Susan Scott, MD
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
Host: Stephen Liu, MD
Guest: Joshua K. Sabari, MD
Guest: Susan Scott, MD
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
Host: Stephen Liu, MD
Guest: Joshua K. Sabari, MD
Guest: Susan Scott, MD
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
Host: Stephen Liu, MD
Guest: Joshua K. Sabari, MD
Guest: Susan Scott, MD
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
Guest: Paolo A. Ascierto, MD
Guest: Hussein Tawbi, MD, PhD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
Guest: Paolo A. Ascierto, MD
Guest: Hussein Tawbi, MD, PhD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
Guest: Paolo A. Ascierto, MD
Guest: Hussein Tawbi, MD, PhD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
Guest: Hussein Tawbi, MD, PhD
Guest: Sapna Patel, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
Guest: Rajiv Agarwal, MBBS, MD, FASN, BRCU
Guest: Amy Mottl, MD, MPH
Guest: Muthiah Vaduganathan, MD, MPH
This three-part panel series explores how emerging evidence from the CONFIDENCE trial is shaping the future of cardio-kidney-metabolic (CKM) care. In Chapter 1, the experts discuss the additive benefits and safety of combining a nonsteroidal MRA and an SGLT2 inhibitor. Chapter 2 focuses on patient selection and individualized strategies for initiating combination therapy. Chapter 3 shifts to real-world implementation, highlighting multidisciplinary collaboration and strategies to improve adherence and continuity of care. Together, this series provides a roadmap to optimize outcomes in patients with CKD and T2D.
Guest: Reshma L. Mahtani, DO
In this Virtual Case Clinic, explore three patient case examples with Dr. Mahtani as she demonstrates the application of the latest clinical evidence in HER2-positive, HER2-low, and HER2-ultralow metastatic breast cancer. By illustrating the use of antibody-drug conjugates in HER2-expressing disease, participants will gain insights into optimal evidence-based treatment selection based upon HER2 expression.
Guest: Ghayas Issa, MD
Guest: Amir Fathi, MD
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
Guest: Ghayas Issa, MD
Guest: Amir Fathi, MD
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
Guest: Ghayas Issa, MD
Guest: Amir Fathi, MD
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
Guest: Ghayas Issa, MD
Guest: Amir Fathi, MD
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
Guest: Ghayas Issa, MD
Guest: Amir Fathi, MD
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
Guest: Ghayas Issa, MD
Guest: Amir Fathi, MD
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
Guest: Ghayas Issa, MD
Guest: Amir Fathi, MD
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
Guest: Ghayas Issa, MD
Guest: Amir Fathi, MD
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
Guest: Ghayas Issa, MD
Guest: Amir Fathi, MD
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
Guest: Ghayas Issa, MD
Guest: Amir Fathi, MD
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
Guest: Robert J. Motzer, MD
Guest: Elizabeth R. Plimack, MD, MS, FASCO
Our experts, Drs. Robert Motzer and Elizabeth Plimack, discuss first-line treatment strategies for advanced renal cell carcinoma in a community clinic setting. Drawing from pivotal clinical trials and guideline recommendations, they highlight how to personalize therapy based on IMDC risk stratification and patient characteristics. Practical decision-making in both intermediate- and poor-risk disease is examined through 2 detailed patient cases, with an emphasis on outcomes, therapy sequencing, and real-world considerations. The discussion also addresses immune-related and TKI-associated adverse events and outlines monitoring and management strategies that support patient safety and treatment continuity. Tune in for expert reflections on integrating evolving data into daily oncology practice.
Faculty: Ahmad Masri, MD, MS
Review findings from the UK Biobank presented recently at the Peripheral Nerve Society meeting, revealing that naturally low transthyretin (TTR) levels are associated with a higher prevalence of cardiovascular biomarkers, such as NT-proBNP, and comorbidities, including peripheral arterial disease, stroke, and cognitive decline. The data suggest that low TTR may serve as a marker of broader systemic illness, both in patients with TTR amyloidosis and in the general population.
Host: Scott Kopetz, MD, PhD
Host: Cathy Eng, MD, FACP
This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Host: Scott Kopetz, MD, PhD
Host: Cathy Eng, MD, FACP
This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Host: Scott Kopetz, MD, PhD
Host: Cathy Eng, MD, FACP
This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Guest: Amy Mottl, MD, MPH
Guest: Prof. Christoph Wanner
The CONFIDENCE trial shows that combining an SGLT2 inhibitor with finerenone cuts albuminuria by more than 50% in patients with chronic kidney disease and type 2 diabetes. In this video, 2 nephrologists discuss how they apply these insights in clinical practice. A compelling real-world case highlights the power of 4-pillar therapy to optimize cardio-renal outcomes. Tune in to see how modern treatment strategies are transforming patient care.
Guest: Kevin Kalinsky MD, MS
Guest: Komal Jhaveri, MD, FACP
This online chapterized CME activity features Drs. Kevin Kalinsky and Komal Jhaveri in a discussion on TROP2-targeted antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC). The faculty describe the therapeutic role of TROP2 as well as both approved and investigational ADCs that target TROP2. Clinical trial data on TROP2-targeted ADCs from various studies are reviewed to evaluate their efficacy and safety across hormone receptor–positive and triple-negative disease settings. The discussion contrasts molecular structures, dosing schedules, and toxicity profiles of each ADC, providing insight into their positioning in treatment algorithms. Practical strategies for therapy sequencing, patient selection, and shared decision-making are emphasized throughout.
Host: H. James Ford, MD
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
Host: H. James Ford, MD
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
Guest: Jean M. Elwing, MD
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
Host: H. James Ford, MD
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
Guest: Martha Kingman, DNP, FNP-C
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
Guest: Jean M. Elwing, MD
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
Guest: Martha Kingman, DNP, FNP-C
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
Guest: Hilary M. DuBrock, MD
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
Guest: Hilary M. DuBrock, MD
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
Host: H. James Ford, MD
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
Host: Crystal Proud, MD
Guest: Erika Finanger, MD, MS
By completing this activity, learners will gain the skills and confidence to determine therapeutic candidacy and conduct appropriate assessments for patients with Duchenne Muscular Dystrophy (DMD) across the age spectrum, including older and non-ambulatory individuals. They will improve their ability to interpret and apply the latest clinical data to real-world scenarios and make informed decisions about treatment and monitoring. Through case-based education, learners will enhance their competence in aligning patients to appropriate therapies and managing long-term care in a rapidly evolving treatment landscape.
Host: Natasha B. Leighl, MD, MMSc
This 30-minute Chairperson’s Perspective program explores the evolving landscape of (epidermal growth factor receptor) EGFR-altered metastatic non–small cell lung cancer through guideline-concordant, evidence-based learning. Dr. Natasha Leighl reviews the clinical importance and optimal timing of molecular testing and provides evidence-based strategies for patient selection and treatment sequencing across EGFR mutation subtypes, including common mutations and exon 20 insertions. Emphasis will be placed on emerging therapies, key clinical trial data, and the integration of multidisciplinary care in managing adverse events associated with EGFR-targeted therapies.
Guest: Raman Sankar, MD, PhD
Guest: Scott Aaronson, MD
This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.
Guest: Raman Sankar, MD, PhD
Guest: Scott Aaronson, MD
This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.
Guest: Raman Sankar, MD, PhD
Guest: Scott Aaronson, MD
This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.
Guest: Raman Sankar, MD, PhD
Guest: Scott Aaronson, MD
This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.
Guest: Raman Sankar, MD, PhD
Guest: Scott Aaronson, MD
This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.
Guest: Meena B. Bansal, MD, FAASLD
Guest: Nicholas Pennings, DO, DABOM, MFOMA, FACOFP, FAAFP
Guest: Fernando Bril, MD
The epidemic of metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) is fully upon the US healthcare system, and it's projected to get worse. The prevalence of MASLD in the US is expected to increase from 33.7% in 2020 to 41.4% in 2050, which translates to approximately 122 million adults being affected. Our broadcast on Global Fatty Liver Day provides practical and engaging discussions to help endocrinologists and primary care providers better understand the use of noninvasive tests and biomarkers for timely screening and primary risk assessment, treatment and management of cardiometabolic risk, and assignment to the appropriate level of care for patients with MASLD/MASH.
Guest: Vallerie V. McLaughlin, MD
Guest: Ioana Preston, MD
Guest: Kelly Chin, MD, MSCA
Pulmonary arterial hypertension (PAH) is a serious, progressive condition that involves making the correct diagnosis and identifying patient comorbidities as important first steps to creating a successful treatment approach. And while identifying which WHO Group a patient belongs to is key, part of the art of treating PAH is recognizing that many patients can have overlap between groups. Our experts’ insights can help you elevate your practice and develop effective PAH treatment plans.
Guest: Martha Kingman, DNP, FNP-C
Guest: Ioana Preston, MD
Guest: Jean M. Elwing, MD
Pulmonary arterial hypertension (PAH) is a serious, progressive condition and successfully managing patients can present certain challenges. Treatment selection is multifactorial and often involves the consideration of myriad patient factors, including WHO Group, objective risk stratification score, cardiac functioning on imaging, and shared decision-making. And while all patients who are living with PAH require careful evaluation, those with comorbidities and/or psychosocial challenges can require additional consideration when developing a treatment plan that improves outcomes.
Guest: Vallerie V. McLaughlin, MD
Guest: Marsha Burks, BSN, RN
Guest: Rajan Saggar, MD
Pulmonary hypertension (PH) is a serious, progressive condition and the care pathways for patients who are living with Group 1 versus Group 2 PH can be very different. Join our experts as they discuss key elements for identifying which WHO Group your patient may fall into and review key factors for developing an effective treatment plan and knowing when to refer patients to other professionals that are part of the PH care team.
Guest: Muthiah Vaduganathan, MD, MPH
Guest: Anuradha Lala-Trindade, MD
Guest: Brendon Neuen, MBBS, PhD
Heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent a significant and growing burden for patients and the healthcare system, not only in cardiovascular medicine, but also in the context of cardio-kidney-metabolic (CKM) syndrome. Trials are underway evaluating new therapies that may offer benefits to patients with HFmrEF/HFpEF and may also have broader, multisystem effects. Tune in to stay up to date!
Host: Alejandro A. Rabinstein, MD, FAHA
Guest: Richard E. Pratley, MD
Guest: Jay H. Shubrook, DO, FACOFP, FAAFP
Listen to expert faculty discuss the role of GLP-1RAs in reducing stroke risk for patients with type 2 diabetes in this on-demand webcast with accompanying slides
Host: Brian P. McDonough, MD, FAAFP
Guest: George M. Rodgers, MD, PhD
Guest: Patricia A. Ford, MD
Designed as a dynamic, intensive, and innovative web-based activity, this session will take learners on an in-depth exploration of cancer-related anemia (CRA) and chemotherapy-induced anemia (CIA) as disease states of vast clinical significance, emphasizing the robust prevalence, pathophysiology, and patient burden of CRA/CIA, as well as the prominent role of iron deficiency (ID) in their pathogenesis. Built upon on this foundation, expert faculty will guide attendees through a succinct but comprehensive review of the IV iron evidentiary base in CRA/CIA, including clinical trials, systematic reviews and meta-analyses, and the latest expert consensus guideline recommendations from the NCCN, ASCO/ASH, and ESMO. Practical clinical pearls for safely and effectively implementing IV iron into the real-world hematology/oncology clinic will be emphasized.
Host: Riccardo Maria Inciardi, MD, PhD
Listen to Dr. Riccardo Inciardi’s summary from the ESC Preventive Cardiology 2025 meeting, where he highlights new therapies reshaping the management of cardio-kidney-metabolic (CKM) syndrome and heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Watch as he breaks down the latest clinical trial data showing that SGLT2 inhibitors, GLP-1 receptor agonists, and the nonsteroidal MRA finerenone can meaningfully reduce hospitalizations, kidney disease progression, and cardiovascular mortality. A real-life patient case illustrates how combining these therapies—under the care of a multidisciplinary team—can transform outcomes.
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Guest: Rishi Wadhera, MD, MPP, Mphil
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Guest: Rishi Wadhera, MD, MPP, Mphil
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Guest: Rishi Wadhera, MD, MPP, Mphil
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Guest: Rishi Wadhera, MD, MPP, Mphil
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Guest: Rishi Wadhera, MD, MPP, Mphil
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Guest: Rishi Wadhera, MD, MPP, Mphil
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
Host: Rishi Wadhera, MD, MPP, Mphil
Guest: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Guest: Rishi Wadhera, MD, MPP, Mphil
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
Host: Rishi Wadhera, MD, MPP, Mphil
Guest: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Guest: Rishi Wadhera, MD, MPP, Mphil
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
Host: Darren Brenner, MD
Irritable bowel syndrome with constipation (IBS-C) significantly impacts patients, not only with its physical symptoms of persistent constipation, abdominal pain, and bloating, but also through a considerable psychological and social burden. Do you know how to effectively treat IBS-C to increase your patients’ quality of life? Tune in for an overview of the latest data.
Guest: prof. Hiddo Heerspink
These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trialand FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic significance of albuminuria reduction. The series delves into the mechanistic rationale, therapeutic implications, and real-world potential of nonsteroidal MRAs in managing patients with chronic kidney disease, type 2 diabetes, and heart failure. Viewers will gain practical insights on integrating these data into their clinical practice to improve patient outcomes.
Guest: Finnian R. McCausland, MD
These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trialand FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic significance of albuminuria reduction. The series delves into the mechanistic rationale, therapeutic implications, and real-world potential of nonsteroidal MRAs in managing patients with chronic kidney disease, type 2 diabetes, and heart failure. Viewers will gain practical insights on integrating these data into their clinical practice to improve patient outcomes.
Guest: Rajiv Agarwal, MBBS, MD, FASN, BRCU
These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic significance of albuminuria reduction. The series delves into the mechanistic rationale, therapeutic implications, and real-world potential of nonsteroidal MRAs in managing patients with chronic kidney disease, type 2 diabetes, and heart failure. Viewers will gain practical insights on integrating these data into their clinical practice to improve patient outcomes.
Guest: Finnian R. McCausland, MD
These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic significance of albuminuria reduction. The series delves into the mechanistic rationale, therapeutic implications, and real-world potential of nonsteroidal MRAs in managing patients with chronic kidney disease, type 2 diabetes, and heart failure. Viewers will gain practical insights on integrating these data into their clinical practice to improve patient outcomes.
Guest: prof. Hiddo Heerspink
Guest: Jennifer B. Green, MD
Can combining a nonsteroidal MRA and an SGLT2 inhibitor unlock new clinical potential for patients with type 2 diabetes and chronic kidney disease (CKD)? In this expert discussion, Dr. Jennifer Green and Dr. Hiddo Heerspink review the latest findings from the CONFIDENCE trial, which demonstrated a significant additive reduction in albuminuria—an important surrogate marker for kidney and cardiovascular risk—when finerenone and empagliflozin are used together. They explore the clinical rationale behind combination therapy, address persistent challenges in CKD detection, and consider the practical implications for implementing these therapies in high-risk populations.
Host: Cynthia J. Bither, ACNP-BC, MSN
Guest: Andrea Wallace, MSN, FNP-C, HF-Cert
Medical devices such as Barostim – or baroreflex activation therapy (BAT) – can play an important role in improving the quality of life and providing symptom relief for patients with heart failure with reduced ejection fraction, or HFrEF. NPs and nurses are key members of the healthcare team who identify patients as potential candidates for this therapy, due in large part to their expertise in eliciting symptoms and getting the full picture from patients regarding the impact of HFrEF on their quality of life. As the direct – and oftentimes most frequent – point of contact for patients, advanced care and allied health professionals can lead the way to open and honest communication with the goal of optimizing treatment plans and positively impacting patient outcomes.
Guest: Kenneth Lieberman, MD
Guest: Howard Trachtman, MD, FASN
Focal segmental glomerulosclerosis (FSGS) is a prominent cause of kidney failure globally, necessitating dialysis for patient survival as the disease progresses. However, the current absence of FDA-approved treatments tailored specifically for treating adult and pediatric patients with FSGS poses a significant challenge to effectively managing this disease. Moreover, it is imperative for nephrologists to enhance their skills to implement practical strategies that improve the diagnostic approach for suspected FSGS cases, especially considering the profound impact of FSGS on patients' quality of life. This activity has been designed to provide practical guidance for the accurate diagnosis of FSGS and appropriate treatment selection, as well as to offer an expert assessment of the clinical trial data supporting emerging therapies in this setting.
Guest: Michael Crotty, MB, BCh, BAO
This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.
This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org
Guest: Michael Crotty, MB, BCh, BAO
Guest: Barbara McGowan, PhD, MBBS
This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.
This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org
Guest: Pam R. Taub, MD, FACC, FASPC
Guest: Kausik Ray, MBChB, MD, MPhil
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
Guest: Børge G. Nordestgaard, MD, DMSc
Guest: Kausik Ray, MBChB, MD, MPhil
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
Guest: Børge G. Nordestgaard, MD, DMSc
Guest: Kausik Ray, MBChB, MD, MPhil
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
Guest: Daniel Gaudet, MD, PhD
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
Guest: Faiez Zannad, MD, PhD
Guest: John McMurray, MD
Join Drs. John McMurray and Faiez Zannad as they explore the evolving role of MRAs in heart failure management. From RALES and TOPCAT to the recent FINEARTS-HF trial, they highlight key findings that shape how steroidal and nonsteroidal MRAs are used in clinical practice. Discover how the nonsteroidal MRA finerenone is expanding treatment options for patients with HFmrEF and HFpEF.
Guest: Pam R. Taub, MD, FACC, FASPC
Guest: Prof. Kausik Ray
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
Guest: Michael Crotty, MB, BCh, BAO
Guest: Ana Maria Cebrián-Cuenca, MD, PhD
This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.
This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org
Guest: Michael Crotty, MB, BCh, BAO
Guest: Ana Maria Cebrián-Cuenca, MD, PhD
This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.
This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org
Guest: Barbara McGowan, PhD, MBBS
Guest: Ana Maria Cebrián-Cuenca, MD, PhD
This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.
This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org
Guest: Pam R. Taub, MD, FACC, FASPC
Guest: Kausik Ray, MBChB, MD, MPhil
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
Guest: Børge G. Nordestgaard, MD, DMSc
Guest: Kausik Ray, MBChB, MD, MPhil
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
Guest: Pam R. Taub, MD, FACC, FASPC
Guest: Kausik Ray, MBChB, MD, MPhil
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
Guest: Daniel Gaudet, MD, PhD
Guest: Pam R. Taub, MD, FACC, FASPC
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
Guest: Neal Shore, MD, FACS
Guest: Sarah Psutka, MD, MS
This online CME program features expert discussions on new research presented at AUA 2025. Drs. Neal Shore and Sarah Psutka explore emerging data on treatment strategies for high-risk BCG-naïve and BCG-unresponsive non–muscle invasive bladder cancer (NMIBC). They also highlight advances in biomarker-directed therapies, including investigational agents targeting HER2 and FGFR alterations. The program emphasizes the clinical relevance and practical application of these findings, offering clinicians actionable insights on evolving bladder cancer care.
Host: Fernanda P. Silveira, MD, MS, FIDSA, FAST
Guest: Jennifer Saullo, MD, PharmD, FIDSA
Join experts, Fernanda P. Silveira, MD, MS, FIDSA, FAST and Jennifer Saullo, MD, PharmD, FIDSA, as they delve into the complexities of cytomegalovirus (CMV) prevention and treatment following solid organ transplantation (SOT). Presentations will feature detailed case discussions with a focus on managing resistant and refractory disease, addressing treatment-related toxicities, and optimizing therapeutic strategies. This program is an essential primer on the scientific challenges and solutions in this critical area of transplant medicine.
Host: Crystal Proud, MD
Guest: John Brandsema, MD
Guest: Omer Abdul Hamid, MD
Explore the latest treatment options, age-specific management strategies, and clinical trial data for patients with Duchenne muscular dystrophy (DMD). Through expert-led discussions and real-world patient cases, you’ll gain practical insights to help you confidently navigate today’s ever-evolving treatment landscape and deliver personalized, informed care.
Guest: Pedro Barata, MD, MSc, FACP
Guest: Sumanta K. Pal, MD, FASCO
Stay at the forefront of nccRCC care by exploring the latest advances in treatment strategies. Gain key insights into optimizing patient selection, enhancing diagnostic accuracy, and managing adverse events to improve patient outcomes. This comprehensive activity delves into emerging data, the rationale for ICI/TKI combination therapy, the latest clinical trial findings, and best practices for treatment sequencing. Take action today to refine your approach and deliver the best possible care for your patients.
This series of video briefs features Dr. Neal Shore reporting from AUA 2025 in Las Vegas. Tune in for timely updates on innovatively delivered intravesical therapies for non–muscle invasive bladder cancer (NMIBC). Dr. Shore presents key findings from the SunRISe-1 trial, highlighting 1-year durability and patient-reported outcomes data in BCG-unresponsive high-risk NMIBC. He also covers the first results from cohort 4 of SunRISe-1, with a focus on papillary disease-only patients, along with the study design of the phase 3 MoonRISe-3 trial in patients with BCG-treated high-risk NMIBC and FGFR alterations. Each brief distills the clinical relevance of these studies and their potential impact on future NMIBC treatment strategies.
This series of video briefs features Dr. Neal Shore reporting from AUA 2025 in Las Vegas. Tune in for timely updates on innovatively delivered intravesical therapies for non–muscle invasive bladder cancer (NMIBC). Dr. Shore presents key findings from the SunRISe-1 trial, highlighting 1-year durability and patient-reported outcomes data in BCG-unresponsive high-risk NMIBC. He also covers the first results from cohort 4 of SunRISe-1, with a focus on papillary disease-only patients, along with the study design of the phase 3 MoonRISe-3 trial in patients with BCG-treated high-risk NMIBC and FGFR alterations. Each brief distills the clinical relevance of these studies and their potential impact on future NMIBC treatment strategies.
Host: Stephanie Ambrose, DO
Guest: Jenny McDaniel, MD
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
Host: Stephanie Ambrose, DO
Guest: Jenny McDaniel, MD
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
Host: Jenny McDaniel, MD
Guest: Stephanie Ambrose, DO
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
Host: Jenny McDaniel, MD
Guest: Stephanie Ambrose, DO
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
Host: Stephanie Ambrose, DO
Guest: Jenny McDaniel, MD
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
Host: Stephanie Ambrose, DO
Guest: Jenny McDaniel, MD
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
Host: Jenny McDaniel, MD
Guest: Stephanie Ambrose, DO
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
Host: Jenny McDaniel, MD
Guest: Stephanie Ambrose, DO
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
Host: Stephanie Ambrose, DO
Guest: Jenny McDaniel, MD
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
Host: Stephanie Ambrose, DO
Guest: Jenny McDaniel, MD
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
Host: Vera Bril, MD
Guest: Neelam Goyal, MD
Traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial for many patients in the short term but often come with unacceptable side effects. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) has created a groundbreaking paradigm shift in our approach to both the short- and longer-term management of affected patients. Join Drs. Vera Bril and Neelam Goyal as they take a deep dive into this topic and discuss how FcRn inhibitors are changing the therapeutic landscape of gMG.
Host: Carlos M. de Castro, MD
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by hemolytic anemia and associated with thrombophilia and bone marrow failure. Early and accurate diagnosis and classification of PNH is essential to optimize outcomes. However, the diagnosis of PNH may be delayed or missed for months or even years in practice, and only 25% of newly diagnosed patients receive any PNH-specific treatment. Moreover, up to 20% of patients treated with C5 inhibitors continue to experience clinically significant extravascular hemolysis, leading to residual anemia and its complications. Thus, several new and novel complement inhibitors have been developed and approved. In this activity, Dr. Carlos de Castro reviews the diagnostic criteria for PNH and best practices for the selection of optimal treatment regimens.
Host: Aditya Bardia, MD, MPH
The recent approvals of therapies for hormone-receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC) have augmented the treatment armamentarium in this setting, giving clinicians more options for their patients. However, it may be challenging to select the optimal therapy for individual patients. Moreover, it is important to differentiate between the 2 available TROP2-directed antibody-drug conjugates (ADCs). This activity reviews challenges in treating HR+, HER2- MBC, the role of TROP2-directed ADCS, and how to tailor therapy for individual patients.
Host: Tycel Phillips, MD
Dr. Tycel Phillips presents a summary and offers expert insights on relevant and timely advances in bispecific antibody therapy for the treatment of R/R FL. The activity reviews topics including differentiating approved bispecific antibodies, evidence- and guideline-based treatment planning, patient selection, practical considerations, and optimizing safety in the application of bispecific antibody therapy in R/R FL.
Guest: Fernando López-Ríos, MD, PhD
Guest: Christian Rolfo, MD, PhD
Guest: Charlie Gourley, MD, PhD
In this on-demand replay of a recent interactive webinar, renowned experts Prof. Fernando López-Ríos, Prof. Christian Rolfo, and Prof. Charlie Gourley review the latest data, guidelines, and patient cases as they explore best practices for HER2 testing and the evolving role of IHC in lung and ovarian cancers.
Topics of conversation include the following:
- An overview of challenges related to HER2 immunohistochemistry, guidance, and interpretation of the results
- Targeting HER2 in lung cancer: where does IHC testing fit in?
- Ovarian cancer: challenges and considerations for HER2 IHC testing
Watch the on-demand video to gain expert insights on optimising IHC HER2 testing and interpreting results in lung and ovarian cancer.
The full programme is also featured on the COR2ED website, here: HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Guest: Marilyn Yuanxin Ma Bui, MD, PhD
Guest: Anne Vincent-Salomon, MD
With the availability of HER2-directed therapies, it’s important to accurately identify patients who would benefit from these therapies, particularly in breast cancer, where we now have a spectrum of HER2 positivity. Advances in technology have augmented the role of digital pathology (DP) and artificial intelligence (AI) in oncologic pathology. This activity demonstrates how DP/AI can be used for more accurate biomarker assessment and explores the impact this may have on patient outcomes.
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Host: Rishi Wadhera, MD, MPP, Mphil
This on-demand knowledge primer explores key challenges and evidence-based strategies for improving atherosclerotic cardiovascular disease (ASCVD) management in rural populations. Led by two expert faculty members, the program provides a comprehensive overview of disparities in ASCVD care, guideline-directed therapies, and practical approaches to overcoming barriers in rural settings. Participants will gain essential knowledge to enhance patient outcomes and optimize cardiovascular care in underserved communities.
Guest: Vera Bril, MD
Guest: Nicholas J. Silvestri, MD
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
Guest: Vera Bril, MD
Guest: Nicholas J. Silvestri, MD
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
Guest: Vera Bril, MD
Guest: Hans Katzberg, MD
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
Guest: Vera Bril, MD
Guest: Hans Katzberg, MD
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
Guest: Vera Bril, MD
Guest: Nicholas J. Silvestri, MD
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
Guest: Vera Bril, MD
Guest: Nicholas J. Silvestri, MD
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
Guest: Vera Bril, MD
Guest: Hans Katzberg, MD
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
Guest: Vera Bril, MD
Guest: Nicholas J. Silvestri, MD
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
Guest: Vera Bril, MD
Guest: Hans Katzberg, MD
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
Guest: Vera Bril, MD
Guest: Nicholas J. Silvestri, MD
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
Host: Vera Bril, MD
Guest: Jonathan Strober, MD
The adult and pediatric diagnostic and treatment landscapes of generalized myasthenia gravis (gMG) are both similar and different. While current traditional therapies are often effective in the short term, selecting the most appropriate short- and longer-term treatment for each patient, whether adult or pediatric, brings with it unique individual challenges. These challenges include how best to utilize newer targeted agents in the treatment of gMG, such as the neonatal Fc receptor (FcRn) inhibitors. Join Drs. Vera Bril and Jonathan Strober as they tackle these issues from both the adult and pediatric perspective.
Guest: Akshay S. Desai, MD
These video briefs feature expert insights on the latest clinical data presented at ACC 2025. Leading cardiologists discuss emerging nonsteroidal mineralocorticoid receptor antagonists (MRAs), their efficacy in heart failure management, and their potential advantages over traditional steroidal MRAs. The series explores key trial findings, safety considerations, and clinical implications for optimizing patient care. Viewers will gain practical knowledge on integrating these novel therapies into clinical practice to improve patient outcomes.
Host: Fortunato Ciardiello, MD, PhD
Host: Jenny Seligmann, MBChB, PhD
This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Host: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Harry Yoon, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Harry Yoon, MD
Guest: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Fortunato Ciardiello, MD, PhD
Host: Jenny Seligmann, MBChB, PhD
This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Host: Fortunato Ciardiello, MD, PhD
Host: Jenny Seligmann, MBChB, PhD
This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Host: Fortunato Ciardiello, MD, PhD
Host: Jenny Seligmann, MBChB, PhD
This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Host: Harry Yoon, MD
Host: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Harry Yoon, MD
Host: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Harry Yoon, MD
Host: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Harry Yoon, MD
Host: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Fortunato Ciardiello, MD, PhD
Host: Jenny Seligmann, MBChB, PhD
This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Host: Elizabeth R. Plimack, MD, MS, FASCO
Guest: Shilpa Gupta, MD
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs).
This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide management strategies for common AEs seen with newer immunotherapy.
Host: James R. Bateman, MD, MPH
Guest: B. Joy Snider, MD, PhD
Guest: Jerome A. Barakos, MD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: Jerome A. Barakos, MD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: Danya Khoujah, MBBS, MEHP, FACEP, FAAEM
Guest: Jerome A. Barakos, MD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: B. Joy Snider, MD, PhD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: Aditya Bardia, MD
Host: Tiffany Traina, MD, FASCO
When choosing an antibody-drug conjugate (ADC) for the second-line treatment of triple-negative breast cancer (TNBC), efficacy, sequencing, and management of toxicities are key. Do you know how best to choose a therapy for your patients? Our experts have the answers and strategies you need!
Host: James R. Bateman, MD, MPH
Guest: Danya Khoujah, MBBS, MEHP, FACEP, FAAEM
Guest: B. Joy Snider, MD, PhD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: Jerome A. Barakos, MD
Guest: Danya Khoujah, MBBS, MEHP, FACEP, FAAEM
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: B. Joy Snider, MD, PhD
Guest: Jerome A. Barakos, MD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: B. Joy Snider, MD, PhD
Guest: Charles P. Vega, MD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: Charles P. Vega, MD
Guest: B. Joy Snider, MD, PhD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: B. Joy Snider, MD, PhD
Guest: Jerome A. Barakos, MD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: B. Joy Snider, MD, PhD
Guest: Jerome A. Barakos, MD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: M. Edip Gurol, MD, MSc
Guest: Robin Novakovic, MD
Guest: Shadi Yaghi, MD
Guest: Jeffrey Weitz, MD
Despite significant efforts to prevent stroke in patients, there remains an unmet need among providers regarding the optimization and benefit-risk profile of anticoagulation therapies. Learn how these therapies may impact the prevention of ischemic stroke and secondary stroke in patients with atrial fibrillation.
Host: Daniel P. Petrylak, MD
Guest: Elizabeth R. Plimack, MD, MS, FASCO
Guest: Evan Y. Yu, MD
This online educational activity, derived from a live satellite symposium at ASCO GU 2025, explores innovative strategies for personalized care in bladder cancer. Participants will gain a deeper understanding of molecular targets and profiling methodologies, review cutting-edge clinical trial evidence, and examine the latest advances in therapy delivery. The program also focuses on creating effective, evidence-based treatment plans and strategies for sequencing molecularly targeted therapies, as well as integrating interprofessional protocols for managing adverse events. This collaborative approach will equip learners with practical insights to enhance treatment outcomes in bladder cancer.
Host: Eric Jonasch, MD
Guest: Brad McGregor, MD
Guest: Ulka Vaishampayan, MBBS
This online educational activity, derived from a live satellite symposium at ASCO GU 2025, explores the latest advances in risk stratification and evidence-based approaches for managing advanced renal cell carcinoma (RCC). Participants will gain a deeper understanding of guideline-driven treatment strategies across RCC histologies and learn strategies for the integration of multidisciplinary approaches to optimize patient care. Emphasis will be placed on shared decision-making and innovative solutions for monitoring and managing treatment-related adverse events. Learners will gain actionable insights for personalizing RCC care and improving patient outcomes.
Host: William D. Tap, MD
Host: John Healey, MD
In this activity, a medical oncologist and orthopedic surgeon discuss evidence-based surgical and systemic therapy approaches for the treatment of tenosynovial giant cell tumors (TGCT). Topics include differentiating TGCT by presentation; surgical candidacy, approaches, and limitations; systemic treatment options with CSF1R inhibitors; and considerations for treatment selection with surgical, nonsurgical, or combination interventions. A patient case example is used to demonstrate optimal multidisciplinary and patient-centered treatment considerations and selection. Strategies for multidisciplinary collaboration to ensure comprehensive monitoring and effective disease management are also explored. Tune in to find out how to enhance the collaborative capacity of multidisciplinary teams in developing individualized, patient-centered treatment plans for patients with TGCT.
Vimseltinib is now FDA-approved for adult patients with symptomatic TGCT, for which surgical resection will potentially cause worsening functional limitation or severe morbidity. This activity was recorded prior to this FDA approval.
Host: Nathan A. Boggs, MD
Host: Tracy George, MD
Host: Lindsay Rein, MD
The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.
Host: Nathan A. Boggs, MD
Host: Tracy George, MD
Host: Lindsay Rein, MD
The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.
Host: Nathan A. Boggs, MD
Host: Tracy George, MD
Host: Lindsay Rein, MD
The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.
Host: Nathan A. Boggs, MD
Host: Tracy George, MD
Host: Lindsay Rein, MD
The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.
Guest: Leonard H. Calabrese, DO
With at least 4 percent of patients who experience COVID-19 developing long COVID, improving care for post-infectious chronic conditions is critical. By prioritizing research and education on the rheumatological effects of acute infections, we can address these patients’ unmet needs. Join Dr. Leonard Calabrese, Vice Chairman of the Department of Rheumatic and Immunologic Disease and Head of Clinical Immunology at the Cleveland Clinic Foundation, as he explains what we know so far about these conditions.
Host: Elizabeth R. Plimack, MD, MS, FASCO
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs).
This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.
Host: Elizabeth R. Plimack, MD, MS, FASCO
Guest: Lillibeth Velasco, MSN, RN
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs).
This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.
Host: Elizabeth R. Plimack, MD, MS, FASCO
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs).
This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.
Guest: Valeria Caso, MD, PhD
The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you’re up to date and providing the care your patients deserve.
Host: Renato D. Lopes, MD, MHS, PhD
The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you’re up to date and providing the care your patients deserve.
Host: Andreas Kronbichler, MD
Guest: Bernhard Hellmich, MD
Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
Host: Silke R. Brix, MD, MRCP, SCPR
Guest: Andreas Kronbichler, MD
Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
Host: Bernhard Hellmich, MD
Guest: Andreas Kronbichler, MD
Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
Host: Bernhard Hellmich, MD
Guest: Silke R. Brix, MD, MRCP, SCPR
Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
Host: Silke R. Brix, MD, MRCP, SCPR
Guest: Bernhard Hellmich, MD
Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
Guest: Silke R. Brix, MD, MRCP, SCPR
Host: Andreas Kronbichler, MD
Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
Host: Renato D. Lopes, MD, MHS, PhD
Guest: Alexander T. Cohen, MD, MBBS
The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you’re up to date and providing the care your patients deserve.
Host: Renato D. Lopes, MD, MHS, PhD
Guest: Alexander T. Cohen, MD, MBBS
The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you’re up to date and providing the care your patients deserve.
Guest: Alexander T. Cohen, MD, MBBS
The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you’re up to date and providing the care your patients deserve.
Guest: Alexander T. Cohen, MD, MBBS
The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you’re up to date and providing the care your patients deserve.
Host: Renato D. Lopes, MD, MHS, PhD
Guest: Valeria Caso, MD, PhD
The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you’re up to date and providing the care your patients deserve.
Host: Renato D. Lopes, MD, MHS, PhD
Guest: Valeria Caso, MD, PhD
The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you’re up to date and providing the care your patients deserve.
Host: Renato D. Lopes, MD, MHS, PhD
Guest: Valeria Caso, MD, PhD
The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you’re up to date and providing the care your patients deserve.
Host: Renato D. Lopes, MD, MHS, PhD
The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you’re up to date and providing the care your patients deserve.
Guest: Sarah Sammons, MD
The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.
Guest: Sarah Sammons, MD
Guest: Carey Anders, MD, FASCO
The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.
Guest: Sarah Sammons, MD
The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.
Guest: Carey Anders, MD, FASCO
The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.
Guest: Carey Anders, MD, FASCO
Guest: Sarah Sammons, MD
The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.
Guest: Carey Anders, MD, FASCO
Guest: Sarah Sammons, MD
The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.
Guest: Carey Anders, MD, FASCO
The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.
Guest: Heather McArthur, MD
Guest: Margaret Gatti-Mays, MD, MPH
Tune in for a deep dive into the evolving landscape of immuno-oncology (IO) in early-stage triple-negative breast cancer (TNBC). Our experts focus on identifying eligible patients for neoadjuvant and adjuvant IO regimens, understanding current and emerging treatment options, and effectively utilizing shared decision-making (SDM) techniques to tailor treatment plans. The activity also covers the importance of recognizing and managing immune-related adverse events (irAEs) in the perioperative setting. Learn to optimize the use of IO in early-stage TNBC and improve your patients’ outcomes and quality of life.
Host: Melissa Magwire, RN, MSN, CDE
Guest: Matthew Bullington, PharmD
Guest: Dawn M. Denicola, FNP-C
Guest: Keith Miller, MD
Are you up to date on the plethora of benefits patients may receive from SGLT2 inhibitors? Learn from a multidisciplinary faculty panel as they use patient case vignettes to review emerging evidence and evolving treatment guidelines related to cardio-renal-metabolic comorbidities such as type 2 diabetes, heart failure, chronic kidney disease, and management of patients post-MI. Tune in for the insights you need to enhance your practice.
Guest: Karin J. Blakemore, MD
Guest: Emilie L. Vander Haar
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.
Guest: Karin J. Blakemore, MD
Guest: Emilie L. Vander Haar
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.
Guest: Karin J. Blakemore, MD
Guest: Emilie L. Vander Haar
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.
Guest: Karin J. Blakemore, MD
Guest: Emilie L. Vander Haar
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.
Guest: Karin J. Blakemore, MD
Guest: Emilie L. Vander Haar
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.
Guest: Karin J. Blakemore, MD
Guest: Emilie L. Vander Haar
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.
Guest: Karin J. Blakemore, MD
Guest: Emilie L. Vander Haar
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.
Host: Kieran McCafferty, MD
Guest: Maurizio Gallieni, MD
Patients with chronic kidney disease-associated pruritus (CKD-aP) often face delays in diagnosis and treatment, as well as potential side effects from some prescribed medicines. Tune in as our experts dive into the burden of CKD-aP symptoms and break down the long-term outcomes and benefits of new and emerging treatments.
Guest: Clete A. Kushida, MD, PhD
Guest: Sally Ibrahim, MD, FAAP
Sodium content and the disruption associated with the twice-nightly dosing of sodium oxybate are common concerns when treating patients with narcolepsy. Is sodium content truly a risk factor for cardiovascular sequelae in patients with narcolepsy? Does twice-nightly dosing lead to medically unacceptable dosing errors? Join Drs. Sally Ibrahim and Clete Kushida as they dive into these questions and provide actionable answers for you to use in your clinical practice.
Guest: Karin J. Blakemore, MD
Guest: Emilie L. Vander Haar
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.
Guest: Karin J. Blakemore, MD
Guest: Emilie L. Vander Haar
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.
Guest: Karin J. Blakemore, MD
Guest: Emilie L. Vander Haar
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.
This program contains important information about the limitations of current therapies used to treat plaque psoriasis. Drs. Kim Papp and Jerry Bagel discuss these shortcomings and outline clinical data on investigational oral medications for plaque psoriasis.
Guest: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Guest: Ahmed Z. Obeidat, MD, PhD
This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
Guest: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Guest: Ahmed Z. Obeidat, MD, PhD
This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
Host: Brian P. McDonough, MD, FAAFP
Guest: Andrew Allegretti, MD, MSc
Guest: Ram Subramanian, MD
In patients with cirrhosis and kidney dysfunction who are candidates for liver transplantation, transplant decisions are impacted by kidney function impacting MELD scores. This podcast explores ICU management of these patients, including the use of dialysis, and emphasizes the importance of considering multiple factors such as the etiology of liver disease, presence of chronic kidney disease, and individual patient characteristics. The experts highlight recent changes in transplant criteria, particularly for alcoholic hepatitis patients, and discuss the challenges of managing an increasingly diverse patient population ranging from young alcohol-related liver disease patients to older patients with metabolic-associated liver disease and multiple comorbidities.
Host: Nancy S. Reau, MD
Guest: Andrew Allegretti, MD, MSc
Guest: Kevin Regner, MD
Guest: Ram Subramanian, MD
In patients with decompensated cirrhosis and multi-organ failure, intensive care units must coordinate care between hepatologists, transplant surgeons, intensivists, and nephrologists to optimize patient outcomes. This roundtable highlights the importance of well-coordinated processes between floor units and ICU teams, including early response systems and regular multidisciplinary rounds to discuss management strategies and transplant considerations. Different specialists must collaborate effectively to make decisions about various treatments, including terlipressin administration, dialysis initiation, and transplant timing, particularly in challenging cases like alcoholic hepatitis. This activity also covers how teams must carefully balance improving kidney function against maintaining transplant priority scores.
Guest: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Guest: Ahmed Z. Obeidat, MD, PhD
This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
Guest: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Guest: Ahmed Z. Obeidat, MD, PhD
This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
Guest: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Guest: Ahmed Z. Obeidat, MD, PhD
This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
Guest: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Guest: Ahmed Z. Obeidat, MD, PhD
This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
Guest: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Guest: Ahmed Z. Obeidat, MD, PhD
This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
Guest: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Guest: Ahmed Z. Obeidat, MD, PhD
This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
Guest: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Guest: Ahmed Z. Obeidat, MD, PhD
This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
Guest: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Guest: Ahmed Z. Obeidat, MD, PhD
This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Guest: Nicholas J. Silvestri, MD
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: Nicholas J. Silvestri, MD
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: Nicholas J. Silvestri, MD
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: Nicholas J. Silvestri, MD
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: Nicholas J. Silvestri, MD
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: Nicholas J. Silvestri, MD
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: Nicholas J. Silvestri, MD
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: Nicholas J. Silvestri, MD
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: Nicholas J. Silvestri, MD
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Host: Brian P. McDonough, MD, FAAFP
Guest: Nancy S. Reau, MD
Guest: Kevin Regner, MD
In patients with advanced liver disease, decompensated cirrhosis and portal hypertension can impact kidney function through development of acute kidney injury (AKI). Multiple different etiologies of AKI can be seen in cirrhotic patients, including prerenal AKI, acute tubular injury, and hepatorenal syndrome (HRS), which require different treatment approaches. This podcast will emphasize the importance of multidisciplinary care and use of established protocols in treating these patients, particularly when considering a bridge to liver transplantation, and discuss specific considerations for patients with transjugular intrahepatic portosystemic shunt (TIPS).
Guest: Nicholas J. Silvestri, MD
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: David Wirta, MD
Guest: Selina McGee, OD, FAAO
Increased understanding of the neurobiology of dry eye disease (DED) has led to a greater emphasis on its significant and potentially serious impact on patients’ vision and quality of life. Emerging treatments for DED go beyond mere symptom management to target its neurobiology. Join an expert panel consisting of an ophthalmologist and an optometrist to discuss the burden and causes of DED, the role of the lacrimal functional unit in its pathophysiology, and the rationale for targeted neuromodulation. The panel will also explore the symptoms of DED and the new pharmacologic agents that target the LFU along with clinical evidence supporting their use. The program will also include a video vignette of a patient with DED to highlight the challenges and realities of living with DED.
Host: Mikhail Kosiborod, MD
Guest: Stephen J. Greene, MD, FACC, FHFSA
Patients with CKD or heart failure face the risk of developing hyperkalemia, and healthcare providers often experience clinical inertia in their treatment. Join the experts as they explore chronic hyperkalemia management, and the role of potassium binders.
Guest: Jeffrey V. Matous, MD
Guest: Donna Catamero, NP
This 15-minute audio podcast uses real-world patient cases to illustrate effective strategies for managing adverse events (AEs) associated with GPRC5D-directed therapies in multiple myeloma. Expert faculty discuss how to safely implement these therapies to achieve deep, durable responses while optimizing patient tolerability and quality of life. Listeners will gain insights into specific prophylaxis, dosing, and interprofessional management protocols to address unique AEs such as cytokine release syndrome, skin toxicity, and dysgeusia. This practical case-based discussion will equip healthcare professionals with actionable tools to improve outcomes for their patients with relapsed/refractory multiple myeloma.
Host: Jorge E. Cortes, MD
Although the first-generation tyrosine kinase inhibitors (TKIs) revolutionized the treatment of Ph+ CML-CP, the rate of resistance to these agents is high, and many patients require further treatment with second- and third-line therapy. The development of newer drugs with unique mechanisms that can overcome these resistance phenotypes offers new treatment strategies that can maintain response rates. This activity reviews the current treatment options for newly diagnosed disease and the importance of integrating patient preference when planning therapeutic regimens.
Guest: Efrat Dotan, MD
Guest: Shubham Pant, MD, MBBS
Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens.
This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups.
Complete both modules, answer pre- and post-test questions and start earning CME credits.
This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment
Guest: Efrat Dotan, MD
Guest: Shubham Pant, MD, MBBS
Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens.
This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups.
Complete both modules, answer pre- and post-test questions and start earning CME credits.
This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment
Guest: Muthiah Vaduganathan, MD, MPH
Guest: Orly Vardeny, MD
Discover the transformative potential of nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs) in optimizing care for patients with the Cardiovascular-Kidney-Metabolic syndrome. Emerging data presented at EASD, HFSA, ASN and AHA, highlight their ability to improve cardiorenal outcomes in the spectrum of the Cardiovascular-Kidney-Metabolic syndrome. By integrating ns-MRAs into individualized treatment plans, healthcare professionals can offer their patients advanced care backed by cutting-edge research.
Guest: Orly Vardeny, MD
Guest: Muthiah Vaduganathan, MD, MPH
Discover the transformative potential of nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs) in optimizing care for patients with the Cardiovascular-Kidney-Metabolic syndrome. Emerging data presented at EASD, HFSA, ASN and AHA, highlight their ability to improve cardiorenal outcomes in the spectrum of the Cardiovascular-Kidney-Metabolic syndrome. By integrating ns-MRAs into individualized treatment plans, healthcare professionals can offer their patients advanced care backed by cutting-edge research.
Guest: Donna Ryan, MD
Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.
Guest: Sudipto Mukherjee, MD, PhD, MPH
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
Host: Vallerie V. McLaughlin, MD
During a satellite symposium at the AHA 2024 Annual Meeting, experts reviewed the role of novel disease-modifying therapies (DMTs) in treating and managing pulmonary hypertension (PH) and the impact of current PH treatments vs novel DMTs. They also discussed how to identify appropriate patients for DMTs and strategies to customize treatment with risk-based assessments. In addition, highlights from the 7th World Symposium in PH were discussed. Tune in to keep up!
Guest: Andreea Ciudin, MD, PhD
Guest: Marta Comas
Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.
Guest: Charles P. Vega, MD
Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.
Guest: Charles P. Vega, MD
Guest: Walmir Coutinho, MD
Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.
Guest: Donna Ryan, MD
Guest: Andreea Ciudin, MD, PhD
Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.
Guest: Donna Ryan, MD
Guest: Andreea Ciudin, MD, PhD
Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.
Guest: Walmir Coutinho, MD
Guest: Charles P. Vega, MD
Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.
Host: Peter Schmid, FRCP, MD, PhD
Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.
Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.
Host: Sara Lonardi, MD
The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.
Host: Jörg Latus, MD
Guest: Chee Kay Cheung, MBCHB, MRCP, PHD
Because renal biopsy is required for diagnosis, providers must be able to identify the histopathological characteristics of IgA nephropathy and implement a systemic diagnostic approach. In addition, the mechanisms of action of some IgAN therapies may offer advantages over others in targeting specific pathways in disease pathophysiology. Join the experts for an exploration of these important clinical topics using a patient case study.
Host: William J. Gradishar, MD
Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.
Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.
Host: Peter Schmid, FRCP, MD, PhD
Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.
Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.
Host: Erica L. Mayer, MD, MPH
Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.
Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.
Host: Sara Lonardi, MD
The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.
Host: Sara Lonardi, MD
The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.
Host: Alan Venook, MD
The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.
Host: Aparna R. Parikh, MD
The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.
Host: Aparna R. Parikh, MD
The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.
Host: Aparna R. Parikh, MD
The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.
Host: Alan Venook, MD
The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.
Host: Alan Venook, MD
The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.
Host: Sara Lonardi, MD
Host: Aparna R. Parikh, MD
Host: Alan Venook, MD
The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.
Host: Peter Schmid, FRCP, MD, PhD
Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.
Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.
Host: William J. Gradishar, MD
Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.
Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.
Host: William J. Gradishar, MD
Guest: Erica L. Mayer, MD, MPH
Guest: Peter Schmid, FRCP, MD, PhD
Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.
Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.
Host: Erica L. Mayer, MD, MPH
Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.
Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.
Host: Peter Schmid, FRCP, MD, PhD
Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.
Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.
Host: Erica L. Mayer, MD, MPH
Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.
Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.
Host: James R. Bateman, MD, MPH
Guest: Jerome A. Barakos, MD
Guest: Danya Khoujah, MBBS, MEHP, FACEP, FAAEM
Guest: B. Joy Snider, MD, PhD
Amyloid-related imaging abnormalities (ARIA) can represent a significant clinical challenge in the acute management of some patients with Alzheimer's disease receiving anti-amyloid beta monoclonal antibodies (anti-Aβ mAbs). "Time Out: A Case-Based Deep Dive into the Challenges of ARIA Management" is an educational program designed to enhance clinicians' practical skills through the examination of complex, real-world case scenarios. This interactive program equips all members of the multidisciplinary care team with effective strategies for acute ARIA management, fostering confidence in handling intricate emergency situations. Join our expert panel to deepen your expertise and contribute meaningfully to patient care in the evolving landscape of ARIA.
Host: Ignacio Duran, MD
Host: Sandy Srinivas, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Ignacio Duran, MD
Host: Sandy Srinivas, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Wenxin Xu, MD
Host: Sandy Srinivas, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Wenxin Xu, MD
Host: Sandy Srinivas, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Wenxin Xu, MD
Host: Sandy Srinivas, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Ignacio Duran, MD
Host: Wenxin Xu, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Sandy Srinivas, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Ignacio Duran, MD
Host: Wenxin Xu, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Ignacio Duran, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Guest: Vallerie V. McLaughlin, MD
Guest: Thomas Cascino, MD
Guest: Bradley A. Maron, MD
Providers face challenges when it comes to pulmonary hypertension (PH), especially when distinguishing between PAH with comorbidities and group 2 PH. In addition, PH resulting from left heart disease may further complicate diagnosis and treatment. Hear what the experts have to say about identifying and treating these patient populations.
Host: Ignacio Duran, MD
Host: Wenxin Xu, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Mark Socinski, MD
This animated podcast explores the evolving role of ALK inhibitors in managing early-stage non-small cell lung cancer (NSCLC). Dr. Mark Socinski discusses molecular profiling as a cornerstone for identifying ALK fusion–positive cases and highlights clinical data from pivotal trials. He also addresses the challenges of treatment adherence, toxicity management, and the importance of surrogate endpoints in early-stage disease. The discussion concludes with key takeaways on integrating targeted therapies into standard care for early-stage resectable NSCLC.
Guest: Robert P. Frantz, MD, FACC
Guest: Vallerie V. McLaughlin, MD
Guest: Sonja Bartolomei, MD
Hear about the latest updates in risk assessment and find out how you can accurately use risk stratification to categorize patients in a timely manner to improve both their care and quality of life. You’ll also discover changing practice trends and the latest evidence that may impact your practice.
Guest: Vallerie V. McLaughlin, MD
Guest: Victor Moles, MD
Guest: Ioana Preston, MD
The landscape of medication management for patients with pulmonary hypertension (PH) has significantly changed with the introduction of combination therapy and recent trial data. This activity presents the latest evidence and breaks down new approaches to the management of PH. Join our experts to find out how your daily practice will be affected.
Host: James R. Bateman, MD, MPH
Guest: Jerome A. Barakos, MD
Guest: Danya Khoujah, MBBS, MEHP, FACEP, FAAEM
Guest: B. Joy Snider, MD, PhD
Guest: Charles P. Vega, MD
Amyloid-related imaging abnormalities (ARIA) can pose a significant challenge in the management of Alzheimer's disease, necessitating a collaborative, interdisciplinary approach. "The ARIA Toolkit: An Interdisciplinary Curriculum" is a comprehensive program designed to equip healthcare professionals with in-depth knowledge and practical skills for effective ARIA management. Featuring the latest advances in anti-amyloid beta monoclonal antibodies (anti-Aβ mAbs), this educational format aims to prepare participants for real-world scenarios. Join our panel of expert faculty in this essential session to enhance team-based strategies and optimize patient outcomes.
Host: Naim Alkhouri, MD, FAASLD, DABOM
MASLD/MASH is a serious, chronic, progressive disease that will soon be the most common indication for liver transplantation and a major driver of the development of liver cancer. The good news is we now have a recently approved liver-directed therapy. Tune in to ensure you know how to effectively identify and treat MASLD/MASH in your patients.
Host: Helena Yu, MD
Guest: Pasi Antero Jänne, MD, PhD
Since the development of this educational activity, the Biologics License Application (BLA) seeking accelerated approval for patritumab deruxtecan (HER3-DXd), based on the HERTHENA-Lung01 Phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies, has been voluntarily withdrawn.
This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for implementing novel HER3-directed antibody-drug conjugates (ADCs). Our experts also focus on the adoption of a team-based approach to help you monitor and manage treatment-related adverse events associated with HER3-directed ADCs.
Host: Helena Yu, MD
Guest: Pasi Antero Jänne, MD, PhD
Since the development of this educational activity, the Biologics License Application (BLA) seeking accelerated approval for patritumab deruxtecan (HER3-DXd), based on the HERTHENA-Lung01 Phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies, has been voluntarily withdrawn.
This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for implementing novel HER3-directed antibody-drug conjugates (ADCs). Our experts also focus on the adoption of a team-based approach to help you monitor and manage treatment-related adverse events associated with HER3-directed ADCs.
Host: Helena Yu, MD
Since the development of this educational activity, the Biologics License Application (BLA) seeking accelerated approval for patritumab deruxtecan (HER3-DXd), based on the HERTHENA-Lung01 Phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies, has been voluntarily withdrawn.
This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for implementing novel HER3-directed antibody-drug conjugates (ADCs). Our experts also focus on the adoption of a team-based approach to help you monitor and manage treatment-related adverse events associated with HER3-directed ADCs.
Host: Pasi Antero Jänne, MD, PhD
Since the development of this educational activity, the Biologics License Application (BLA) seeking accelerated approval for patritumab deruxtecan (HER3-DXd), based on the HERTHENA-Lung01 Phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies, has been voluntarily withdrawn.
This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for implementing novel HER3-directed antibody-drug conjugates (ADCs). Our experts also focus on the adoption of a team-based approach to help you monitor and manage treatment-related adverse events associated with HER3-directed ADCs.
Host: Pasi Antero Jänne, MD, PhD
Guest: Helena Yu, MD
Since the development of this educational activity, the Biologics License Application (BLA) seeking accelerated approval for patritumab deruxtecan (HER3-DXd), based on the HERTHENA-Lung01 Phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies, has been voluntarily withdrawn.
This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for implementing novel HER3-directed antibody-drug conjugates (ADCs). Our experts also focus on the adoption of a team-based approach to help you monitor and manage treatment-related adverse events associated with HER3-directed ADCs.
Host: Naim Alkhouri, MD, FAASLD, DABOM
MASLD/MASH is a serious, chronic, progressive disease that will soon be the most common indication for liver transplantation and a major driver of the development of liver cancer. Do you know how to effectively treat MASLD/MASH in your patients, and are you familiar with drugs currently in development? Tune in for an overview of the latest data.
Host: Pasi Antero Jänne, MD, PhD
Guest: Helena Yu, MD
Since the development of this educational activity, the Biologics License Application (BLA) seeking accelerated approval for patritumab deruxtecan (HER3-DXd), based on the HERTHENA-Lung01 Phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies, has been voluntarily withdrawn.
This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for implementing novel HER3-directed antibody-drug conjugates (ADCs). Our experts also focus on the adoption of a team-based approach to help you monitor and manage treatment-related adverse events associated with HER3-directed ADCs.
Host: Megan Conroy, MD, MA(Ed), FCCP
Guest: Nathan Falk, MD, MBA, FAAFP
Primary care providers can play a pivotal role in a patient’s COPD diagnosis by looking out for signs and symptoms and referring patients to pulmonologists when appropriate. The goal of this activity is to educate clinicians about managing patients with COPD symptoms and facilitating earlier diagnosis. Hear both primary care and pulmonary perspectives on diagnostic strategies.
CLINICIANS: To access additional resources for COPD diagnosis, visit chestnet.org/timely- diagnosis-COPD or scan the QR code.
Guest: Jörg Latus, MD
Patients with advanced kidney disease undergoing dialysis are frequently affected by the symptom clusters of chronic kidney disease-associated pruritus, or CKD-aP. These symptoms have the potential to significantly diminish patients’ quality of life by affecting sleep, mental health, and more. This activity reviews best practices for communicating with patients about symptoms and how to use shared decision-making strategies to develop personalized CKD-aP treatment plans.
Host: Jörg Latus, MD
Guest: Sydney Tang, MBBS, MD
In this review of clinical trial results, experts cover the latest data in IgA nephropathy and discuss how their application can improve outcomes for your patients. Studies presented include SPARTAN, SPARTACUS, and the PROTECT open-label extension. Throughout this conversation, faculty also consider the anticipated updates to the KDIGO clinical guidelines.
Host: John Russell, MD
Guest: Noel Dasgupta, MD, FACC
Guest: Sami Khella, MD
Amyloidosis, often unrecognized, misdiagnosed, and either inappropriately treated or undertreated, is a collection of diseases caused by the misfolding of proteins that aggregate into insoluble amyloid fibrils and deposit in tissues. There are two prominent forms of amyloidosis misfolding of light chain proteins (AL amyloidosis) and transthyretin protein misfolding (ATTR amyloidosis). In this program, two experts in amyloidosis, cardiologist Dr. Noel Dasgupta and neurologist Dr. Sami Khella, will explain the pathophysiology of amyloidosis, describe the prognosis for patients, discuss timely patient screening and diagnostic testing, and provide updated treatment options.
Host: Pablo Garcia-Pavia, MD, PhD
Guest: Francesco Cappelli, MD
Achieving optimal outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) remains a challenge as diagnosis is often delayed. Patients have a reduced life expectancy and experience debilitating pain and poor quality of life. Hear from the experts as they review the latest information on new and emerging treatment options for transthyretin amyloidosis and how this condition affects patients with cardiomyopathy.
Host: Brian Slomovitz, MD
Guest: Robert L. Coleman, MD, FACOG, FACS
In recent years, the treatment landscape for recurrent or metastatic cervical cancer has undergone significant shifts with FDA approvals of first-line pembrolizumab plus platinum-doublet with or without bevacizumab and second-line tisotumab vedotin. The introduction of frontline immune checkpoint blockade also added to the challenges faced by clinicians as they choose optimal regimens for their patients. In this online CME activity, Dr. Coleman and Dr. Slomovitz offer strategies for treatment selection and sequencing with immune checkpoint inhibitors and antibody-drug conjugates for relapsed cervical cancer. Tune in to hear their expert perspectives on biomarker testing, clinical trial evidence, and multidisciplinary management of adverse events associated with these therapies to make sure your patients are getting the most out of these advances.
Host: Mary E. Rinella, MD, FAASLD
Guest: Naga Chalasani, MD, FAASLD
Guest: Mazen Noureddin, MD, MHSc
Join us for a CME online broadcast replay of a live satellite symposium from ACG 2024, where experts discuss MASLD/MASH, a serious disease that is both chronic and progressive. What’s most concerning is that MASLD/MASH will soon be the most common indication for liver transplantation and a major driver of the development of liver cancer. Until recently there was no liver-directed therapy for this disease, and the metabolic benefits of pharmacologic modification of body weight were underappreciated. This activity will also provide practical interactive discussions of cardiometabolic pathophysiologic pathways; early identification and risk stratification; advances in treatment; monitoring for disease progression; and long-term medical management, including the role of incretin agonists.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Guest: Ira J. Goldberg, MD
Guest: Kausik Ray, MBChB, MD, MPhil
Guest: Christie Ballantyne, MD
Patients with familial chylomicronemia (FCS) and severe hypertriglyceridemia (SHTG) suffer from multiple complications, the most severe being acute pancreatitis. Current therapeutic agents, which include fibrates, omega-3 fatty acids, statins, and niacin, are generally ineffective. There are new developments with investigational siRNA therapeutics that silence APOC3, a key regulator of triglycerides and triglyceride-rich lipoproteins. Recent presentations have highlighted outcomes of trials evaluating APOC3 siRNA therapeutics in patients with FCS or SHTG. Drs. Ray, Goldberg, and Ballantyne discuss the findings of these trials, including the PALISADE trial and SHASTA-2 trial with plosaziran, and the potential implications for patients with FCS and SHTG.
Host: James Burton, DM, FRCP
Guest: Carol Pollock, AO, MBBS, PhD, FRACP, FAHMS
Patients with chronic kidney disease may be experiencing severe itch, known as CKD-associated pruritus (CKD-aP). Itching and related symptoms, such as reduced sleep and depression, may be causing a significant negative impact on their quality of life. Join our experts as they use real-world patient cases to illustrate how to identify and treat itch, provide relief from itch-related symptoms, and improve quality of life in your patients with CKD-aP.
Host: Jürgen Floege, MD
Guest: Jonathan Barratt, PhD
Given that IgA nephropathy is a leading cause of kidney failure, early diagnosis and treatment are essential. In the landscape of the many evolving treatment guidelines, how can nephrologists apply emerging evidence and utilize newer therapies to achieve proteinuria remission and maintain eGFR to improve the outcomes of their patients? Hear the experts answer these questions by reviewing a real-world clinical patient case.
Host: Gideon Hirschfield, MB, BChir, PhD
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.
Guest: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.
Host: Gideon Hirschfield, MB, BChir, PhD
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.
Guest: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.
Host: Gideon Hirschfield, MB, BChir, PhD
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.
Guest: Elizabeth K. Goacher, PA-C
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.
Guest: Elizabeth K. Goacher, PA-C
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.
Guest: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.
Host: Joyce O'Shaughnessy, MD
Hormone receptor-positive, HER2-negative cancer is the most common subtype of breast cancer. Initial treatment consists of surgery with or without radiotherapy or chemoradiotherapy, followed by adjuvant endocrine therapy for 5 to 10 years. Although endocrine therapy improves outcomes in these patients, recurrence is high (40% to 60% of patients). In disease with no BRCA mutation, treatment intensification by adding a CDK4/6 inhibitor to endocrine therapy has been shown to improve survival outcomes in high-risk disease. This activity explores the role of CDK4/6 inhibitors in HR-positive, HER2-negative early breast cancer in a patient case vignette, with an emphasis on shared decision-making.
Host: Raymond Townsend, MD
Guest: Melissa Magwire, RN, MSN, CDE
Guest: Michael Weber, MD
The outcomes of large clinical trials such as EMPA-REG have demonstrated that SGLT2 inhibitors are effective, but they do more than lower blood sugar and improve A1c. Similar to statins a long time ago, SGLT2 inhibitors offer many advantages for patients with potential atherosclerotic endpoints. Learn from our expert multidisciplinary panel as they explore the various approaches to treatment that can improve outcomes and quality of life in your patients with cardiorenal comorbidities.
Guest: Surya Bhatt, MD
Guest: MeiLan Han, MD, MS
Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.
Guest: Surya Bhatt, MD
Host: MeiLan Han, MD, MS
Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.
Guest: Surya Bhatt, MD
Guest: MeiLan Han, MD, MS
Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.
Guest: Surya Bhatt, MD
Guest: MeiLan Han, MD, MS
Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.
Guest: Surya Bhatt, MD
Guest: MeiLan Han, MD, MS
Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.
Host: Stefan H. Jacobson, MD, PhD
Guest: Carlos Narváez Mejía, MD
Chronic kidney disease-associated pruritus (CKD-aP) is an underreported and underdiagnosed condition that affects a significant proportion of patients with advanced kidney disease undergoing dialysis. But with the approval of difelikefalin, many patients have experienced symptom improvement not only in their itching but in their quality of life. Join the experts as they review the newest real-world data and clinical results of difelikefalin presented at ERA.
Guest: Surya Bhatt, MD
Guest: MeiLan Han, MD, MS
Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.
Host: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Guest: Scott Solomon, MD
Guest: Mikhail Kosiborod, MD
There are limited therapeutic options for patients with heart failure with mid-range or preserved ejection fraction (HFmrEF/HFpEF). Recently, new data were released on the efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists (MRAs) in patients with HFmrEF/HFpEF. What are the outcomes of the FINEARTS-HF trial with finerenone in this patient population, and what do these findings mean for clinical practice?
Three cardiologists discuss the topic of novel therapies, with a focus on nonsteroidal MRAs, to improve cardiovascular outcomes in patients with HFmrEF/HFpEF.
Guest: David Wheeler, MB, CHB, MD, FRCP
Hyperkalemia is a common complication in patients on renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. Join Dr. David Wheeler as he explores strategies for managing hyperkalemia while optimizing treatment benefits. Learn about patient-centered communication techniques, risk factors, and treatment options. Discover the importance of ongoing monitoring and follow-up to ensure optimal management. You don’t want to miss this opportunity to improve your clinical practice and enhance patient outcomes.
Host: Martha Kingman, DNP, FNP-C
Guest: Susanne McDevitt, DNP, ACNP-BC
This program focuses on early symptom identification and timely diagnosis in patients with pulmonary hypertension (PH). Learn how appropriate risk stratification can facilitate the effective management of PH. Our experts also stress the importance of asking the right questions and offer strategies for achieving well-rounded communication with patients and their caregivers.
Guest: Joseph F. Goldberg, MD
Guest: Roger McIntyre, MD
Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.
Guest: Joseph F. Goldberg, MD
Guest: Roger McIntyre, MD
Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.
Guest: Joseph F. Goldberg, MD
Guest: Roger McIntyre, MD
Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.
Guest: Roger McIntyre, MD
Guest: Joseph F. Goldberg, MD
Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.
Guest: Roger McIntyre, MD
Guest: Joseph F. Goldberg, MD
Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.
Guest: Roger McIntyre, MD
Guest: Joseph F. Goldberg, MD
Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.
Guest: C. Brendan Montano, MD
Guest: Anton P. Porsteinsson, MD
This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.
Guest: C. Brendan Montano, MD
Guest: Anton P. Porsteinsson, MD
This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.
Guest: C. Brendan Montano, MD
Guest: Anton P. Porsteinsson, MD
Early diagnosis and management of agitation in Alzheimer’s disease (AAD) is part of a comprehensive treatment plan. How can you help caregivers recognize subtle signs of AAD to facility early treatment? Our experts have the answers you need!
Guest: C. Brendan Montano, MD
Guest: Anton P. Porsteinsson, MD
This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.
Guest: C. Brendan Montano, MD
Guest: Anton P. Porsteinsson, MD
This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.
Guest: C. Brendan Montano, MD
Guest: Anton P. Porsteinsson, MD
This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.
Guest: C. Brendan Montano, MD
Guest: Anton P. Porsteinsson, MD
This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.
Guest: C. Brendan Montano, MD
Guest: Anton P. Porsteinsson, MD
This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.
Guest: C. Brendan Montano, MD
Guest: Anton P. Porsteinsson, MD
This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.
Guest: C. Brendan Montano, MD
Guest: Anton P. Porsteinsson, MD
This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.
Guest: C. Brendan Montano, MD
Guest: Anton P. Porsteinsson, MD
This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.
Guest: C. Brendan Montano, MD
Guest: Anton P. Porsteinsson, MD
This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.
Guest: Joseph F. Goldberg, MD
Guest: Roger McIntyre, MD
Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.
Guest: Joseph F. Goldberg, MD
Guest: Roger McIntyre, MD
Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.
Host: Joseph F. Goldberg, MD
Guest: Roger McIntyre, MD
Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.
Guest: Roger McIntyre, MD
Guest: Joseph F. Goldberg, MD
Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.
Guest: Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
Guest: Jyoti Patel, MD
The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). Early studies of MET tyrosine kinase inhibitors (TKIs) demonstrated limited clinical benefit; however, newer selective MET TKIs, such as capmatinib and tepotinib, have improved efficacy and acceptable safety profiles. In this activity, our experts assess the role of the role of MET gene aberrations in NSCLC and optimal testing modalities, as well as the clinical evidence supporting the use of MET TKIs and the potential role of these therapies in other subsets of disease.
Host: Sara M. Tolaney, MD, MPH
This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adverse events associated with these treatments to optimize patient outcomes. Designed for healthcare professionals, this program aims to enhance clinical decision-making in the evolving landscape of metastatic breast cancer care.
Host: Amir T. Fathi, MD
Guest: Courtney DiNardo, MD
Guest: Brian A. Jonas, MD, PhD
While the expanding arsenal of therapies available for patients with AML allows practitioners to further hone treatment and individualize care, the complexity of treatment decision-making requires careful consideration of potential risks and benefits of each treatment option. This real-world, case-based program will provide a format for community hematology-oncologists to hear current updates on the latest targeted therapies in AML and engage in pointed, practical discussions on how to best integrate these data into current and local AML treatment paradigms.
Host: Christina Economides, MD
Guest: Brian Howard, MD
Guest: David N. Kenigsberg, MD, FACC
Despite guideline-directed medical therapy, many patients with heart failure will continue to develop worsening symptoms and diminishing quality of life. Baroflex activation therapy (BAT) may be a treatment option for patients with heart failure with reduced ejection fraction. Data show clinical benefit with this treatment approach including long-term symptom improvement and reduction in all-cause death. To ensure optimal outcomes with BAT, a multidisciplinary approach is necessary. In this activity, expert faculty review the rationale for BAT therapy, the supporting clinical data, the surgical procedure for the BAT device, and best practices for optimizing a multidisciplinary approach.
Host: Matthew S. Davids, MD, MMSc
This program addresses the educational needs for relapsed or refractory (R/R) B-cell leukemias and lymphomas, particularly chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and reveals crucial practice gaps. Key challenges include managing poor treatment responses and patient health deterioration, necessitating therapies that extend survival and improve quality of life. Noncovalent Bruton’s tyrosine kinase inhibitors (ncBTKi) show promise in these cases, but clinicians need updated knowledge on their use, including response rates and management of associated toxicities. Additionally, the evolving landscape of B-cell lymphoma therapies complicates treatment choices, requiring expert guidance on individualized therapy selection and sequencing.
Host: Caroline Piatek, MD
Guest: Irina Murakhovskaya, MD
Warm autoimmune hemolytic anemia (wAIHA) is a rare condition characterized by the premature destruction of red blood cells mainly by pathogenic IgG optimally active at 37oC. Innovative targeted therapies to address wAIHA are emerging, and many are likely to greatly improve patient outcomes when they reach the clinic. Join Drs. Caroline Piatek and Irina Murakhovskaya as they discuss in detail current and emerging non-antibody and monoclonal antibody therapies for wAIHA and how each has the potential to dramatically improve the treatment landscape for wAIHA.
Host: Helena Yu, MD
The treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional therapies have yielded only modest results. However, recent findings show that targeting HER3 can produce dramatically improved clinical outcomes. Data are rapidly emerging from late-phase trials evaluating HER3-directed antibody-drug conjugate therapies, and it is thus crucial for community-based oncologists and interprofessional care team members to be aware of these findings so they can be prepared to integrate these therapies into practice once they are available. In this activity, expert faculty in the field of NSCLC will evaluate recent data supporting the use of HER3-directed ADCs in the treatment of locally advanced and metastatic EGFR-mutated NSCLC that has progressed on EGFR TKI therapy, optimal management strategies for treatment-emergent adverse events related to these therapies, and the potential role of these agents in the current treatment paradigm. Faculty will also discuss best practices for a successful multidisciplinary approach and for optimized shared decision-making with the patient. Finally, case discussions will conclude the program to reinforce key learnings from the didactic section of the activity.
Host: Shubham Pant, MD, MBBS
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
Host: Shubham Pant, MD, MBBS
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
Host: Ritu Salani, MD, MBA
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
Host: Shubham Pant, MD, MBBS
Host: Ritu Salani, MD, MBA
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
Host: Ritu Salani, MD, MBA
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
Host: Ritu Salani, MD, MBA
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
Host: Shubham Pant, MD, MBBS
Host: Ritu Salani, MD, MBA
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
Host: Ritu Salani, MD, MBA
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
Host: Thomas Kipps, MD, PhD
Host: William Wierda, MD, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: Thomas Kipps, MD, PhD
Host: William Wierda, MD, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: Thomas Kipps, MD, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: Thomas Kipps, MD, PhD
Host: William Wierda, MD, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: Talha Munir, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: William Wierda, MD, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: Thomas Kipps, MD, PhD
Host: William Wierda, MD, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: Talha Munir, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: William Wierda, MD, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: Thomas Kipps, MD, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: Saad Z. Usmani, MD, MBA, FACP
Guest: Joshua Richter, MD
Guest: Ashley Steinberger, APP
Release date: 8/15/2024
Expiration date: 8/15/2025
Estimated time to complete: 1.0 hour
This activity is not accredited for CME/CE credit.
This episode of Myeloma Matters reviews the latest data on bispecific antibody therapy for relapsed/refractory multiple myeloma (RRMM) discussed at the 2024 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings, including information about the use of fixed-duration dosing to mitigate adverse events (AEs).
The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in managing RRMM. Expert faculty will place abstract findings into clinical context and discuss strategies for preventing and managing AEs associated with bispecific antibody therapy in RRMM treatment, which include cytokine release syndrome (CRS), neurotoxicity, and infection.
Host: Justin Gainor, MD
Guest: Jacob Sands, MD
The treatment landscape of non-small cell lung cancer (NSCLC) has dramatically changed over the past 20 years. In recent years, the discovery of targetable molecular alterations and the development of targeted therapies have dramatically changed the treatment outlook for NSCLC. Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, is a receptor tyrosine kinase encoded by the ERBB2 proto-oncogene. Its activation affects downstream signaling pathways implicated in cell proliferation, survival, differentiation, and migration. The inclusion of HER2-directed antibody-drug conjugate (ADC) therapy in lung cancer is relatively new; these agents have been shown to greatly improve outcomes in patients with HER2-expressing NSCLC. In this case-based activity, expert faculty illustrate best practices for the use of HER2-directed ADCs in NSCLC.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
Guest: Sawsan As-Sanie, MD
GnRH antagonists have emerged as a viable first-line (or subsequent-line) medical therapy for the management of endometriosis. They have proven to be effective and safe, and their use avoids the flare response observed with GnRH agonists. Join Drs. Lee Shulman, Ayman Al-Hendy, and Sawsan As-Sanie as they discuss the estrogen threshold hypothesis from the perspective of GnRH antagonists and delve into clinical data supporting the use of GnRH antagonists in the medical management of endometriosis.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Sawsan As-Sanie, MD
Guest: Linda Bradley, MD
Endometriosis is often called a public health crisis for women. The delay in diagnosis can be greater than 10 years, during which time women suffer many physical and psychosocial issues that negatively impact their quality of life. Join Drs. Lee Shulman, Sawsan As-Sanie, and Linda Bradley as they identify strategies to overcome the diagnostic delay and its associated consequences.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Linda Bradley, MD
Guest: Melissa Simon, MD
The use of validated patient questionnaires, notably the SF-36 and EHP-30 scales, can greatly hasten the suspicion for an endometriosis diagnosis. Coupled with shared decision-making, or SDM, this patient-centered process can help ensure therapeutic adherence. Join Drs. Lee Shulman, Melissa Simon, and Linda Bradley as they discuss how to utilize the SF-36 and EHP-30 questionnaires in clinical practice and explore strategies to facilitate patient-healthcare provider discussions to improve overall short- and long-term patient outcomes.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Linda Bradley, MD
Guest: Melissa Simon, MD
Both provider- and patient-related healthcare disparities exist in the diagnosis and management of endometriosis. Many disparities derive from incorrect historical biases, while others are associated with social determinants of health, or SDOH. Join Drs. Lee Shulman, Linda Bradley, and Melissa Simon as they address these issues to help facilitate a patient-centered practice environment for all patients.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
Guest: James A. Simon, MD, CCD, NCMP, IF, FACOG
While both medical therapy and surgery often play a role in a woman’s journey with endometriosis, it is less clear how to best sequence these approaches to optimize a patient’s outcomes. Under what circumstances should you consider using a GnRH antagonist either before or after conservative surgery? Join Drs. Lee Shulman, Ayman Al-Hendy, and James Simon as they provide their collective thoughts on how best to sequence a GnRH antagonist with conservative surgery when managing endometriosis.
Host: Josep Tabernero, MD, PhD
Guest: Sara Lonardi, MD
Guest: Zev A. Wainberg, MD
Join us for a CME online broadcast replay of a live satellite symposium from ESMO GI 2024, where experts discuss strategies to overcome barriers to implementing a collaborative, biomarker-based approach in precision oncology for HER2+ GI cancers. Learn how to individualize therapeutic planning and sequencing for patients with HER2+ gastric/GEJ cancers and improve response and durability in mCRC with HER2-directed therapies. The symposium also covers the role of genomic profiling in guiding treatment decisions for HER2+ BTC and emphasizes the importance of interprofessional collaboration in managing adverse events associated with HER2-directed therapies in patients with GI cancer.
Host: Professor Sir John Hardy
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Marwan Noel Sabbagh, MD, FAAN, CCRI
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Professor Sir John Hardy
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Professor Sir John Hardy
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Marwan Noel Sabbagh, MD, FAAN, CCRI
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Marwan Noel Sabbagh, MD, FAAN, CCRI
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Professor Sir John Hardy
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Professor Sir John Hardy
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Marwan Noel Sabbagh, MD, FAAN, CCRI
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Marwan Noel Sabbagh, MD, FAAN, CCRI
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Matthew S. Davids, MD, MMSc
Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment paradigm as well as practice guidelines. Understanding key differences between the covalent and non-covalent BTK inhibitors, along with recent clinical trial data, will allow the clinical care team to introduce and integrate newly approved practice-altering therapies into current treatment plans to best meet the needs of their diverse patients with CLL/SLL or MCL.
In this educational activity, the expert faculty Chairperson will review the latest clinical evidence supporting the efficacy, safety, and tolerability of reversible, non-covalent BTK inhibitors to enhance incorporation into evidence-driven treatment sequencing for patients with CLL/SLL and MCL. The Chairperson will present a summary of the most relevant and timely advances with non-covalent BTK inhibitors while layering in their own personal, expert perspectives on how community care teams can …
Host: Joshua E. Reuss, MD
Alterations in ERBB2, the gene encoding HER2, have been recognized as drivers in the development of NSCLC. Therefore, HER2 is an actionable biomarker that has emerged in NSCLC diagnosis and treatment. HER2 mutations activate the HER2 signaling pathway, which facilitates oncogenic transformation and increases tumor proliferation. Although practice guidelines recommend molecular testing to identify alterations, the interpretation of tests and application of testing results to treatment decisions remain areas of educational need. Despite HER2 testing and targeted therapies changing the treatment practices for other solid tumors, the previous standard of care for NSCLC has resulted in persistently low 5-year survival rates in contrast to the high rates of survival for breast cancer. However, successful targeting of HER2-activating mutations in advanced NSCLC has now been achieved through the use of antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd). By effectively targeting HER2-activating mutations, ADCs have emerged as a promising treatment approach for advanced NSCLC.
In this educational activity, the expert faculty Chairperson will summarize relevant and timely information on NSCLC with HER2-mutant or overexpressing alterations and highlight the use of HER2-directed ADCs in NSCLC. The Chairperson will also provide their perspectives on the top key takeaways and why they are …
Host: Gabriela Hobbs, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Host: John Mascarenhas, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Host: Gabriela Hobbs, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Host: John Mascarenhas, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Host: Gabriela Hobbs, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Host: John Mascarenhas, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Host: Gabriela Hobbs, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Host: John Mascarenhas, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Host: John Mascarenhas, MD
Host: Gabriela Hobbs, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Guest: Marwan Noel Sabbagh, MD, FAAN, CCRI
Autophagy through sigma-1 receptor activation is a novel mechanism of action (MOA) in development for the treatment of Alzheimer’s disease. Join Dr. Marwan Noel Sabbagh as he breaks down this new MOA and recent clinical trial data.
Host: Jason Hafron, MD
Guest: Carissa Chu. MD
Despite treatment advances in genitourinary cancers, most patients will develop relapsed disease. Thus, new treatment approaches are needed, as well as improved methods to identify patients who will derive the optimal benefit from established and emerging therapies. Real-world data provide crucial insight into practice patterns and response rates, ultimately guiding individualization of treatment selection. In this activity, expert faculty assess key findings from prostate and bladder cancer trials and explore the relevance of these data to clinical practice.
Host: Ghassan K. Abou-Alfa, MD
Host: Aiwu Ruth He, MD, PhD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Ghassan K. Abou-Alfa, MD
Guest: Aiwu Ruth He, MD, PhD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Aiwu Ruth He, MD, PhD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Ghassan K. Abou-Alfa, MD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Ghassan K. Abou-Alfa, MD
Guest: Aiwu Ruth He, MD, PhD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Patrick Forde, M.B.B.Ch.
Guest: Jarushka Naidoo, MBBCh, MHS
Struggling to navigate the latest immunotherapy options for advanced NSCLC? This online CME program delves into optimizing dual immune checkpoint inhibitor therapy for patients with driver-negative advanced NSCLC. Learn how to leverage recent clinical trial data and patient characteristics to individualize treatment for the best possible outcomes, including for those with challenging brain metastases.
Host: Ghassan K. Abou-Alfa, MD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Aiwu Ruth He, MD, PhD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Ghassan K. Abou-Alfa, MD
Host: Aiwu Ruth He, MD, PhD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Aiwu Ruth He, MD, PhD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Ghassan K. Abou-Alfa, MD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Guest: Elizabeth Montgomery, MD
Guest: John L. Marshall, MD
This 1.0-credit activity provides oncology clinicians with practical insights into the importance of biomarker testing in patients diagnosed with metastatic colorectal cancer (mCRC), optimizing biomarker testing procedures, and the role of biomarkers in guiding treatment selection. Case vignettes will provide the basis for expert faculty discussions that explore ways to address common barriers to biomarker testing, benefits of tissue versus liquid biopsy, when to test and why, and the use of biomarkers in prediction and prognosis. Finally, individualizing the treatment of mCRC based on molecular (eg, RAS, BRAF, MSI-high, HER2), patient (eg, comorbidities, age), and tumor (location, resectability) characteristics, as well as patient preferences (quality of life, treatment toxicities) will be discussed.
Host: Perry Shieh, MD, PhD
Explore this on-demand webcast for an in-depth expert presentation and case discussion. This educational initiative is designed to help neurologists enhance their clinical approach by providing individualized, evidence-based care for adult SMA patients. Gain insights into the latest treatment options, safety and efficacy data, and effective patient communication strategies. Equip yourself with the knowledge to meet the unique clinical and psychosocial needs of adults with SMA and improve patient outcomes.
Host: Jennifer Caudle, DO
Guest: Patricia A. Mangan, RN, MSN, APRN-BC
The expansion of treatment options and strategies across the disease continuum is good news for patients who previously had few options; however, it can be a challenge for clinicians to stay up–to date in this very dynamic setting.
Guest: Jessica Griffiths, PA-C
Guest: Anna L. Rourke, NP
The BeAT-HF clinical trial showed that Barostim plus GDMT resulted in significant and meaningful improvements in exercise capacity, functional status, and quality of life. Learn best practices from advanced practice providers for successfully integrating Barostim into your clinical practice.
Host: Joseph Kim, MD, MPH
This video brief will discuss quality improvement in myelofibrosis management. To highlight ways to improve care for patients with both primary and secondary myelofibrosis, we’ll examine the experiences of two cancer centers that engaged in quality improvement programs.
- Molecular Testing
- Symptom Assessment
- Prognostic Risk Assessment
- JAK Inhibitor Therapy
- Shared Decision-Making
- Interprofessional Team-Based Care Coordination
Host: Diana V. Do, MD
Guest: Peter K. Kaiser, MD
This case consult with Dr Do and Dr Kaiser will consider a treatment-experienced patient referred for a 2nd opinion with decreased vision and prior diagnosis of neovascular AMD (nAMD). Dr Do and Dr Kaiser will discuss the recently approved anti-vascular endothelial growth factor (VEGF) agents with greater durability and longer dosing intervals that can decrease treatment burden. These retina specialists will evaluate the treatment responses in this patient and discuss whether to modify dosing intervals or switch therapies. This case illustrates the burden of care for patients with neovascular AMD (nAMD), and shows how to use the more durable anti-VEGF therapies in clinical practice to reduce treatment burden.
Host: Matthew Lunning, DO, FACP
In the rapidly evolving landscape of treating patients with relapsed or refractory large/diffuse large B-cell lymphoma (R/R LBCL/DLBCL), recent advancements are providing newfound hope. Immunochemotherapy with R-CHOP has long been the standard first-line treatment, but a significant portion of patients experience relapses and refractory disease. Until recently, salvage chemotherapy followed by autologous stem cell transplant (ASCT) was the only curative option. However, the introduction of novel therapies including T-cell engaging therapies has sparked a paradigm shift in R/R LBCL/DLBCL management.
In this transforming landscape, bispecific antibodies (BsAbs) stand out as a remarkable addition. They offer readily available, "off-the-shelf" options that do not require a manufacturing process tailored to each patient, with the advantage of lower rates of severe side effects compared to CAR T-cell therapy, making them a promising choice, particularly for older patients and those with late-stage disease.
This web-based, on-demand activity highlights key clinical trial evidence for bispecific antibodies targeting CD20 and CD3, and how to contextualize the rationale for and clinical utility of integrating CD20 X CD3 bispecific antibodies into community-based clinical practice. Expert faculty offer insights and advice based on their own real-world clinical practice experiences regarding the management and treatment of R/R DLBCL/LBCL and appropriate …
Host: Valeria Caso, MD, PhD
Guest: Ashkan Shoamanesh, MD
How can you improve long-term secondary stroke prevention in patients with a history of noncardioembolic ischemic stroke or transient ischemic attack (TIA)? An understanding of how to apply emerging clinical trial data is critical, as is the evaluation of potential alternative agents that could expand the therapeutic options for these patients. In this activity, our expert faculty will add to your knowledge by reviewing the coagulation cascade and the relevance of inhibiting factors XI and XIa in stroke management.
Host: Warner K. Huh, MD
Guest: Kimberly Levinson, MD, MPH
More effective triage tests are essential to improving cervical cancer risk-stratification and thus reducing the potential for unnecessary colposcopies. Enduring consensus cervical cancer screening recommendations, published in 2024, describe specific-use algorithms for p16/Ki-67 dual-staining cytology as an effective triage test, and also offer insight on how this test can best fit into clinical practice. Join Drs. Warner Huh and Kimberly Levinson as they first establish the rationale for using p16/Ki-67 dual-staining cytology and then break down the most salient algorithms for its use as offered in the recent recommendations.
Host: Hongya Chen, PharmD
Guest: Jennifer Day, PharmD
Guest: Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Join us in this educational endeavor to empower pharmacists with the latest insights and strategies for improved decision-making in ATTR-CM management. The program emphasizes the latest clinical insights in this evolving therapeutic landscape, addressing changes in diagnostic approaches over the last decade, and providing a nuanced perspective on ATTR-CM progression for more effective patient care. Don’t miss out on this opportunity to elevate the standard of care for your patients.
Host: Jhanelle E. Gray, MD
Guest: Joshua E. Reuss, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Jhanelle E. Gray, MD
Guest: Joshua E. Reuss, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Joshua E. Reuss, MD
Guest: Jhanelle E. Gray, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Joshua E. Reuss, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Jhanelle E. Gray, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Joshua E. Reuss, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Jhanelle E. Gray, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Jhanelle E. Gray, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Joshua E. Reuss, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Mazyar Shadman, MD, MPH
Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.
Host: Mazyar Shadman, MD, MPH
Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.
Host: Mazyar Shadman, MD, MPH
Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.
Host: Marianna Fontana, MD
Guest: Ronald Witteles, MD
Struggling to manage ATTR-CM? Our faculty are exploring the key considerations shaping current clinical trial design and how innovations might change our approach to the management of ATTR-CM in the future. They'll also discuss the use of outpatient diuretic intensification as a potential endpoint in trials and the ongoing challenge of defining and measuring “clinically meaningful benefit” for patients with ATTR-CM. Don't miss this opportunity to gain valuable insights and elevate your understanding of ATTR-CM treatment strategies!
Host: Javier Cortes, MD, PhD
Guest: Komal Jhaveri, MD, FACP
The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast cancer has greatly improved outcomes for patients in this setting. However, selecting the appropriate ADC and determining the optimal sequencing of these therapies may be challenging. In this activity, expert faculty in the field of breast cancer review the clinical burden related to endocrine-refractory disease, the role of ADCs in this setting, and best practices for the sequencing of these agents.
Host: Arshad M. Khanani, MD, MA
Guest: Karl Csaky, MD, PhD
Guest: Christina Y. Weng, MD, MBA, FASRS
Anti-vascular endothelial growth factor (VEGF) therapy acts on only 1 of the multiple pathways involved in the pathophysiology of retinal vascular diseases. Dual inhibition therapy that acts on 2 pathways—VEGF-A and angiopoietin-2 (Ang-2)—is now available. Are 2 pathways better than 1? Find out in this engaging roundtable-style eye care forum, which will demonstrate direct comparisons of dual anti-Ang-2/VEGF-A therapy and anti-VEGF monotherapy, enhanced by real-life case studies and anecdotes from the expert faculty members’ own practices.
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Craig M. McDonald, MD
Guest: Crystal Proud, MD
Guest: Aravindhan Veerapandiyan, MD
There are ongoing clinical trials and approvals for new genetic and non-genetic therapies for Duchenne muscular dystrophy. Determining the most suitable therapy for each patient is a developing process. This education covers dystrophin disruption and restoration, recent clinical trial outcomes from different treatment methods, and a case study exploring novel patient management strategies.
Host: Philip D. Harvey, PhD
Guest: Martin Strassnig, MD
This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
Host: Daniel Gaudet, MD, PhD
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
Host: Marc P. Bonaca, MD, MPH
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
Host: Marc P. Bonaca, MD, MPH
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
Host: Manesh R. Patel, MD
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
Host: Manesh R. Patel, MD
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
Host: Martin Strassnig, MD
Guest: Philip D. Harvey, PhD
This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
Host: Philip D. Harvey, PhD
Guest: Martin Strassnig, MD
This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
Host: Philip D. Harvey, PhD
Guest: Martin Strassnig, MD
This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
Host: Philip D. Harvey, PhD
Guest: Martin Strassnig, MD
This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
Host: Philip D. Harvey, PhD
Guest: Martin Strassnig, MD
This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
Host: Martin Strassnig, MD
Guest: Philip D. Harvey, PhD
This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
Host: Jennifer I. Lim, MD, FARVO
Guest: Carl Regillo, MD
What evidence do we have that blocking Ang-2 and VEGF-A is beneficial for patients? Tune in to hear Dr. Jennifer Lim and Dr. Carl Regillo examine the anatomical and biomarker evidence surrounding dual inhibition of Ang-2 and VEGF-A. Find out how bispecific targeting can benefit patients with neovascular age-related macular degeneration and diabetic macular edema.
Host: Martin Strassnig, MD
Guest: Philip D. Harvey, PhD
This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
Host: Martin Strassnig, MD
Guest: Philip D. Harvey, PhD
This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
Host: Martin Strassnig, MD
Guest: Philip D. Harvey, PhD
This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
Host: David Lynch, MB, BCh
Learn about making timely and accurate diagnoses of ILD, review radiologic patterns, and discuss the importance of multidisciplinary care in radiology.
Guest: Vallerie V. McLaughlin, MD
Host: Melisa A. Wilson, DNP, APRN, ACNP, BC
Host: Sarah Kesler, MD
Learn how to use guideline recommendations to establish a diagnosis of pulmonary arterial hypertension (PAH), develop evidence-based individualized treatment plans, and explore innovative therapies under investigation for PAH management. Hear from expert faculty on how to integrate the patient’s perspective when personalizing management plans for PAH.
Host: Pietro A. Canetta, MD
Expert Nephrologist Pietro Canetta, MD, MS, gives an overview of top abstracts from Kidney Week 2023 and new therapies for IgAN.
Host: Allison Betof Warner, MD, PhD
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Host: Hussein Tawbi, MD, PhD
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Host: Hussein Tawbi, MD, PhD
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Host: Hussein Tawbi, MD, PhD
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Host: Hussein Tawbi, MD, PhD
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Host: Allison Betof Warner, MD, PhD
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Host: Allison Betof Warner, MD, PhD
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Host: Mario E. Lacouture, MD
Host: Sapna Patel, MD
This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.
Host: Mario E. Lacouture, MD
This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.
Host: Sapna Patel, MD
This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.
Host: Jeffrey S. Weber, MD, PhD
This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.
Host: Sapna Patel, MD
This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.
Host: Jeffrey S. Weber, MD, PhD
This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.
Host: Richard Lafayette, MD, FACP
Expert Nephrologist Richard Lafayette, MD, FACP, gives an overview of top abstracts from Kidney Week 2023 and updates on emerging therapies for IgAN.
Host: Robert F. Kushner, MD
Host: Donna Ryan, MD
Host: Christopher D. Still, DO, FACN, FACP, FTOS
Obesity experts review obesity management strategies and provide insight on best practices for implementation in a primary care setting.
Host: Jonathan Chung, MD
Host: Seth Kligerman, MD
Learn from experts about differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases and the role of radiology in effectively diagnosing IPF with a multidisciplinary team approach.
Host: Robert Shin, MD, FANA, FAAN
Guest: Enrique Alvarez, MD, PhD
Guest: Jiwon Oh, MD, PhD, FRCPC
The field of multiple sclerosis (MS) is evolving at a rapid pace from disease modifying therapies (DMTs) to diagnostic/monitoring tools to fundamental principles that shape how clinicians think about the disease. Though such advancements are welcome, they continue to raise new questions about how to optimize management for individual patients. In this program, real clinicians who treat MS pose their most pressing clinical questions to an expert panel. These specialists then provide their best answers through literature and their own clinical experience.
Host: Cem Akin, MD, PhD
Guest: Daniel J. DeAngelo, MD, PhD
New tyrosine kinase inhibitor (TKI) treatment options can significantly reduce symptom burden in patients with moderate to severe indolent systemic mastocytosis (ISM). Studies report that systemic mastocytosis and ISM are often undiagnosed for years. Improve your diagnosis and treatment of ISM by tapping into the expertise of a multidisciplinary team, including allergists, gastroenterologists, and hematologists, and increase your awareness of diagnostic criteria, the varied presentations of ISM, and new treatment options that move beyond traditional anti-mediator therapy.
Host: Cem Akin, MD, PhD
Guest: Daniel J. DeAngelo, MD, PhD
Guest: Matthew J. Hamilton, MD
Patients with indolent systemic mastocytosis frequently report a symptom burden disproportionate to measurable disease burden. Anti-mediator intervention is not always successful in improving the quality of life of these patients. But the treatment landscape is changing. Join Drs. Cem Akin, Daniel DeAngelo, and Matthew Hamilton offer key clinical insights into this changing standard of care for ISM and discuss why allergists, hematologists, and gastroenterologists are at the vanguard of this change.
Guest: John Berk, MD
Guest: Sami Khella, MD
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
Guest: Sami Khella, MD
Guest: Marcia Waddington-Cruz, MD, PhD
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
Guest: Noel Dasgupta, MD, FACC
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
Guest: John Berk, MD
Guest: Sami Khella, MD
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
Guest: Sami Khella, MD
Guest: Marcia Waddington-Cruz, MD, PhD
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
Guest: Sami Khella, MD
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
Guest: Sami Khella, MD
Guest: Marcia Waddington-Cruz, MD, PhD
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
Guest: John Berk, MD
Guest: Noel Dasgupta, MD, FACC
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
Host: Omer Abdul Hamid, MD
Guest: Nancy Kuntz, MD
Guest: Migvis Monduy, MD
There are many unmet needs associated with the use of anti-inflammatory glucocorticoids when treating Duchenne muscular dystrophy, or DMD. These include multiple, often debilitating comorbidities that occur with long-term exposure. Join Drs. Hamid, Kuntz, and Monduy as they discuss key clinical trial data for a novel corticosteroid that may be a safer and possibly more effective option for patients with DMD than our current standard of care.
Host: Carl Regillo, MD
Guest: Jennifer I. Lim, MD, FARVO
What are the biomarkers that indicate dual targeting helps to reduce vascular leakage and suppress neovascularization? Join Dr. Carl Regillo and Dr. Jennifer Lim as they discuss the biomarkers of Ang-2 and VEGF-A suppression. Hear how to achieve earlier and faster fluid resolution in both neovascular age-related macular degeneration and diabetic macular edema.
Host: Jeffrey V. Matous, MD
Guest: Donna Catamero, NP
Guest: Ajai Chari, MD
GPRC5D-directed therapy is associated with impressive overall response rates and substantially positive clinical outcomes in heavily pretreated relapsed/refractory multiple myeloma. Identification and appropriate management of treatment-emergent adverse events is important to ensure that patients can stay on therapy safely to achieve optimal outcomes. In this educational podcast, myeloma experts weigh in on best-practice management strategies for these toxicities.
Host: Arshad M. Khanani, MD, MA
Guest: Theodore Leng, MD, MS
Let’s get real. Clinical trial data can be difficult to apply to retina practices. Patient populations are often limited, and injection schedules are strictly enforced in clinical trial settings. Fortunately, real-world evidence based on large registry data are amassing to shed light on current treatment practices and their effects on patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Join our expert faculty as they reveal real-world experience with anti-vascular endothelial growth factor (VEGF) therapy and novel dual inhibition therapy and assess how this information might be used to guide practice changes.
Host: Tauseef Ali, MD, FACG, AGAF
Host: Sabina Ali, MD
Host: Neil Nandi, MD, FACP
Host: Tina Aswani-Omprakash, MPH
A South Asian pediatric gastroenterologist discusses the epidemiology of IBD, distinct phenotypes, the latest clinical data from the mainland and diaspora, patient burden, and the importance of providing culturally competent care.
Host: Bruce L. Davidson, MD, MPH
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Alfonso J. Tafur, MD, MS, MBA, RPVI
Host: Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Meghan Mooradian, MD
This Patient Clinician Connection CME activity, led by Dr. Meghan Mooradian, focuses on the use of adjuvant immunotherapy in early-stage melanoma. The activity aims to educate clinicians on the role of immunotherapy in reducing the risk of disease recurrence post-surgery, particularly in patients with resected stage IIB to III melanoma. Through patient clinical vignettes and audience education vignettes, participants will gain insights into patient-centered approaches, shared decision-making, and the management of immune-related adverse events associated with adjuvant immunotherapy, ultimately enhancing their ability to optimize treatment outcomes and patient care in this setting.
Host: Alfonso J. Tafur, MD, MS, MBA, RPVI
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Anne Marie Morse, DO, FAASM
One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be easily implemented to ensure that the necessary steps are taken to get the patients into treatment and to improve patient outcomes. The purpose of this educational program is to help primary care providers learn how to screen for OSA, implement an OSA screening process, and develop a road map for cross-specialty collaborative relationships between sleep specialists and primary care clinicians.
Host: Seema Khosla, MD, FCCP, FAASM
One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be easily implemented to ensure that the necessary steps are taken to get the patients into treatment and to improve patient outcomes. The purpose of this educational program is to help primary care providers learn how to screen for OSA, implement an OSA screening process, and develop a road map for cross-specialty collaborative relationships between sleep specialists and primary care clinicians.
Host: Michael E. Yurcheshen, MD, FAASM
One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be easily implemented to ensure that the necessary steps are taken to get the patients into treatment and to improve patient outcomes. The purpose of this educational program is to help primary care providers learn how to screen for OSA, implement an OSA screening process, and develop a road map for cross-specialty collaborative relationships between sleep specialists and primary care clinicians.
Host: Kevin Trice, MD
One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be easily implemented to ensure that the necessary steps are taken to get the patients into treatment and to improve patient outcomes. The purpose of this educational program is to help primary care providers learn how to screen for OSA, implement an OSA screening process, and develop a road map for cross-specialty collaborative relationships between sleep specialists and primary care clinicians.
Host: Alcibiades J. Rodriguez, MD, FAASM
One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be easily implemented to ensure that the necessary steps are taken to get the patients into treatment and to improve patient outcomes. The purpose of this educational program is to help primary care providers learn how to screen for OSA, implement an OSA screening process, and develop a road map for cross-specialty collaborative relationships between sleep specialists and primary care clinicians.
Host: Scott Kaatz, DO, MSc, FACP, SFHM
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Bruce L. Davidson, MD, MPH
Host: Victor F. Tapson, MD
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Victor F. Tapson, MD
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Bruce L. Davidson, MD, MPH
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Deborah Siegal, MD, MSc, FRCPC
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Scott Kaatz, DO, MSc, FACP, SFHM
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Deborah Siegal, MD, MSc, FRCPC
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Guest: Durga Borkar, MD, MMCi
Guest: Diana Do, MD
Guest: Peter K. Kaiser, MD
The CME News Broadcast webinar will engage retina specialists and treating ophthalmologists with education needed to integrate the new durable anti-vascular endothelial growth factor (VEGF) therapies for neovascular AMD (nAMD) into clinical practice. This will include recent data on the efficacy, safety, and durability of these new therapies and the imaging approaches that can be used to facilitate monitoring of nAMD disease progression and treatment success. This activity will create understanding of the new durable therapies and how they can extend dosing intervals. The expert faculty will discuss the latest data on new anti-VEGF therapies with the potential to reduce treatment burden and improve vision outcomes.
Host: Arun B. Jesudian, MD
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Arun B. Jesudian, MD
Host: Robert Rahimi, MD, MSCR
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Robert Rahimi, MD, MSCR
Host: Arun B. Jesudian, MD
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Patricia P. Bloom, MD
Host: Robert Rahimi, MD, MSCR
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Patricia P. Bloom, MD
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Patricia P. Bloom, MD
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Robert Rahimi, MD, MSCR
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Arun B. Jesudian, MD
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Michael A. Levine, MD, FAAP, MACE, FACP
Host: B. Michelle Schweiger, DO, MPH
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
Host: Michael A. Levine, MD, FAAP, MACE, FACP
Host: B. Michelle Schweiger, DO, MPH
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
Host: Michael A. Levine, MD, FAAP, MACE, FACP
Host: B. Michelle Schweiger, DO, MPH
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
Host: Michael A. Levine, MD, FAAP, MACE, FACP
Host: B. Michelle Schweiger, DO, MPH
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
Guest: Aasma Shaukat, MD, MPH
Guest: David Johnson, MD
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
Guest: Aasma Shaukat, MD, MPH
Guest: David Johnson, MD
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
Guest: David Johnson, MD
Guest: Douglas Rex, MD
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
Guest: David Johnson, MD
Guest: Aasma Shaukat, MD, MPH
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
Guest: Douglas Rex, MD
Guest: Aasma Shaukat, MD, MPH
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
Guest: Douglas Rex, MD
Guest: Aasma Shaukat, MD, MPH
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
Guest: Douglas Rex, MD
Guest: David Johnson, MD
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
Guest: David Johnson, MD
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
Host: Stephen Krieger, MD
Guest: Tirisham Gyang, MD
Guest: Augusto Miravalle, MD, FAAN
New strategies for early intervention in multiple sclerosis (MS) are focusing on progression independent of relapse. These strategies include incorporation of high-efficacy disease modifying therapies in the early stages of MS coupled with effective management of treatment-related adverse events. Join Drs. Stephen Kreiger, Tirisham Gyang, and Augusto Miravalle for a lively, case-based exchange that will provide key ideas to take back into the clinic.
Guest: Douglas Rex, MD
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
Host: Manesh R. Patel, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Sean Pokorney, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Sean Pokorney, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Sean Pokorney, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Mina K. Chung, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Manesh R. Patel, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Kevin Thomas, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Manesh R. Patel, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Sean Pokorney, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Caitlin Costello, MD
Guest: Sagar Lonial, MD, FACP
Bispecific antibodies are the newest immunotherapies approved for heavily pretreated relapsed/refractory myeloma, and they are shown to double response rates. Are you ready to use them in your practice? Join Drs. Costello and Lonial as they explore a case study that demonstrates how to select patients, prepare them for treatment, and effectively manage treatment-related side effects.
Host: David J. Kuter, MD, DPhil
Guest: Spero R. Cataland, MD
Guest: Catherine Broome, MD
Guest: Cindy Neunert, MD, MSCS
Because immune-mediated rare blood disorders are uncommon, healthcare providers often lack the knowledge and experience necessary to identify, diagnose, and treat them in accordance with best practices. As a result, there are significant gaps in care, including delays in diagnosis and suboptimal treatment. To ensure that more patients with these rare disorders are offered quality, evidence-based care, it’s essential that healthcare providers possess up-to-date information about best practices and new developments in this area of medicine. In this activity, composed of 3 podcasts, an expert moderator will interview 3 expert faculty members about evidence-based guidelines for the diagnosis and treatment of acquired thrombotic thrombocytopenic purpura, developments in the diagnosis and treatment of cold agglutinin disease, and the challenges of achieving enduring remission in patients with immune thrombocytopenia.
Host: Jyoti Patel, MD
Guest: Pasi Antero Jänne, MD, PhD
Dive into the forefront of precision oncology with Drs. Pasi Janne and Jyoti Patel, where they unravel the potential of HER3-directed antibody-drug conjugates (ADCs) in revolutionizing treatment for NSCLC. Discover the transformative potential of HER3-directed ADCs in overcoming resistance to EGFR-targeted TKI therapies. This program offers a unique blend of trial results and practical strategies through the lens of a clinical case. Join us to lead the change in cancer care.
Host: Helena Yu, MD
Dr. Helena Yu of Memorial Sloan Kettering Cancer Center presents an insightful overview of HER2 targeted therapy in non-small cell lung cancer (NSCLC), emphasizing the critical role of broad molecular profiling in ensuring effective treatment, particularly for the 2-4% of NSCLC patients with HER2 mutations. Dr. Yu highlights the effectiveness of newer antibody–drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) for NSCLC with HER2 mutations, while also detailing identification and management of potential side effects. Through a patient engagement vignette, she underscores the importance of aligning treatment choices with patient and clinician goals, highlighting shared decision-making in managing HER2-mutant NSCLC.
Host: Caitlin Costello, MD
Guest: Sagar Lonial, MD, FACP
Dive into the cutting-edge realm of bispecific antibodies for relapsed/refractory multiple myeloma with our experts, Dr. Caitlin Costello and Dr. Sagar Lonial. They explore the efficacy, safety, and practical integration of bispecific antibodies into clinical practice. Tune in to gain invaluable insights on optimizing patient care and navigating treatment-related adverse events to elevate your oncology practice.
Host: Benjamin Levy, MD
Guest: Alexander Spira, MD, PhD, FACP
Drs. Benjamin Levy and Alex Spira discuss the emerging role of TROP2 as a therapeutic target in non-small cell lung cancer (NSCLC) on ReachMD. They delve into the mechanisms and clinical implications of TROP2-targeted antibody-drug conjugates (ADCs), highlighting ongoing clinical trials evaluating their safety and efficacy. The conversation covers the potential of these therapies to change treatment paradigms, especially in the context of TROP2 overexpression associated with poor prognosis in lung cancers. They also address the nuances of managing side effects and the importance of understanding TROP2's role in cancer regulation, underscoring the significance of keeping up-to-date with the latest clinical trial data in this rapidly evolving field.
Host: Naomi Fisher, MD
Guest: Florian Rader, MD
Dive into the realm of hypertension management through a chapterized expert interview CME activity on ultrasound renal denervation. In the first chapter, explore the significance of addressing hypertension. Delve into the sympathetic nervous system, ultrasound renal denervation mechanism, and clinical trial data in the second chapter. The third chapter offers dual perspectives on the role of the Hypertension Center, and walks learners through the development process for effective implementation. Gain comprehensive insights from leading experts, Drs. Naomi Fisher and Florian Rader, in this educational series.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Charu Aggarwal, MD, MPH
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Charu Aggarwal, MD, MPH
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Charu Aggarwal, MD, MPH
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Charu Aggarwal, MD, MPH
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Charu Aggarwal, MD, MPH
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Charu Aggarwal, MD, MPH
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Sagar Lonial, MD, FACP
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Charu Aggarwal, MD, MPH
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Heidi M. Munger Clary, MD, MPH
Guest: Jay Salpekar, MD, FANPA
A crucial aspect of epilepsy care that often goes underappreciated is the intersection of epilepsy and depression. Join Drs. Munger Clary and Salpekar, leading experts in the field, as they raise awareness about the high prevalence of comorbid mental health disorders, particularly depression, among epilepsy patients. Together, they explore the bidirectional relationship between epilepsy and depression, emphasizing the importance of early detection and comprehensive treatment. They’ll also cover implantable therapies, specifically vagal nerve stimulation devices, as potential tools to manage both epilepsy and depression.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Andrew Keaveny, MD
Guest: Don Rockey, MD
Extrahepatic manifestations of decompensated cirrhosis confer significant additional risks for mortality, and a multidisciplinary team of healthcare professionals is involved in the care of these patients. This program will discuss two critical aspects of advanced liver disease: variceal bleeding and hepatorenal syndrome (HRS). These complications pose significant challenges in the management of patients with cirrhosis. Clinically-significant portal hypertension, identified by a hepatic venous pressure gradient >10mmHg, predicts the development of variceal hemorrhage, hepatic encephalopathy, ascites, and HRS, all hallmarks of decompensation and multi-organ failure. Faculty will discuss a common patient presentation to highlight best practices in evidence-based care of patients with variceal bleeding and HRS/acute kidney injury.
Guest: Kathleen Moore, MD, MS
The establishment of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as an effective therapeutic strategy in ovarian cancer has been made possible through a deepened understanding of the impact of mutations in DNA damage response pathways on tumorigenesis. The success of this approach has led to the regulatory approval of PARP inhibitors for the treatment of patients with advanced ovarian cancer. PARP inhibitors as first-line maintenance therapy demonstrate a substantial and clinically meaningful benefit in progression-free survival among patients with newly diagnosed advanced ovarian cancer, including BRCA-mutated and HRD-positive disease. In some cases, regulatory approvals of PARP inhibitors have brought approvals for companion diagnostics or complementary diagnostic tests. Together, these developments have yielded a wealth of new options for managing ovarian cancer but have also complicated the effectiveness of the multidisciplinary care team, which is essential for the highest standard of cancer care delivery, linking emerging treatments and guidelines with patient education and empowerment. Another vital component of ovarian cancer care is the use of shared decision-making and patient-reported outcomes to increase patient satisfaction, therapy adherence, and quality of life.
In this educational activity, expert faculty will review the role of genetic testing in identifying patients likely to benefit …
Guest: Kathleen Moore, MD, MS
The establishment of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as an effective therapeutic strategy in ovarian cancer has been made possible through a deepened understanding of the impact of mutations in DNA damage response pathways on tumorigenesis. The success of this approach has led to the regulatory approval of PARP inhibitors for the treatment of patients with advanced ovarian cancer. PARP inhibitors as first-line maintenance therapy demonstrate a substantial and clinically meaningful benefit in progression-free survival among patients with newly diagnosed advanced ovarian cancer, including BRCA-mutated and HRD-positive disease. In some cases, regulatory approvals of PARP inhibitors have brought approvals for companion diagnostics or complementary diagnostic tests. Together, these developments have yielded a wealth of new options for managing ovarian cancer but have also complicated the effectiveness of the multidisciplinary care team, which is essential for the highest standard of cancer care delivery, linking emerging treatments and guidelines with patient education and empowerment. Another vital component of ovarian cancer care is the use of shared decision-making and patient-reported outcomes to increase patient satisfaction, therapy adherence, and quality of life.
In this educational activity, expert faculty will review potential treatment-related complications that may occur with PARP inhibitor-based therapy. These …
Host: Manesh R. Patel, MD
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Rhonda Cadena, MD, FNCS, FCCM
Host: Adrian R. Parry-Jones, FRCP, PhD
Host: Stuart Connolly, MD, FRCPC
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: Ashkan Shoamanesh, MD
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: Valeria Caso, MD, PhD
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: Mike Sharma, MD, MSc, FRCPC
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Greg Albers, MD
Host: Rhonda Cadena, MD, FNCS, FCCM
Host: Adrian R. Parry-Jones, FRCP, PhD
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Stuart Connolly, MD, FRCPC
Host: Rhonda Cadena, MD, FNCS, FCCM
Host: Greg Albers, MD
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Adrian R. Parry-Jones, FRCP, PhD
Host: Stuart Connolly, MD, FRCPC
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Natalie Kreitzer, MD, MS
Host: Adrian R. Parry-Jones, FRCP, PhD
Host: Rhonda Cadena, MD, FNCS, FCCM
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: Mikhail Kosiborod, MD
Guest: Biff F. Palmer, MD
Delve into refining the management of hyperkalemia in CKD patients and their associated comorbidities, striking a delicate balance that preserves guideline-recommended RAASi therapy. Join Dr. Biff Palmer and Dr. Mikhail Kosiborod as they guide the exploration of novel potassium binders for optimal hyperkalemia management, all while upholding the integrity of established treatment guidelines.
Guest: Carl Danzig, MD
Guest: Arshad M. Khanani, MD, MA
Dr. Carl Danzig, Director of Vitreoretinal Services and Retina Clinical Research of Rand Eye Institute in Deerfield Beach, Florida, and Dr. Arshad Khanani, Clinical Associate Professor at the University of Nevada in Reno, Nevada, will present key data about anti-VEGF therapies for retinal vein occlusion (RVO). Join the discussion on developing treatment protocols that use current therapies most effectively to improve outcomes and individualized treatment protocols for patients who are nonresponsive to first-line therapies and who require chronic treatment for macular edema.
Host: Scott Kahan, MD, MPH
Guest: Ken Fujioka, MD
Guest: Carol Wysham, MD
Embark on a transformative journey to redefine patient care for individuals with type 2 diabetes by transitioning from the conventional focus on glycemic control to a pioneering obesity-centered approach. Immerse yourself in the expertise of 3 distinguished professionals: Drs. Carol Wysham, Scott Kahan, and Ken Fujioka. These esteemed experts will guide you through the dynamic terrain of weight loss medications, including GLP-1/GIP dual receptor agonists, and provide invaluable insights to elevate and optimize patient outcomes in the realm of type 2 diabetes management.
Host: Jessica Ailani, MD
Guest: Dawn C. Buse, PhD
Half of the women in the US with migraine are never diagnosed. Of those who are, the journey to effective treatment may last a decade or longer. But newer and more effective targeted treatments are beginning to make a difference. Join Drs. Jessica Ailani and Dawn Buse as they discuss a novel approach to managing migraine and interview a patient whose migraine journey is unfortunately one traversed by many women.
Guest: Michael J. Mauro, MD
Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by disordered growth of myeloid cells. The hallmark of chronic myeloid leukemia (CML) is an acquired reciprocal translocation between the long arms of chromosomes 9 and 22. This translocation results in the BCR-ABL1 fusion protein, with constitutively active tyrosine kinase activity, and is the underlying driver of CML. BCR-ABL1 testing is widely used to confirm the clinical diagnosis of CML and to assess response to TKI therapy. The development of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of CML, dramatically improving patient outcomes. Although most CML patients experience excellent clinical outcomes, some CML patients (20-30%) exhibit an acquired resistance to treatment during the disease course, often requiring second- or third-line therapy. Novel TKIs designed to overcome TKI resistance have shown efficacy in early clinical trials and are offering promise to CML patients who do not respond to any of the multiple therapeutic options currently available.
AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions and answers provide incredible insight and address
Guest: Sara M. Tolaney, MD, MPH
HER2 is a well-established negative prognostic factor for metastatic breast cancer (mBC) and determining HER2 levels is essential for proper treatment decisions. Several studies have reported scoring inaccuracies for HER2 status, particularly in the low range (0 and 1+), and challenges with IHC assessment and interpretation can lead to the misassignment of many patients for treatment. Antibody-drug conjugates (ADCs), a new and promising class of therapeutics designed as targeted therapy for mBC, target and kill tumor cells while sparing healthy cells. Rapid advances in ADC development are transforming HER2-positive and HER2-low mBC patient outcomes. With recent FDA approvals of HER2-targeting agents and emerging positive trial data, clinicians and pathologists are faced with staying abreast of and integrating new treatment options into real-world clinical practice.
AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions and answers provide incredible insight regarding testing methodologies to classify metastatic breast cancer according to HER2 status, addressing the strengths and limitations of different techniques. The clinical implications of these tests for guiding HER2-targeted therapies such as antibody-drug conjugates will be addressed, as well as evidence-based methods to address challenges such as treatment-associated adverse events and drug resistance, and key …
Host: Samuel J. Klempner, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Host: Yelena Janjigian, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Host: Samuel J. Klempner, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Host: Yelena Janjigian, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Host: Yelena Janjigian, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Host: Yelena Janjigian, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Host: John K. Botson, MD, RPh
Guest: Xu He, MD
Many patients with gout don’t achieve their target urate levels with conventional urate-lowering therapies. Join renowned experts Drs. Xu He and John Botson as they dissect the potential benefits of urate reduction, discuss management options for patients with uncontrolled gout, and underscore the critical significance of timely referrals from primary care to specialty care in optimizing outcomes for patients with uncontrolled gout.
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Renuka Jain, MD
The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.
Host: Renuka Jain, MD
Guest: Steven Yakubov, MD, MSCAI, FACC
The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.
Host: Hemal Gada, MD
The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.
Host: Pam R. Taub, MD, FACC, FASPC
Guest: Steven Yakubov, MD, MSCAI, FACC
The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Guest: Caron A. Jacobson, MD
CD19-directed chimeric antigen receptor (CAR) T-cell therapies are revolutionizing the treatment of aggressive non-Hodgkin lymphoma (NHL), offering patients with refractory/relapsed disease the chance for a potential cure after a single infusion. However, the widespread use of CAR T-cell therapies faces several challenges, from the production of the therapies to the management of toxicities to issues of inpatient vs outpatient administration. While CAR T-cell therapies have historically been given in the inpatient setting, interest in outpatient delivery is growing, and this option may become more feasible if logistical issues and lack of multidisciplinary collaboration between the community provider and the CAR-T cell therapy center can be overcome.
AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer, helping to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent educational series on CAR T-cell therapies in large B-cell lymphoma regarding practical considerations for CAR T-cell therapies.
Host: Michael J. Thorpy, MD
Guest: Anne Marie Morse, DO
Half of children who develop narcolepsy do so before age 16. However, the majority do not get diagnosed in childhood. In fact, many children are misdiagnosed and, as a result, are medically treated for conditions they do not have. Join Drs. Thorpy and Morse as they delineate the differences between adult and pediatric narcolepsy and offer strategies to optimize treatment adherence and outcomes in children.
Host: Clete A. Kushida, MD, PhD
Guest: Michael J. Thorpy, MD
Three different sodium oxybate formulations are available for the management of narcolepsy with/without cataplexy. While they are equally efficacious, there are differences such as dosing that require shared decision- making between patient and clinician to select the right formulation for each patient. Join Drs. Kushida and Thorpy as they share their approach to making the right treatment decision for each patient, one that includes ensuring patient preferences are considered.
Host: Manesh R. Patel, MD
Host: Sean Pokorney, MD
Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.
Host: Manesh R. Patel, MD
Host: Sean Pokorney, MD
Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.
Host: William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPE
Guest: Georges Chahoud, MD, FACC, FAHA, FHFSA, FASE
Guest: Patrick J. McCann, MD
Even with guideline-directed medical therapy, or GDMT, many patients with heart failure are limited in their daily activities, due to increasing symptoms and reduced functionality. However, new data from BeAT-HF, a clinical trial that examines the long-term effects of baroreflex activation therapy, or BAT, shows that BAT may provide patients with sustained and durable benefits in exercise capacity, functional status, and quality of life.
Host: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Guest: Atoosa Rabiee, MD
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Marlyn Mayo, MD
Guest: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Manesh R. Patel, MD
Host: Sean Pokorney, MD
Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.
Host: Marlyn Mayo, MD
Guest: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Guest: Atoosa Rabiee, MD
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Atoosa Rabiee, MD
Guest: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Guest: Marlyn Mayo, MD
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Atoosa Rabiee, MD
Guest: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Guest: Marlyn Mayo, MD
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Manesh R. Patel, MD
Host: Sean Pokorney, MD
Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.
Host: Martin Reincke, MD
Guest: Maria Fleseriu, MD, FACE
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
Host: Maria Fleseriu, MD, FACE
Guest: Martin Reincke, MD
Designed with primary care physicians (PCPs) in mind, this continuing medical education activity focuses on efficient screening for Cushing’s syndrome by emphasizing clinical indicators and targeted tests. Tune in to discover practical tools that can help you reach an accurate diagnosis by distinguishing between physiologic and pathologic causes. Our experts also discuss when to refer for a specialist consultation. PCPs play a pivotal role in early detection and management of Cushing's syndrome, so be sure to add these skills to your armamentarium in the primary care setting.
Host: Maria Fleseriu, MD, FACE
Guest: Richard Auchus, MD
Take your endocrinology practice to the next level and gain in-depth knowledge on disease recurrence, treatment options, and patient-centered care strategies. Join us as Dr. Maria Fleseriu and Dr. Richard Auchus discuss ways to optimize outcomes for your patients with Cushing's disease.
Host: Maria Fleseriu, MD, FACE
Guest: Martin Reincke, MD
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
Host: Kevin C.J. Yuen, MD
Guest: Eliza B. Geer, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Susan L Samson, MD, PhD, FRCPC, FACE
Guest: Kevin C.J. Yuen, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Susan L Samson, MD, PhD, FRCPC, FACE
Guest: Eliza B. Geer, MD
Guest: Kevin C.J. Yuen, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Eliza B. Geer, MD
Guest: Susan L Samson, MD, PhD, FRCPC, FACE
Guest: Kevin C.J. Yuen, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Susan L Samson, MD, PhD, FRCPC, FACE
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Eliza B. Geer, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Eliza B. Geer, MD
Guest: Kevin C.J. Yuen, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Kevin C.J. Yuen, MD
Guest: Susan L Samson, MD, PhD, FRCPC, FACE
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Maria Fleseriu, MD, FACE
Guest: Richard Auchus, MD
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
Host: Maria Fleseriu, MD, FACE
Guest: Richard Auchus, MD
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
Host: Richard Auchus, MD
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
Host: Maria Fleseriu, MD, FACE
Guest: Richard Auchus, MD
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
Host: Maria Fleseriu, MD, FACE
Guest: Martin Reincke, MD
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
Host: Martin Reincke, MD
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
Host: Manesh R. Patel, MD
Host: Steve Deitelzweig, MD, MMM, SFHM, FACP, FACC
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Tatjana Potpara, MD, PhD, FESC
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: John Alexander, MD, MHS
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Elaine Hylek, MD, MPH
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Tatjana Potpara, MD, PhD, FESC
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Dennis I. Narcisse, MD, MS
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Dennis I. Narcisse, MD, MS
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Manesh R. Patel, MD
Host: Elaine Hylek, MD, MPH
Host: Renato D. Lopes, MD, MHS, PhD
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Geoffrey Barnes, MD, MSc
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Geoffrey Barnes, MD, MSc
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Geoffrey Barnes, MD, MSc
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Manesh R. Patel, MD
Host: John Alexander, MD, MHS
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Christopher B. Granger, MD
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Steve Deitelzweig, MD, MMM, SFHM, FACP, FACC
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: John Alexander, MD, MHS
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Christopher B. Granger, MD
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Manesh R. Patel, MD
Host: Elaine Hylek, MD, MPH
Host: Renato D. Lopes, MD, MHS, PhD
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Guest: Kathleen Moore, MD, MS
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Guest: Kathleen Moore, MD, MS
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Guest: Kathleen Moore, MD, MS
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Guest: Kathleen Moore, MD, MS
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Host: Kathleen Moore, MD, MS
Guest: Brad McGregor, MD
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Host: Annie Levesque, MD, MSc
Guest: Ethan A. Cowan, MD
Alcohol use disorder, or AUD, is a rising health crisis that often goes undiagnosed. And many patients that are diagnosed with AUD do not receive appropriate pharmacologic intervention or even a referral. Join Drs. Levesque and Cowan in this case-based educational program as they provide critical diagnostic and treatment strategies for use in the office/clinic setting and the Emergency Department.
Guest: James M. Cleary, MD, PhD
Guest: Kathleen Madden, FNP, MSN, AOCNP, APHN
This on-demand features an expert case discussion on the current landscape of gastric cancer, from patient selection to treatment management to maximize benefit. Join Dr. James M. Cleary, Associate Professor of Medicine at Harvard Medical School, and Kathleen Madden, Family Nuse Practitioner at the Melanoma Program at NYU Langone Perlmutter Cancer Center in New York, NY, to learn more.
Guest: Colleen Kelly
Guest: Andrea Banty, DNP, FNP
Explore this series of three modules on C difficile infection and the impact of gut dysbiosis on the development of recurrent disease with Dr. Colleen Kelly, Associate Professor of Medicine in the Division of Gastroenterology at Warren Alpert Medical School of Brown University in Providence, Rhode Island, and Andrea Banty, Nurse Practitioner of Gastroenterology at Cedars-Sinai IBD Center in Los Angeles.
Guest: Susana Banerjee, MBBS, MA, FRCP, PhD
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Guest: Shubham Pant, MD, MBBS
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Guest: Shubham Pant, MD, MBBS
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Guest: Brad McGregor, MD
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Host: Kathleen Moore, MD, MS
Guest: Susana Banerjee, MBBS, MA, FRCP, PhD
Guest: Shubham Pant, MD, MBBS
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Host: Ana C. Krieger, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Logan Schneider, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Logan Schneider, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Logan Schneider, MD
Host: Diana Kimmel
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Matthew Davis, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Matthew Davis, MD
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Matthew Davis, MD
Host: Logan Schneider, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Matthew Davis, MD
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Kevin Trice, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Kevin Trice, MD
Host: Ana C. Krieger, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Kevin Trice, MD
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Kevin Trice, MD
Host: Ana C. Krieger, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Guest: Terry Faleye, MPAS, PA-C
Guest: Jonathan I. Silverberg, MD, PhD, MPH
Atopic dermatitis (AD) significantly impacts physical, social, and psychological well-being. Recently, novel and more effective treatment options have been approved, including those targeting interleukin (IL)-13. Tune in to watch this webcast on incorporating these agents to optimize care for patients with moderate to severe AD with Terry Faleye, Dermatology Physician Assistant at DermSurgery Associates in Houston, Texas, and Dr. Jonathan Silverberg, Professor, Director of Clinical Research, and Director of Patch Testing at George Washington University School of Medicine and Health Sciences in Washington, DC.
Host: Anita L. Nelson, MD
Guest: Barbara Dehn, Np, FAANP, NCMP
Understanding the physiologic basis for the vasomotor symptoms of perimenopause/menopause has led to an improved ability to match a therapeutic approach to each individual patient. New and improved agents are helping to facilitate this dynamic. Join Anita Nelson, MD, and Barbara Dehn, NP, as they provide insights into making the right treatment decision for each patient—one that includes ensuring patient preferences are considered.
Host: Raymond Townsend, MD
Despite many available drug therapies, patients with hypertension continue to experience elevated blood pressures, putting them at risk for cardiovascular-related morbidities and mortality. However, renal denervation, a minimally invasive procedure, has been shown to result in sustained and durable reductions in blood pressure. Find out what this approach could mean for your patients.
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
Guest: Rasheda Persinger MSN, AGNP-C, AOCNP
Learn from a leading expert in the field about the most recent recommendations for biomarker/molecular testing and personalized treatment plans for patients with non-small-cell lung cancer (NSCLC) based on testing results.
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
Guest: Mary Weinstein Dunn
Learn about evolving standards in the care of patients with advanced renal cell carcinoma in this on-demand webcast capturing a live presentation by Mary Weinstein Dunn, MSN, NP-C, OCN, RN.
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
Guest: Frank dela Rama, RN, MS, AOCNS, AGN-BC
Learn about the APP’s evolving role in caring for patients receiving PARP inhibitors for prostate cancer in this on-demand webcast capturing a live presentation by Clinical Nurse Specialist Frank dela Rama, RN, MS, AOCNS, AGN-BC.
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
Guest: Jeremy Force
Get up to date on how APPs can optimize care for patients with HER2-positive breast cancer in this on-demand webcast capturing a live presentation by Dr Jeremy Force.
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
Guest: Robert Lentz, MD
Get up to date with this on-demand webcast from a live symposium focused on the latest approaches to treating patients with metastatic colorectal cancer, including immunotherapy and targeted therapy strategies.
Guest: Donna Ryan, MD
Guest: Daniel Zalinov, PA-C
Guest: Megan Adelman, PharmD, BCPS, BCGP, CDCES
Experts review best practices for the incorporation of motivational interviewing and shared decision-making strategies to improve the treatment of obesity. Tune in with Dr. Megan Adelman, Clinical Pharmacist of Family Medicine at Cleveland Clinic Akron General in Ohio, Dr. Donna Ryan, Professor Emerita at Pennington Biomedical Research Center in Baton Rouge, Louisiana, and Daniel Zalinov, Physician Assistant who specializes in Internal Medicine at Atrium Health in Charlotte, North Carolina.
Guest: Joyce O'Shaughnessy, MD
By 2040, the global breast cancer burden is expected to increase by 40%, resulting in more than 3 million new cases and 1 million deaths per year. Approximately 65% of cases among women less than 50 years of age and 75% of cases among women over 50 years of age are classified as HR+/HER2-. Although endocrine therapy is employed as standard-of-care treatment for many patients with HR+/HER2- breast cancer, not all such patients respond to endocrine therapy, and many who do initially respond will relapse. CDK 4/6 inhibitors can help overcome mechanisms of endocrine resistance, decrease tumor cell growth, and act synergistically with anti-estrogens. Clinicians are faced with constant change in the breast cancer treatment landscape. Disease heterogeneity, drug resistance, and incorporation of genetic testing into the treatment formula for HR+/HER2- breast cancer patients are all things they must contend with. Understanding practice guideline recommendations and the evidence behind them will allow clinicians to better integrate CDK 4/6 inhibitors into their clinical practice.
This Chairman’s Perspective activity features a highlight summary from a nationally recognized expert with relevant and timely information on HR+/HER2- BC, including the latest trial results and accumulating real-world evidence that demonstrates the efficacy and overall safety …
Guest: Donna Ryan, MD
Guest: Caroline M. Apovian, MD, FTOS
Guest: Susan M. Tiso, DNP, APRN, FNP-BC, FAANP
Experts review guideline-recommended criteria for diagnosis and treatment of obesity and describe best practices for prioritization of obesity management. Tune in to learn more with Dr. Caroline Apovian, Co-Director at Center for Weight Management and Wellness at Brigham and Women’s Hospital in Boston, Dr. Donna Ryan, Professor Emerita at Pennington Biomedical Research Center in Baton Rouge, Louisiana, and Dr. Susan M. Tiso, Retired Family Nurse Practitioner from Family Medicine at the University of California, Irvine.
Guest: Caroline M. Apovian, MD, FTOS
Guest: Daniel Zalinov, PA-C
Guest: W. Scott Butsch, MD, MSc
Experts provide practical suggestions for incorporating obesity management into clinical practice and designing a comprehensive obesity care clinic. Dive in for more with Dr. Caroline Apovian, Co-Director of Center for Weight Management and Wellness at Brigham and Women’s Hospital in Boston, Dr. Scott Butsch, Director of Obesity Medicine at Bariatric and Metabolic Institute in Cleveland, Ohio, and Daniel Zalinov, Physician Assistant of Internal Medicine at Atrium Health in Charlotte, North Carolina.
Host: Ezra Cohen, MD, FRCPSC, FASCO
Guest: Sue S. Yom, MD, PhD
The emergence of early clinical endpoints compared to the current gold standard of overall survival may change the landscape of how clinical trials are designed as well as how patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) are managed. At the forefront of this change are unique small molecule agents that help to overcome the inhibitory influence of tumors on the apoptotic pathway. Join Drs. Ezra Cohen and Susan Yom as they focus on why utilizing early endpoints in clinical trials, and eventually the clinic, may provide therapeutic advantages compared to our current gold standard of overall survival.
Host: Jonathan D. Schoenfeld, MD, MPhil, MPH
Guest: Robert L. Ferris, MD, PhD
The treatment of LA SCCHN has remained largely unchanged for >2 decades and the standard of care, concurrent chemoradiotherapy (CRT) with high-dose cisplatin, is associated with substantial toxicity and limited efficacy. Inhibitors of apoptosis proteins (IAPs) may well change that dynamic. Join Drs. Jonathan Schoenfeld and Robert Ferris as they focus attention on this unmet need and critically evaluate how therapeutic modulation of the apoptotic pathway may improve patient outcomes.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Guest: Neeraj Agarwal, MD, FASCO
Guest: Elena Castro, MD, PhD
Guest: Neal Shore, MD, FACS
Guest: Axel S. Merseburger, MD
While the development of advanced prostate cancers is largely influenced by androgen receptor (AR) signaling, DNA-damage response (DDR) pathways also contribute to disease progression. AR axis-targeted therapies (ARATs) have been the standard of care for first-line mCRPC. Inhibiting PARP activity is an effective strategy for targeting malignant cells with limited DNA repair capacity due to DDR gene mutations, leading to synthetic lethality. There may be a synergy between ARATs and PARP inhibitors (PARPi), as ARATs can induce HRR deficiencies and PARP inhibitors can increase the activity of ARATs through AR-dependent transcription. Recent clinical trial results have demonstrated that the combination of PARPi with ARATs is safe and effective for the first-line treatment of patients with mCRPC, with 3 combinations now FDA-approved: olaparib + abiraterone, talazoparib + enzalutamide, and niraparib + abiraterone.
This activity will provide expert contextualization of evidence from first-line mCRPC clinical trials exploring these combinations, including insights about the differentiation of both treatment and patient selection, as well as management of treatment-related toxicities. Given the differences in approvals and guidelines between the US and European context, this Ryder Cup themed Expert Panel Discussion will compare and contrast the approach in both regions, giving participants comprehensive education on …
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Leslie Citrome, MD, MPH
This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.
Host: Christoph U. Correll, MD
This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.
Host: Martha Grogan, MD, FACP, FACC
Guest: Marianna Fontana, MD
Guest: Nitasha Sarswat, MD
Once considered rare and untreatable, amyloid transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) has increased in incidence over the last decade and is now a treatable condition. This is partly due to our better understanding of the biology of the disease and recognition of its comorbid or co-occurring conditions in both cardiac and noncardiac patients with cardiac amyloidosis. In an open discussion, chairperson Martha Grogan, MD, and faculty members Marianna Fontana, MD, and Nitasha Sarswat, MD, provide an updated review of the disease state that includes a better understanding of the mechanism of the disease, discuss the pathogenic and protective genetic variants, and examine evidence from clinical trials that are impacting the evolving landscape.
Host: Heather Wakelee, MD, FASCO
Guest: Lyudmila Bazhenova, MD
We now have FDA approved targeted therapies to treat NSCLC with EGFR exon 20 insertion mutations. Drs. Wakelee and Bazhenova discuss the most current data on both approved therapies and drugs in development.
Host: Christoph U. Correll, MD
Host: Leslie Citrome, MD, MPH
This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.
Host: Christoph U. Correll, MD
Host: Leslie Citrome, MD, MPH
This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.
Host: Christoph U. Correll, MD
This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.
Host: Adam Brufsky, MD, PhD
Host: Christopher M. Gallagher, MD
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
Host: Christopher M. Gallagher, MD
Host: Adam Brufsky, MD, PhD
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
Host: Adam Brufsky, MD, PhD
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
Host: Christopher M. Gallagher, MD
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
Host: Adam Brufsky, MD, PhD
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
Host: Adam Brufsky, MD, PhD
Host: Christopher M. Gallagher, MD
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
Host: Christopher M. Gallagher, MD
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
Host: Pranshu Mohindra, MD
Guest: Melissa Teply, MD
Guest: Judith Paice, PhD, RN
Guest: Fionnuala Crowley, MD
This enduring program of the live-virtual symposium will focus on the challenges of managing cancer pain using the Evolve KOL Knockout™ case-based format. The key opinion leaders (KOLs) will be challenged by the host/moderator to diagnose and manage patient scenarios with varying levels of difficulty. Learners will vote on the winner of each case presentation round and the moderator will declare a match winner at the conclusion.
There will be learning, laughter, and only one KOL left standing!
Host: Jessica Ailani, MD
Guest: Dawn C. Buse, PhD
Upwards of 47 million people in the U.S. suffer from migraines, often accompanied by widespread personal, professional, and social disabilities. Though a similar prevalence is initially observed between men and women, by mid-adulthood the prevalence of migraine is 3-fold greater in women than men. Newer agents, both injectable and oral and focused on modulating the calcitonin gene-related peptide pathway, have emerged and have proven highly effective in managing both acute and chronic migraine. Join Drs. Jessica Ailani and Dawn Buse as they provide an overview of the changing landscape of migraine therapy, especially as it impacts women across different life-stages.
Host: Lee Shulman MD, FACOG, FACMG
Guest: Kristina Deligiannidis, MD
The recent development and approval of two neuroactive steroids is likely to change the treatment paradigm for moderate to severe postpartum depression (PPD). These agents have a quick onset and function as GABAA positive allosteric modulators. Join Drs. Shulman and Deligiannidis as they address the burdens and impacts of PPD on mothers, babies, and partners, and deep dive into the pathophysiologic role and clinical findings associated with the use of neuroactive steroids in the management of PPD.
Host: Stefan D. Anker, MD, PhD
Guest: John Cleland, MD
Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA
Iron deficiency is a common heart failure comorbidity with a negative impact on patients’ quality of life and mortality. Recent world events may have influenced clinical trial outcomes with IV iron in heart failure, and secondary analysis has become commonplace. Are the findings still clinically relevant, and are we still getting a clinical benefit? Join Drs. Stefan Anker, Piotr Ponikowski, and John Cleland as they differentiate the design of IV iron trials and break down the relevance of key clinical endpoints. Are we still asking the right questions?
Host: Vallerie V. McLaughlin, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Guest: Cara Dolin, MD
Guest: Jennifer Simpson
Guest: Diana Girnita, MD ,PhD
Explore this video roundtable featuring an interdisciplinary panel of experts discussing a woman’s journey with mycophenolate therapy and strategies to approach risk mitigation. Learn more about how to provide critical education on the risks of mycophenolate, the importance of effective contraception, and navigating family planning.
Host: Ticiana Leal, MD
Host: Jacob Sands, MD
In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.
Host: Manesh R. Patel, MD
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: Manesh R. Patel, MD
Host: M. Cecilia Bahit, MD
Host: Elaine Hylek, MD, MPH
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: Joshua E. Reuss, MD
Host: Jessica S. Donington, MD, MSCR
The objective of this program is to enhance knowledge and awareness of the latest clinical trial data for immune checkpoint inhibitors (ICIs) that have been approved for use in the perioperative setting. Furthermore, the program aims to improve clinicians’ understanding of the ideal candidates for neoadjuvant/adjuvant ICI therapy, the sequencing of agents, and the challenges associated with comparing treatments across trials with varying criteria.
Through our focused microlearning approach, we will explore the ongoing debate surrounding the optimal timing of immunotherapy in relation to surgery. We will also delve into the role of predictive biomarkers in therapy selection and address the question of whether there is a universally “best” approach for choosing between neoadjuvant or adjuvant therapy, or if a personalized approach to treatment should be adopted for each patient.
Host: Joshua E. Reuss, MD
Host: Jessica S. Donington, MD, MSCR
The objective of this program is to enhance knowledge and awareness of the latest clinical trial data for immune checkpoint inhibitors (ICIs) that have been approved for use in the perioperative setting. Furthermore, the program aims to improve clinicians’ understanding of the ideal candidates for neoadjuvant/adjuvant ICI therapy, the sequencing of agents, and the challenges associated with comparing treatments across trials with varying criteria.
Through our focused microlearning approach, we will explore the ongoing debate surrounding the optimal timing of immunotherapy in relation to surgery. We will also delve into the role of predictive biomarkers in therapy selection and address the question of whether there is a universally “best” approach for choosing between neoadjuvant or adjuvant therapy, or if a personalized approach to treatment should be adopted for each patient.
Host: Joshua E. Reuss, MD
Host: Jessica S. Donington, MD, MSCR
The objective of this program is to enhance knowledge and awareness of the latest clinical trial data for immune checkpoint inhibitors (ICIs) that have been approved for use in the perioperative setting. Furthermore, the program aims to improve clinicians’ understanding of the ideal candidates for neoadjuvant/adjuvant ICI therapy, the sequencing of agents, and the challenges associated with comparing treatments across trials with varying criteria.
Through our focused microlearning approach, we will explore the ongoing debate surrounding the optimal timing of immunotherapy in relation to surgery. We will also delve into the role of predictive biomarkers in therapy selection and address the question of whether there is a universally “best” approach for choosing between neoadjuvant or adjuvant therapy, or if a personalized approach to treatment should be adopted for each patient.
Host: Michael J. Cuttica, MD, MS
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Ravi B. Patel, MD, MSc
Host: Vallerie V. McLaughlin, MD
Host: Michael J. Cuttica, MD, MS
Host: Yasmin Raza, MD
Host: Victor Moles, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Vallerie V. McLaughlin, MD
Host: Ruben Mylvaganam, MD
Host: Michael J. Cuttica, MD, MS
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: George Hanna, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Ruben Mylvaganam, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Daniel Schimmel, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Jonathan Haft, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Victor Moles, MD
Host: Jonathan Haft, MD
Host: Daniel Schimmel, MD
Host: Michael J. Cuttica, MD, MS
Host: Thomas Cascino, MD
Host: Ruben Mylvaganam, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Sydney Schacht, DO
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Michael J. Cuttica, MD, MS
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Victor Moles, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Michael J. Cuttica, MD, MS
Host: Victor Moles, MD
Host: Vallerie V. McLaughlin, MD
Host: Ruben Mylvaganam, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Yasmin Raza, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Ravi B. Patel, MD, MSc
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Thomas Cascino, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Vallerie V. McLaughlin, MD
Host: Ravi B. Patel, MD, MSc
Host: Thomas Cascino, MD
Host: Yasmin Raza, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Vallerie V. McLaughlin, MD
Host: Victor Moles, MD
Host: Michael J. Cuttica, MD, MS
Host: Ravi B. Patel, MD, MSc
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Victor Moles, MD
Host: Michael J. Cuttica, MD, MS
Host: Vallerie V. McLaughlin, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Ticiana Leal, MD
Host: Jacob Sands, MD
In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.
Host: Ticiana Leal, MD
Host: Jacob Sands, MD
In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.
Host: Ticiana Leal, MD
Host: Jacob Sands, MD
In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.
Host: Ticiana Leal, MD
Host: Jacob Sands, MD
In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.
Host: Christopher B. Granger, MD
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: Elaine Hylek, MD, MPH
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: M. Cecilia Bahit, MD
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Guest: Alan C. Moss, MD, FACG, FEBG, AGAF, FRCPI
Guest: Sophie M. Balzora, MD
Guest: Latonia Ward, M.Min
The goal of this program is to improve the overall management of patients with ulcerative colitis (UC). Specifically, we aim to improve clinician knowledge and competence with respect to the novel mechanisms of action of sphingosine-1-phosphate receptor (S1P) modulators and Janus kinase (JAK) inhibitors and their respective roles in the overall treatment paradigm of UC. We also aim to improve patient-centered approaches to the management of UC with a particular focus on underserved communities and Black, Indigenous, and people of color (BIPOC). To bolster our commitment to these patient populations, Boston University Chobanian & Avedisian School of Medicine partnered with Color of Crohn’s & Chronic Illness (COCCI) for this initiative.
Endorsed by the AGA Institute
Host: Kimberly A. Brown, MD
This chairman’s perspective highlights the role of gastroenterologists in improving patient care and outcomes and will increase their awareness of NAFLD/NASH. Dr. Kimberly Brown takes a deep dive into late-stage clinical trials to address unmet clinical needs and the potential for new agents to address these needs. Gastroenterologists will benefit from reviewing the safety and efficacy data, as it will help prepare them to quickly integrate new agents into their practice when they become available.
Host: George L. Bakris, MD, FAHA, FASN
Guest: David Bushinsky, MD
Guest: Lars Lund, MD
Hyperkalemia is a limiting factor when treating patients with heart failure and CKD on RAASi therapy. It’s especially challenging when these patients are on chronic hemodialysis. Join Drs. George Bakris, David Bushinsky, and Lars Lund as they identify the barriers of optimal treatment in patients on hemodialysis and discuss the real-world evidence using potassium-lowering agents in challenging patient group.
Guest: Jacob Sands, MD
Host: Charu Aggarwal, MD, MPH
We now have an FDA-approved targeted therapy to treat HER2-mutated NSCLC. Drs. Aggarwal and Sands discuss the most current clinical data, including management of adverse events.
Host: Ezra Cohen, MD
Guest: Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Guest: Deborah J. Wong, MD, PhD
Join our international multidisciplinary panel of experts in exploring revolutionary approaches to treating patients with unresectable locally advanced squamous cell carcinoma of the head and neck. The panel will address key aspects of patient management, including new and emerging therapies, the clinical significance of early endpoints used in clinical trials, and future directions in treatment.
Guest: David E. Bernstein, MD, MACG, FAASLD
Guest: Steven Flamm, MD, FAASLD, FACG
Join us as expert faculty, Dr. Steven Flamm and Dr. David Bernstein, take us through the clinical care pathway to help PCPs recognize patients with risk factors for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). This 15-minute activity incorporates elements of role-play, reflection, and learning from one’s mistakes to improve the competence of PCPs in recognizing risk factors for NAFLD/NASH in their patients and taking the best next steps for their care.
Guest: Julie A. Barta, MD, ATSF
Host: Peter J. Mazzone, MD, MPH, FCCP
Early detection of lung cancer is difficult, with many cases going undetected until it is too late. New methods using minimally invasive liquids biopsy and molecular biomarkers are in development to improve early detection of lung cancer. Join Dr. Peter Mazzone and Dr. Julie Barta as they discuss the latest data around two new blood-based assays with promising results for detecting lung cancer in high-risk individuals and the potential for improving patient survival.
Host: Stefan D. Anker, MD, PhD
Guest: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA
Iron deficiency is an independent predictor of decreased functional capacity and reduced survival in our patients with heart failure. Multiple clinical trials have addressed the issue, but we continue to struggle with the clinical implications of the data. Join Drs. Stefan Anker, Robert Mentz, and Piotr Ponikowski as they discuss the evidence from IV iron trials in heart failure, past and present, and what the results mean for your practice and patients.
Host: Richard N. Channick, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Sonia Jasuja, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Richard N. Channick, MD
Host: Khushboo Goel, MD
Host: Michael Troy, MD
Host: Sonia Jasuja, MD
Host: Christopher B. Cooper, MD, PhD
Host: Michael Lewis, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Rajan Saggar, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Christopher B. Cooper, MD, PhD
Host: Alexander Sherman, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Adam J. Brownstein, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Christopher B. Cooper, MD, PhD
Host: Alexander Sherman, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Houda Boucekkine, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Michael Troy, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Rajan Saggar, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Rajan Saggar, MD
Host: Houda Boucekkine, MD
Host: Yuri Matusov, MD
Host: Sivagini Ganesh, MD, MPH
Host: Shelley Shapiro, MD, PhD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Siyuan Cao, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Suzanne Kafaja, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Suzanne Kafaja, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Suzanne Kafaja, MD
Host: Siyuan Cao, MD
Host: Michael Lewis, MD
Host: Rajan Saggar, MD
Host: Shelley Shapiro, MD, PhD
Host: Antoine Hage, MD
Host: Richard N. Channick, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Paul Paik, MD
Guest: D. Ross Camidge, MD, PhD
Guest: Keith Kerr, BSc, MB ChB
Drs. Paul Paik, Keith Kerr, and Ross Camidge take us through testing considerations for MET exon 14 skipping mutations and optimal treatment approaches once a mutation is detected. They also discuss the emerging data and how to apply what we’re learning to everyday clinical practice.
Host: Richard Johnson, MD
Guest: Brittany Weber, MD, PhD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Abdul Abdellatif, MD, FASN
Guest: Richard Johnson, MD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: Abdul Abdellatif, MD, FASN
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: Abdul Abdellatif, MD, FASN
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: John K. Botson, MD, RPh
Guest: Abdul Abdellatif, MD, FASN
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Abdul Abdellatif, MD, FASN
Guest: John K. Botson, MD, RPh
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Abdul Abdellatif, MD, FASN
Guest: Richard Johnson, MD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: John K. Botson, MD, RPh
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: John K. Botson, MD, RPh
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Marco Metra, MD
Guest: Gianluigi Savarese, MD
Clinical trials provide evidence to support guideline recommendations. What’s changed with the recommendations for iron deficiency in heart failure? Watch as experts Giuseppe Rosano, MD, Marco Metra, MD, and Gianluigi Savarese, MD discuss the recent updates to the ESC guidelines, including the latest clinical trial evidence, and the expanded use of IV iron in iron deficient heart failure patients.
Host: Stephen Silberstein, MD
This program focuses on preventative treatment strategies for patients with chronic migraines. Its purpose is to improve healthcare providers’ understanding of the how excessive use of over-the-counter (OTC) and prescription pain medications can negatively affect the quality of life for those with chronic migraines. The program also covers the most up-to-date evidence-based treatment guidelines and emphasizes patient-centered approaches when using preventative therapies for managing chronic migraines. Additionally, the program explores the latest advancements in preventative treatments and emerging options for individuals with chronic migraines.
Host: Stephen Silberstein, MD
Host: Stewart J. Tepper, MD, FAHS
This program focuses on preventative treatment strategies for patients with chronic migraines. Its purpose is to improve healthcare providers’ understanding of the how excessive use of over-the-counter (OTC) and prescription pain medications can negatively affect the quality of life for those with chronic migraines. The program also covers the most up-to-date evidence-based treatment guidelines and emphasizes patient-centered approaches when using preventative therapies for managing chronic migraines. Additionally, the program explores the latest advancements in preventative treatments and emerging options for individuals with chronic migraines.
Host: Stewart J. Tepper, MD, FAHS
This program focuses on preventative treatment strategies for patients with chronic migraines. Its purpose is to improve healthcare providers’ understanding of the how excessive use of over-the-counter (OTC) and prescription pain medications can negatively affect the quality of life for those with chronic migraines. The program also covers the most up-to-date evidence-based treatment guidelines and emphasizes patient-centered approaches when using preventative therapies for managing chronic migraines. Additionally, the program explores the latest advancements in preventative treatments and emerging options for individuals with chronic migraines.
Host: Stephen Silberstein, MD
This program focuses on preventative treatment strategies for patients with chronic migraines. Its purpose is to improve healthcare providers’ understanding of the how excessive use of over-the-counter (OTC) and prescription pain medications can negatively affect the quality of life for those with chronic migraines. The program also covers the most up-to-date evidence-based treatment guidelines and emphasizes patient-centered approaches when using preventative therapies for managing chronic migraines. Additionally, the program explores the latest advancements in preventative treatments and emerging options for individuals with chronic migraines.
Guest: Stephen Doyle, DO, MBA, FCCP
Guest: Navitha Ramesh, MD, FCCP
Host: Sandhya Khurana, MD, FCCP
The goal of this activity is to use case-based learning to highlight the importance of targeting TSLP in the three types of severe asthma to raise awareness about optimal available treatments and best-practices for designing treatment plans to ultimately improve patient outcomes
Host: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Guest: Maria Luiza Caramori, MD, PhD, MSc
Guest: Ana Maria Cebrián-Cuenca, MD, PhD
Guest: Pam R. Taub, MD, FACC, FASPC
Optimal treatment with guideline-directed therapies, including RAS inhibitors, SGLT2 inhibitors, and nonsteroidal MRAs, is paramount in preventing progressive renal dysfunction and cardiorenal events in patients with chronic kidney disease and type 2 diabetes. As the patient becomes more complex, a multidisciplinary approach is often necessary to improve their outcomes. Listen in as our panel of experts offers strategies to improve collaboration and patient care.
Host: Natalie Kreitzer, MD, MS
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Susann Järhult, MD
Host: Martin Möckel, MD, PhD
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Natalie Kreitzer, MD, MS
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
Host: Tobias Lindner, MD
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Susann Järhult, MD
Host: Richard Body, MB ChB, PhD
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
Host: Antoni Bayés-Genís, MD, PhD, FESC, FHFA
Guest: Patrick Rossignol, MD, PhD
Heart failure and chronic kidney disease can go hand in hand in your patients, and when they do, there are often added comorbidities such as diabetes. If your patients on RAASi therapy develop hyperkalemia, what should you do? Join Drs. Patrick Rossignol and Antoni Bayés-Genís as they consult on a patient with heart failure who has multiple comorbidities and discuss the impact of hyperkalemia in these complex patients.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Tobias Lindner, MD
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
Host: Vinay Sehgal, MBChB, MRCP, PhD
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Susann Järhult, MD
Host: Martin Möckel, MD, PhD
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
Host: Adrian R. Parry-Jones, FRCP, PhD
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Martin Möckel, MD, PhD
Host: Richard Body, MB ChB, PhD
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Vinay Sehgal, MBChB, MRCP, PhD
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Adrian R. Parry-Jones, FRCP, PhD
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
Host: Kevin Trice, MD
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Alicia K. Morgans, MD, MPH
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Kelvin A. Moses, MD, PhD, FACS
Host: Alicia K. Morgans, MD, MPH
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Alicia K. Morgans, MD, MPH
Host: Kelvin A. Moses, MD, PhD, FACS
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Alicia K. Morgans, MD, MPH
Host: Kelvin A. Moses, MD, PhD, FACS
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Stacy Walker, NP
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Lisa Holle, PharmD, BCOP, FHOPA, FISOPP
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Alicia K. Morgans, MD, MPH
Host: Kelvin A. Moses, MD, PhD, FACS
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Kelvin A. Moses, MD, PhD, FACS
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
Guest: Laura M. Spring, MD
Watch this educational activity to learn about the integration of novel agents into the treatment algorithm for patients with triple-negative breast cancer (TNBC) and current guideline-recommended strategies for the treatment and management of treatment-related adverse events in TNBC.
Guest: Sarah Traverso, MMS, PA-C
In this eCourse tailored to advanced practice providers, get up to date on optimal care of metastatic CSPC, including management of treatment-related toxicities and key points for patient counseling.
Guest: Sarah Tinsley-Vance, PhD, MSN, APRN-BC, AOCN
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
In this eCourse tailored to advanced practice providers, get up to date on optimal care of patients with myelodysplastic syndromes (MDS), including risk stratification, anemia management, and novel therapies.
Guest: Rasheda Persinger MSN, AGNP-C, AOCNP
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
In this activity, learn about the most recent recommendations for biomarker/molecular testing and personalized treatment plans for patients with non-small-cell lung cancer (NSCLC) based on results from testing.
Host: Charu Aggarwal, MD, MPH
Host: Patrick Forde, M.B.B.Ch.
The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific evidence. This program aims to address this challenge by bringing together esteemed faculty members who will discuss pivotal scientific advances and practice-altering information related to the use of systemic immunotherapy, targeted therapies, and perioperative immunotherapy in the management of NSCLC across all disease stages.
Host: Charu Aggarwal, MD, MPH
Host: Patrick Forde, M.B.B.Ch.
The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific evidence. This program aims to address this challenge by bringing together esteemed faculty members who will discuss pivotal scientific advances and practice-altering information related to the use of systemic immunotherapy, targeted therapies, and perioperative immunotherapy in the management of NSCLC across all disease stages.
Host: Patrick Forde, M.B.B.Ch.
Host: Charu Aggarwal, MD, MPH
The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific evidence. This program aims to address this challenge by bringing together esteemed faculty members who will discuss pivotal scientific advances and practice-altering information related to the use of systemic immunotherapy, targeted therapies, and perioperative immunotherapy in the management of NSCLC across all disease stages.
Host: Charu Aggarwal, MD, MPH
Host: Patrick Forde, M.B.B.Ch.
The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific evidence. This program aims to address this challenge by bringing together esteemed faculty members who will discuss pivotal scientific advances and practice-altering information related to the use of systemic immunotherapy, targeted therapies, and perioperative immunotherapy in the management of NSCLC across all disease stages.
Host: Charu Aggarwal, MD, MPH
Host: Patrick Forde, M.B.B.Ch.
The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific evidence. This program aims to address this challenge by bringing together esteemed faculty members who will discuss pivotal scientific advances and practice-altering information related to the use of systemic immunotherapy, targeted therapies, and perioperative immunotherapy in the management of NSCLC across all disease stages.
Host: Carlos M. de Castro, MD
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
Host: Catherine Broome, MD
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
Host: Carlos M. de Castro, MD
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
Host: Catherine Broome, MD
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
Host: Carlos M. de Castro, MD
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
Host: Catherine Broome, MD
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
Guest: Mary Weinstein Dunn
Watch this educational activity to learn about the latest guideline-recommended first-line and later-line treatments for advanced renal cell carcinoma (RCC), as well as strategies to manage adverse (AEs) events of novel therapies.
Host: Durga Borkar, MD, MMCi
Host: Christina Y. Weng, MD, MBA, FASRS
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Host: Ellie Kelepouris, MD, FACP, FAHA
Guest: Stephen J. Greene, MD, FACC, FHFSA
Patients with heart failure and chronic kidney disease (CKD) are challenging to manage. The best approach is a multidisciplinary one, which will help to optimize guideline-directed medical therapy in patients at risk for hyperkalemia. Join Drs. Ellie Kelepouris and Stephen Greene as they discuss how to identify patients at high risk of developing hyperkalemia and the available treatment strategies for these complex patients.
Host: Jayanth Sridhar, MD
Host: Sabin Dang, MD
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Host: Sabin Dang, MD
Host: Jayanth Sridhar, MD
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Host: Christina Y. Weng, MD, MBA, FASRS
Host: Durga Borkar, MD, MMCi
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Host: Christina Y. Weng, MD, MBA, FASRS
Host: Durga Borkar, MD, MMCi
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Host: Durga Borkar, MD, MMCi
Host: Christina Y. Weng, MD, MBA, FASRS
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Host: Jayanth Sridhar, MD
Host: Sabin Dang, MD
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Host: Sabin Dang, MD
Host: Jayanth Sridhar, MD
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Host: Christina Y. Weng, MD, MBA, FASRS
Host: Durga Borkar, MD, MMCi
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Guest: Mazen Hanna, MD
Guest: Marianna Fontana, MD
Once thought to be a rare disease, transthyretin amyloidosis that results in cardiomyopathy (ATTR-CM) remains a challenge to diagnose and treat. In this discussion, Drs. Mazen Hanna and Marianna Fontana provide expert advice on imaging techniques to diagnose ATTR-CM, including recognizing diagnostic “red flags.” They also review recent clinical trial data of current and potential therapeutics for ATTR-CM, so listen in to find out how you can put the evidence into practice.
Host: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Antoni Bayés-Genís, MD, PhD, FESC, FHFA
Guest: Ovidiu Chioncel, MD, PhD
Guest: Marco Metra, MD
Experts agree intravenous iron treatment for iron-deficient patients with heart failure can improve outcomes, but what are we learning from the recent clinical trials? Drs. Giuseppe Rosano, Marco Metra, Ovidiu Chioncel, and Antoni Bayés-Genís highlight the latest data as they discuss the recent updates to the ESC guidelines and provide expert analysis regarding clinical trials using IV iron. Discover the clinical relevance of the evidence from these trials in patients with heart failure and iron deficiency.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Charles P. Vega, MD
We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A collaborative approach to addressing residual cardiovascular risk across a variety of risk factors that goes beyond LDL-C-lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients will benefit from a review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.
Host: Guy Young, MD
Hemophilia A is an inherited or spontaneously occurring secondary hemostasis disorder caused by clotting factor VIII deficiency, which affects the formation and stabilization of clots. If left untreated, hemophilia A can cause recurrent and disabling bleeding, leading to severe arthropathy or life- threatening hemorrhage. Prophylaxis is well-documented for its effectiveness in preventing arthropathy and life-threatening bleeds, and improving total bleeding rates. However, limitations of modern factor replacement treatment result in suboptimal outcomes, poor adherence to prophylactic regimens, and reduced QoL. Novel and emerging prophylactic therapies can mitigate some of the hindrances of traditional replacement therapy and enhance the overall effect of treatment in hemophilia A.
In this educational activity, expert faculty will review recent evidence from key clinical trials of prophylactic therapies that are expanding the armamentarium of therapeutic choices, including a novel high-sustained factor VIII replacement therapy, a bispecific antibody non-factor replacement therapy, and other emerging therapies. Evaluating patients’ goals and preferences will also be discussed, so clinicians can co-create treatment plans using a shared decision approach to improve adherence and reduce bleeding episodes in patients with hemophilia A.
Guest: Candace T. Westgate, DO, MPH, FACOG
Guest: Ethan D. Schram, MD, FACP
Early detection of cancer is essential to reducing the significant burdens associated with it. When cancer is detected at earlier stages, treatments can be initiated sooner, resulting in improved outcomes, reduced morbidity and mortality, and better quality of life. While the implementation of current screening guidelines has resulted in an overall reduction in cancer deaths, only 25 percent of cancers are diagnosed using traditional screening modalities, leaving much room for improvement. Blood-based multi-cancer early detection, or MCED, tests that can screen from four to greater than 50 types of cancers have been developed to complement the population-based screening of asymptomatic individuals. At the spring 2023 American Association for Cancer Research, also known as AACR, American Society of Clinical Oncology, or ASCO, and National Comprehensive Cancer Network, orNCCN, annual conferences, a multitude of data was presented on MCEDs, including real-world data, clinical trial data, novel MCEDs in development, MCED accuracy, and the inherent health equity challenges that their implementation will face. This educational activity has two parts. Dr. Candace Westgate delivers an MCED Primer designed to build primary care clinicians’ knowledge about the science of MCEDs and how to implement their use in primary care practice, followed by chapterized discussions between …
Host: Nirav Y. Raval, MD, FACC
Guest: Gurusher Panjrath, MD, FACC, FAHA, FHFSA
Despite the use of guideline-directed medical therapy, many patients with heart failure continue to have worsening symptoms. Enter baroreflex activation therapy, or BAT, an implantable FDA-approved cardiac autonomic modulation device. Listen in as Drs. Brian Howard and William Abraham explore data on its positive effects on exercise capacity, functional status, and quality of life. Do you know which of your patients may benefit from BAT?
Guest: James Galvin, MD, MPH, FANA
Guest: Jon Toledo, MD, PhD
Guest: Charles P. Vega, MD
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this program employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a series of six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This activity focuses on the role of primary care physicians (PCPs) in the monitoring, recognition, and management of ARIA. This includes an overview of baseline needs surrounding Aβ-DMT, potential presentations of ARIA in primary care, courses of action that may be needed regarding its evaluation/treatment, and communication throughout care.
Note that the core activity is supplemented by an
Guest: Kenneth Alexander, MD, PhD
Guest: Noel T. Brewer, PhD
Healthcare providers face challenges in promoting HPV vaccination, which is now recommended for children at age 9. The good news is that there are scientifically validated, effective methods for promoting HPV vaccination. Tune in to learn more about the 3-step Announcement Approach and discover strategies to address parents' hesitation and optimize cancer prevention.
Host: Harry Paul Erba, MD, PhD
Guest: Courtney DiNardo, MD
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Immuno-oncologic agents have changed the treatment landscape for non-small cell lung cancer. Listen as Drs. Harry Erba and Courtney DiNardo discuss advances in molecular profiling and classification of AML, as well as the newest approved treatments.
Host: Joseph Mikhael, MD
Guest: Monique Hartley-Brown, MD
Guest: Brandon Blue, MD
Multiple myeloma (MM) is the most common hematologic malignancy among African Americans, so it’s important that healthcare providers are aware of the disparities in the treatment provided to Black patients and White patients with MM. Listen in as Drs. Joseph Mikhael, Brandon Blue, and Monique Hartley-Brown discuss strategies to manage racial disparities and begin closing these gaps to ensure all patients receive the care they need.
Host: John L. Marshall, MD
Gastric and gastroesophageal junction cancers are the third most common cause of cancer deaths globally. In this Chairman’s Perspective, Dr. John Marshall breaks down the latest data from the 2023 World Congress on GI Cancer in Barcelona, Spain, so you can more effectively treat your patients.
Host: Petros Grivas, MD, PhD
Guest: Thomas Powles, MD, PhD
Survival for patients with metastatic urothelial cancer has increased with the approval of immune therapy, antibody-drug conjugates, and targeted agents. In the maintenance setting, avelumab has become the global standard of care. Do you know how to evaluate and effectively implement immune therapy in the maintenance setting in your practice?
Guest: Tiffany Traina, MD, FASCO
Guest: Gregory Vidal, MD, PhD
Guest: Stephanie Walker, RN
Despite recent advances, triple-negative breast cancer (TNBC) remains difficult to treat due to a poor prognosis and a small number of effective treatments. Thus, clinicians’ priorities need to be aligned with patient goals and perspectives to ensure optimal care and overcome patient misunderstandings about treatment and clinical-trial options.
Join an expert panel of oncologists and oncology nurse practitioners for an in-depth discussion of patient-centered care practices for TNBC that incorporate and align with patient preferences for treatment. Panelists will also discuss effective strategies for TNBC management and the appropriate incorporation of novel therapies into treatment regimens.
Do you have patients who have been diagnosed with TNBC who could use education on treatment options, clinical trials, and available support resources? Direct your patients to MedLive.com to access the activity, “Navigating Treatment and Support for Triple-Negative Breast Cancer.”
Host: Tessa Laubscher, MBChB, CCFP, FCFP
Guest: George L. Bakris, MD, FAHA, FASN
Guest: Mikhail Kosiborod, MD
Managing chronic kidney disease (CKD) and type 2 diabetes (T2D) with multiple medications has become a challenge, and a multidisciplinary approach is needed to achieve optimal cardiorenal outcomes. Join Drs. George Bakris, Mikhail Kosiborod, and Tessa Laubscher as they discuss initiating consensus-based nonsteroidal MRA therapy in their patients with CKD and T2D.
Host: Piotr Ponikowski, MD, PhD, FESC, FHFA
Guest: Robert J. Mentz, MD, FHFSA, FACC, FAHA
While multiple clinical trials demonstrated a positive impact on patient outcomes with IV iron therapy in patients with HFrEF and iron deficiency, few have addressed the long-term effects of IV iron treatment on morbidity, mortality, and exercise tolerance in these patients. Join Dr. Robert Mentz and Dr. Piotr Ponikowski as they discuss the design of the HEART-FID trial and its potential impact on the clinical applications of long-term treatment with IV iron products in patients with heart failure and iron deficiency.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Patrick Rossignol, MD, PhD
With more effective ways to manage hyperkalemia, is it still a challenge in 2023? Chairperson Ileana Piña, MD, and faculty members cardiologist Javed Butler, MD, and nephrologist Patrick Rossignol, MD, use case-based vignettes to provide expert analysis regarding hyperkalemia in patients with HFrEF who are on RAASi therapy. Tune in for insights on applying clinical trial data to the unique challenges of complex cases and learn how a guideline-based approach, innovative treatments, and emerging data are achieving successful outcomes in patients with heart failure with hyperkalemia.
Host: Jennifer Caudle, DO
Guest: John F. Brandsema, MD
Guest: Vamshi K. Rao, MD
Limb-girdle dystrophy (LGMD) is a group of inherited neuromuscular diseases with at least 34 variants, all affecting muscles of the limb-girdle region. Because LGMD is so variable, it can be hard to detect and there are no FDA-approved treatments currently. Advances in gene transfer therapy have been slow to emerge. However, helping clinicians detect LGMD and know the next best steps is critical to effective management of LGMD, along with identifying patients for clinical trials.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Julie Parsons, MD
Guest: Craig Zaidman, MD
Duchenne Muscular Dystrophy, or DMD, is considered a rare disease, affecting 1 in 3,500 boy births. But to the patients afflicted-and to the families who love them-it is a painful, everyday experience. Current advances in gene transfer therapy are exciting. Helping clinicians interpret and utilize the outcomes of gene therapy clinical trials is critical to effective treatment and management of DMD, as is the coordination of multidisciplinary teams for the ongoing care of these patients.
Host: James Galvin, MD, MPH, FANA
Guest: Gloria Chiang, MD
Guest: Christopher Carpenter, MD, MSC, FACEP, FAAEM, AGSF
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a series of six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This activity focuses on the role of emergency medicine clinicians in the recognition and management of ARIA. This includes an overview of how ARIA may present to the emergency department and what courses of action to treat/manage ARIA may be needed from the hospital care team.
Host: James Galvin, MD, MPH, FANA
Guest: Gloria Chiang, MD
Guest: Christopher Carpenter, MD, MSC, FACEP, FAAEM, AGSF
Guest: Charles P. Vega, MD
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a series of six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This activity finishes out the series by first providing an abbreviated outline of what has been addressed across activities 1-5 followed by a multidisciplinary discussion of questions and considerations that may impact the team-based execution of discussed strategies.
Guest: Davinder S. Grover, MD, MPH
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
Guest: Qi Cui, MD, PhD
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
Guest: Qi Cui, MD, PhD
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
Guest: Qi Cui, MD, PhD
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
Guest: Davinder S. Grover, MD, MPH
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
Guest: Davinder S. Grover, MD, MPH
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
Guest: Qi Cui, MD, PhD
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
Guest: Davinder S. Grover, MD, MPH
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
Host: Vallerie V. McLaughlin, MD
Guest: Rajan Saggar, MD
Diagnosis of pulmonary arterial hypertension, or PAH, may be delayed because symptoms are nonspecific. And while there have been many advances in terms of available treatments, it remains imperative that providers perform a thorough risk assessment on each patient. In addition, it’s necessary to develop both a multidimensional approach to caring for patients with PAH and a communication plan to use with patients, care partners, and caregivers. If we can improve how we practice, we can improve outcomes and quality of life. Join us!
Host: Anna Giuliano, PhD
Guest: Joel Heidelbaugh, MD
HPV vaccination guidance for mid-aged adults (27 to 45 years old) was updated by the CDC in 2019. Unfortunately, very few individuals in the US in this age range have ever been vaccinated for HPV, despite the risk for acquiring an HPV infection that can potentially progress to cancer, most notably oropharyngeal, cervical, and anorectal. Join us as Drs. Anna Giuliano and Joel Heidelbaugh discuss strategies for improving HPV vaccination rates across different populations and provide specifics on how and when to use shared clinical decision-making (SCDM) when offering a permissive recommendation.
Host: Charles P. Vega, MD
Obesity and overweight have reached epidemic status in the US. While safe and effective treatment options are available, it remains a challenge for clinicians to initiate conversations about weight with their patients. Learn how to open channels of communication with your patients by watching Dr. Charles Vega interact with a 42-year-old patient using shared decision-making.
Guest: Bruce E. Sands, MD, MS
In this brief medical minute, Bruce E. Sands, MD, MS, an expert in IBD discusses the clinical challenges of IBD management including biologic failure and surgical management.
Guest: Abigail Meyers, PA-C
In this brief medical minute, Abigail Meyers, PA-C, an expert in IBD, discusses strategies to address the clinical challenges of IBD management during pregnancy and engaging patients in shared decision-making.
Guest: Bruce E. Sands, MD, MS
In this short medical minute, Bruce E. Sands, MD, MS, an expert in IBD management, discusses the latest in treat-to-target and therapeutic drug monitoring in patients with IBD.
Guest: Ryan Ungaro, MD, MS
This Medical Minute will discuss how to identify and target objective measures of ulcerative colitis disease activity to achieve mucosal healing.
Guest: Bruce E. Sands, MD, MS
An expert in IBD discusses the latest in early diagnosis, individualizing therapy, and monitoring of IBD. Hear about early signs and symptoms of IBD as well as strategies for individualizing initial therapy in patients with IBD based on available agents and guidelines.
Guest: Bruce E. Sands, MD, MS
Guest: Abigail Meyers, PA-C
In this brief medical minute, two experts in IBD, Abigail Meyers, PA-C and Bruce E. Sands, MD, MS, discuss collaborative and holistic care for IBD management.
Host: John P. Leonard, MD
Guest: Sarah Rutherford, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Alex Herrera, MD
Guest: Alison J. Moskowitz, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Alex Herrera, MD
Guest: Alison J. Moskowitz, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Kami Maddocks, MD
Guest: Matthew J. Matasar, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: John P. Leonard, MD
Guest: Sarah Rutherford, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Kami Maddocks, MD
Guest: Matthew J. Matasar, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Sarah Rutherford, MD
Guest: John P. Leonard, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Matthew J. Matasar, MD
Guest: Kami Maddocks, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Alison J. Moskowitz, MD
Guest: Alex Herrera, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Jason J. Luke, MD, FACP
Guest: Tara Mitchell, MD
The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.
Host: Charles P. Vega, MD
Guest: Pradeep S. Prasad, MD, MBA
Vision loss due to diabetes is preventable, yet minority patients and patients of low socioeconomic status remain at a disproportionate risk of poor outcomes. Find out what Dr. Pradeep Prasad and Dr. Charles Vega are doing to curb the negative outcomes of diabetic eye disease in their patients at high risk for vision loss.
Host: Charles P. Vega, MD
Guest: Ruth Shoge, OD, MPH, FAAO
Racial and ethnic minorities are disproportionately affected by diabetic eye disease, which is one of the leading causes of vision loss in the United States. Hear how Dr. Ruth Shoge and Dr. Charles Vega are approaching patient care and find out what tools are available to you. Join us in overcoming barriers to vision care so that all patients can receive the treatment they need.
Host: Charles P. Vega, MD
Guest: Sharon D. Solomon, MD
New treatments are available to manage diabetic macular edema (DME) that have the added benefit of reducing treatment burden. This can level the playing field and benefit patients who are less likely to access routine healthcare. Tune in to hear Dr. Sharon Solomon and Dr. Charles Vega discuss how the latest clinical data measure up by prolonging treatment intervals and how retina specialists are now better equipped to care for their most vulnerable patients with DME.
Host: Charles P. Vega, MD
Guest: Donna Ryan, MD
Addressing the health issues of your patients with obesity can present a challenge. How can you initiate the conversation and effectively emphasize the benefits of weight loss? Join Drs. Charles Vega and Donna Ryan as they review a case of obesity and use evidence-based medicine to develop a patient-centric treatment plan.
Host: Charles P. Vega, MD
Guest: Donna Ryan, MD
Obesity is a chronic, progressive disease which has often been overlooked by physicians, leaving a considerable proportion of people with obesity underdiagnosed and inappropriately managed. Join Drs. Charles Vega and Donna Ryan as they break down the pathophysiology of obesity and discuss currently available weight-loss medications.
Guest: Qi Cui, MD, PhD
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
Host: Rishi P. Singh, MD
Host: Mark R. Barakat, MD
Host: Arshad M. Khanani, MD, MA
Host: Christina Y. Weng, MD, MBA
This program will focus on the clinical trial and real-world data about the novel and emerging therapies for the treatment of dry age-related macular degeneration, wet age-related macular degeneration, diabetic retinopathy, and diabetic macular edema and how these therapies may be integrated into real-world clinical practice.
Host: Javed Butler, MD, MBA, MPH
Guest: John P. Boehmer, MD
Heart failure contributes to more than 3 million hospital admissions, resulting in a considerable economic burden. Despite significant developments to advance treatment, hospital readmission rates also remain high. Join Drs. Javed Butler and John Boehmer as they discuss fluid overload in patients with heart failure and explore recent clinical evidence in remote monitoring strategies to improve patient outcomes.
Host: Jennifer Caudle, DO
Guest: Sara A. Hurvitz, MD, FACP
Guest: Narjust Florez, MD
This CME-accredited podcast explores the rationale for targeting human epidermal growth factor receptor 3 (HER3) in non–small cell lung cancer (NSCLC) and breast cancer. It includes an in-depth discussion of the mechanism of action, safety, and efficacy of agents that are being investigated to target HER3. The latest results from clinical trials investigating monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates targeting HER3 will also be discussed.
Host: James Galvin, MD, MPH, FANA
Guest: Gloria Chiang, MD
Guest: Christopher Carpenter, MD, MSC, FACEP, FAAEM, AGSF
Guest: Charles P. Vega, MD
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This six-part series features distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This first activity focuses on the rise of amyloid-targeting DMT and the subsequent key features of ARIA that impact all specialties.
Host: Warner K. Huh, MD
Guest: Sarah E. Dilley, MD, MPH, FACOG
Effective triage tests are needed to lessen diagnostic uncertainty when assessing cervical cancer risk and selecting which patients will move on to colposcopy. An FDA-approved dual-staining cytology test is available that can help in decision-making for a wide range of patients. Join Drs. Warner Huh and Sarah Dilley as they address current 2019 ASCCP guidelines and anticipate potential updates to ASCCP’s guidance in 2023.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Wendy Wright, DNP, FNP-BC, ANP-BC, FAANP, FAAN, FNAP
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Wendy Wright, DNP, FNP-BC, ANP-BC, FAANP, FAAN, FNAP
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Michael Auerbach, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Arjeme Denise Cavens, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Michael Auerbach, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Michael Auerbach, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Arjeme Denise Cavens, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Arjeme Denise Cavens, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Michael K. Georgieff, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Arjeme Denise Cavens, MD
Guest: Lee Shulman MD, FACOG, FACMG
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Michael Auerbach, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Mazen Noureddin, MD
Nonalcoholic steatohepatitis (NASH) is an epidemic with enormous health and economic implications. Join us for our chairman’s perspective on best practices to identify, screen, and refer patients. Dr. Mazen Noureddin also examines some of the emerging therapeutics that may change your approach to NASH.
Host: Helena Yu, MD
Guest: Makenzi Evangelist, MD
This Expert Exchange webcast is designed to enhance clinicians’ awareness of the function and role of HER3 in emerging treatment strategies for non-small cell lung cancer and metastatic breast cancer.
Host: Nilika Singhal, MD
Guest: M. Scott Perry, MD
Guest: Elizabeth Anne Thiele, MD, PhD
Lennox-Gastaut syndrome and Dravet syndrome are 2 rare epileptic disorders with a pediatric onset. They‘re often refractory to therapy and have significant side effects due to polytherapy. Listen in as Drs. Nilika Singhal, Elizabeth Thiele, and M. Scott Perry discuss treatment options and how you can lessen the impact of polypharmacy on your patients.
Host: Sudipto Mukherjee, MD, PhD, MPH
Guest: Corey Casper, MD, MPH
Guest: Jovanna De La Pena
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
Host: Corey Casper, MD, MPH
Guest: Sudipto Mukherjee, MD, PhD, MPH
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
Host: Sudipto Mukherjee, MD, PhD, MPH
Guest: Corey Casper, MD, MPH
Guest: Jovanna De La Pena
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
Host: Corey Casper, MD, MPH
Guest: Sudipto Mukherjee, MD, PhD, MPH
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
Host: Corey Casper, MD, MPH
Guest: Sudipto Mukherjee, MD, PhD, MPH
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
Host: Corey Casper, MD, MPH
Guest: Sudipto Mukherjee, MD, PhD, MPH
Guest: Jovanna De La Pena
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
Host: Corey Casper, MD, MPH
Guest: Sudipto Mukherjee, MD, PhD, MPH
Guest: Jovanna De La Pena
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
Host: Corey Casper, MD, MPH
Guest: Sudipto Mukherjee, MD, PhD, MPH
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
Host: Hope S. Rugo, MD, FASCO
Guest: Peter Schmid, FRCP, MD, PhD
HR+/HER2- breast cancer accounts for approximately 70% of early breast cancer. Now that the CDK4/6 inhibitor abemaciclib has been approved in the United States and internationally for the treatment of HR+/HER2- early breast cancer, it’s important to keep up with the latest data for its use. Listen in so Drs. Hope Rugo and Peter Schmid can keep you up to date on the most effective ways to treat your patients.
Host: Mario Cozzolino, MD, PhD
Guest: Jan T. Kielstein, MD, FASN, FERA
A high percentage of patients with chronic kidney disease have low levels of vitamin D leading to secondary hyperparathyroidism (SHPT), which plays a critical role in the development of chronic kidney disease-mineral and bone disorder (CKD-MBD). Our experts, Dr. Mario Cozzolino and Dr. Jan Kielstein, discuss the complexity of the condition, early diagnosis, treatment goals, and emerging therapies. Tune in to be sure you’re using all the tools at your disposal to improve your patients’ quality of life.
Host: Smeeta Sinha, PhD
Guest: Sagar Nigwekar, MD
High-quality evidence for the management of calciphylaxis is lacking due to the rare nature of the disease and its poorly understood pathogenesis. Our experts, Drs. Smeeta Sinha and Sagar Nigwekar, discuss the complexity of the condition, its diagnosis, treatment goals, and emerging therapies. Tune in to be sure you’re using all the tools at your disposal to improve your patients’ quality of life.
Host: David Jayne, MD
Guest: Annette Bruchfeld, MD, PhD
ANCA-associated vasculitis (AAV) may lead to long-term organ damage and has a significant mortality risk for patients. While glucocorticoids are effective, they are associated with adverse events and impaired quality of life. Join our experts as they tackle these unmet needs in the context of the guidelines and current treatments and then dive deeper with an exploration of the potential role of complement receptor inhibition, which may be the answer to improving vasculitis.
Host: Darren Brenner, MD
Host: Brooks D. Cash, MD, AGAF, FACG, FASGE
Despite advances in the treatment of irritable bowel syndrome with constipation (IBS-C), many patients are still struggling. Our experts, Drs. Darren Brenner and Brooks Cash, discuss the complexity of this condition, its diagnosis, treatment recommendations, and clinical trial data. Tune in to be sure you’re using all of the tools at your disposal to improve your patients’ quality of life.
Host: Fortunato Ciardiello, MD, PhD
Guest: Erika Martinelli, MD, PhD
Are you familiar with rechallenge strategies with anti-EGFR therapies to treat metastatic colorectal cancer? Listen as Drs. Fortunato Ciardiello and Erika Martinelli discuss patients most suitable for rechallenge with anti-EGFR therapies for metastatic colorectal cancer while outlining key clinical data.
Host: Julie E. Chang, MD
Bruton’s tyrosine kinase inhibitors (BTKi) have transformed treatment for people with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and other B-cell malignancies. Still, many patients discontinue treatment because of adverse events and treatment resistance. As science moves forward in understanding why some patients do not respond well to treatment with BTKi, a new generation of BTKi with a different mechanism of action (MOA) is emerging as a possible therapeutic alternative.
Now’s the time to learn about this promising new treatment path for CLL and MCL. In this activity, featuring four concise modules, an expert discusses the MOAs of covalent and non-covalent BTKi, current practices for using BTKi in treatment of CLL and MCL, the efficacy and safety data for novel BTKi, and the potential role of non-covalent BTKi in future treatment plans.
Host: Robert Shin, MD, FANA, FAAN
Guest: Jiwon Oh, MD, PhD, FRCPC
Guest: Enrique Alvarez, MD, PhD
Over the past several years, the image of MS has been changing from distinct categories of disease to a complicated spectrum of interwoven pathologies. As this knowledge evolves, so do approaches to prognosticating, monitoring, and responding to disease. With many markers of progression still under investigation and therefore not included in modern guidelines, MS clinicians are left on their own to decide which factors should hold the most weight in influencing clinical decisions. In this “debate-themed” symposium originally held in conjunction with the 2023 ACTRIMS Forum, Drs Shin, Alvarez, and Oh advocate for their preferred disease indicators and why they are the future of successful MS disease management. In the absence of professional guidelines, these expert perspectives may deepen the understanding of exactly how and why these factors should be considered, improving clinicians’ ability to navigate and optimize available tools and strategies for their own patients.
Host: Javed Butler, MD, MBA, MPH
Guest: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Patrick Rossignol, MD, PhD
In heart failure, there is a propensity to down-titrate or discontinue guideline-directed medical therapy in the presence of hyperkalemia, even though it is well known that suboptimal use of these therapies leads to poorer outcomes for our patients with heart failure and chronic kidney disease. Join Drs. Javed Butler, Ileana Piña, and Patrick Rossignol as they take a multidisciplinary approach to a patient case and discuss dosing and other treatment decisions.
Host: Warner K. Huh, MD
Guest: Leigh Anne Cantrell, MD, MSPH
Explore the case of a young patient to see the ACS and ASCCP cervical cancer screening guidelines in action. Who needs to be screened, how is it best to screen, and what's the best test? Leading experts, Drs. Leigh Cantrell and Warner Huh, review the benefits of primary screening as they explore shifts in current guidelines. Find out how you can improve outcomes for patients, not only through appropriate primary HPV testing in lieu of cytology as the screening modality, but also by reinforcing how a “negative” HPV test actually sends a powerful “positive” message. As a bonus, you might just change a young patient’s life.
Host: Tanios S. Bekaii-Saab, MD
Guest: Joleen M. Hubbard, MD
Are you familiar with the most recent clinical data surrounding the treatment of HER2-positive metastatic colorectal cancer? Listen in as Drs. Tanios Bekii-Saab and Joleen Hubbard talk about the recent approval of tucatinib and trastuzumab for the treatment of HER2-positive metastatic CRC and other therapies in development.
Host: Barbara Burtness, MD
Guest: Nabil F. Saba, MD, FACP
KEYNOTE-048 has opened new vistas to managing patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Nonetheless, uncertainties remain in matching the correct patient with the correct strategy. Join Drs. Barbara Burtness and Nabil Saba as they parse the key trials and offer insight into building treatment algorithms designed to optimize outcomes for your patients with R/M HNSCC.
Host: Christina Y. Weng, MD, MBA
Guest: Sophie J. Bakri, MD
This discussion with Program Chair Christina Y. Weng, MD, MBA, and Sophie J. Bakri, MD, includes a case study that highlights challenges with managing diabetic eye disease during the COVID era and how longer duration therapies could be beneficial.
Drs. Weng and Bakri also converse about the latest data on pipeline therapies for diabetic macular edema, including brolucizumab & PDS.
Host: Christina Y. Weng, MD, MBA
Guest: Basil K. Williams Jr, MD
In this video case discussion, Program Chair Christina Y. Weng, MD, MBA, and Basil K. Williams Jr, MD, review details of a patient with wet age-related macular degeneration treated during the COVID-19 pandemic. This case highlights the need for increased durability of treatment options.
Drs. Weng and Williams also discuss the latest data on two investigational anti-VEGFs: an antibody biopolymer conjugate and a pan-VEGF plus placental growth factor inhibitor.
Host: Christina Y. Weng, MD, MBA
Guest: David Eichenbaum, MD
This discussion with Program Chair Christina Y. Weng, MD, MBA, and David A Eichenbaum, MD, includes a case study that highlights challenges with managing diabetic eye disease during the COVID era and how longer duration therapies could be beneficial.
Drs. Weng and Eichenbaum also converse about the latest data on pipeline therapies for diabetic macular edema, including faricimab, KSI-301, and OPT-302.
Host: Christina Y. Weng, MD, MBA
Guest: Glenn Yiu, MD, PhD
This discussion with Program Chair Christina Y. Weng, MD, MBA, and Glenn Yiu, MD, PhD, includes a case study that highlights challenges with managing diabetic eye disease during the COVID era and how longer duration therapies could be beneficial.
Drs. Weng and Yiu also converse about the latest data on pipeline therapies for diabetic macular edema, including high-dose aflibercept & gene therapy.
Host: Christina Y. Weng, MD, MBA
Guest: Peter A. Campochiaro, MD
In this video case discussion, Program Chair Christina Y. Weng, MD, MBA, and Peter A. Campochiaro, MD, review pipeline therapies for wet age-related macular degeneration. The faculty review challenging cases that would have potentially different outcomes with investigative therapies such as gene therapy and a novel, long-acting drug delivery system.
Host: Christina Y. Weng, MD, MBA
Guest: Diana Do, MD
In this video case discussion, Program Chair Christina Y. Weng, MD, MBA, and Diana V. Do, MD, review pipeline therapies for wet age-related macular degeneration. Drs. Do and Weng assess challenging cases and focus specifically on how specific investigative therapies that target VEGF-A, C and D may have the potential to extend treatment intervals.
Host: Ezra Cohen, MD, FRCPSC, FASCO
Guest: Petr Szturz, MD, PhD
While key clinical trials inform our management philosophy for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), the paucity of predictive markers, limited guidance to treatment sequencing, and inherent therapeutic toxicity provide challenges for both clinicians and patients. How can we best stratify our patients to ensure the most optimal outcomes? Join Drs. Ezra Cohen and Petr Szturz as they offer cogent answers to the difficult questions you face in your daily medical practice.
Host: Caron A. Jacobson, MD
Guest: Matthew Lunning, DO
Guest: Loretta J. Nastoupil, MD
Since the first chimeric antigen receptor (CAR) T-cell therapy was approved by the US Food and Drug Administration (FDA) for the treatment of large B-cell lymphoma (LBCL) in the third or later line of therapy, there has been significant development in the field. There are now three approved CAR T-cell therapies for various subtypes of LBCL, and these immunotherapies are now moving into earlier treatment, with axi-cel and liso-cel both FDA approved in the second-line setting. At the same time, researchers have made tremendous strides in managing the hallmark toxicities of CAR T-cell therapy like cytokine release syndrome (CRS) and neurologic events, opening the possibility for this therapy to move safely beyond academic medical centers and into outpatient settings.
The educational activity features an expert roundtable panel discussion on real-world clinical practice experiences with CAR T-cell therapy for the treatment of diffuse large B-cell lymphoma (DLBCL) from the esteemed panelists, with a focus on the second-line setting. The faculty panel will evaluate the most recent clinical data and provide their expert insights on how new emerging evidence can and should be considered for real-world clinical practice. The discussion will also include a summary of second-line clinical trials, differentiation factors among …
Host: Caron A. Jacobson, MD
Since the first chimeric antigen receptor (CAR) T-cell therapy was approved by the US Food and Drug Administration (FDA) for the treatment of large B-cell lymphoma (LBCL) in the third or later line of therapy, there has been significant development in the field. There are now 3 approved CAR T-cell therapies for various subtypes of LBCL, and these immunotherapies are now moving into earlier treatment, with axi-cel and liso-cel both FDA approved in the second-line setting. At the same time, researchers have made tremendous strides in managing the hallmark toxicities of CAR T-cell therapy like cytokine release syndrome (CRS) and neurologic events, opening the possibility for this therapy to move safely beyond academic medical centers and into outpatient settings.
The educational activity features expert faculty evaluating the current treatment landscape of CAR T-cell therapy for relapsed/refractory LBCL, highlighting evidence set to transform clinical practice particularly in the second-line setting. A three-dimensional mechanism of action animation video clip will illustrate similarities and differences within the structure and costimulatory domains of different CAR T-cell therapies. This activity will serve as the foundation for a robust panel discussion activity entitled Paradigm Shifts in CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: A Video …
Host: Danielle Becker, MD, MS, FAES
Host: Ahmed Abdelmoity, MD
Guest: Deborah Holder, MD
Guest: John Stern, MD
Vagus nerve stimulation (VNS) therapy is an add-on neuromodulation treatment designed for adults and children diagnosed with drug-resistant epilepsy (DRE). The device delivers mild pulses to the brain through the vagus nerve to help prevent seizures before they start and help stop them if they do. Join Drs. Danielle Becker, John Stern, Deborah Holder, and Ahmed Abdelmoity as they discuss best practices for initiating, titrating, and dosing adult and pediatric patients to optimize outcomes.
Host: Frederic Rahbari-Oskoui, MD, MSc
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
Host: Mark A. Atkinson, PhD
Guest: Linda DiMeglio, MD, MPH
Autoantibody Screening to Identify Risk for Type 1 DiabetesT1D defines a continuum that begins during an asymptomatic prodrome before the disease manifests clinically. One of the challenges of T1D is identifying persons at high risk before the onset of clinical manifestations by screening for pancreatic β cell autoantibodies. Interventions to delay or prevent the underlying autoantibody-mediated loss of pancreatic β cells are now available to delay or potentially prevent the clinical presentation of T1D as diabetic ketoacidosis and mitigate subsequent, longer-term complications.
Host: Jürgen Floege, MD
Guest: Jonathan Barratt, PhD
Guest: David Jayne, MD
Patients with chronic kidney disease often have a multitude of comorbidities which may present challenges in diagnosis, treatment, and management. In addition, the limitations of currently available treatments may reduce the opportunity for effective improvements in their quality of life. But clinical trial data are emerging, and our understanding about the underlying mechanisms of glomerulonephritis and sclerosis is growing. Find out how these advances could lead to improved outcomes in patients with IgAN, FSGS, and AAV.
Host: Fouad T. Chebib, MD
Guest: Pranav S. Garimella, MD
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
Host: Jillian Ziemanski, OD, PhD, FAAO
Guest: Cynthia Matossian, MD, FACS
How can more advanced measures improve meibomian gland function to relieve dry eye symptoms and improve refraction? Listen as Dr. Cynthia Matossian and Dr. Jillian Ziemanski discuss additional approaches you can try with your patients.
Host: Thomas F. Patterson, MD, FACP, FIDSA
Guest: George Thompson III, MD, FIDSA
The changing epidemiology of invasive fungal infections, ongoing antifungal resistance, drug-drug interactions, and few oral agents leave patients with limited viable treatment options. While the antifungal pipeline has been essentially dry for the past 2 decades, several antifungal drugs are now in late-stage clinical development and poised to address these unmet needs. But take heed: They will need to be treated as precious commodities lest they, too, become ineffective due to resistance.
Host: Andrew H. Lipsky, MD
Guest: Jacob D. Soumerai, MD
Guest: Catherine C. Coombs, MD
The emerging treatment landscape for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has resulted in improved outcomes for patients. However, challenges remain when selecting the best frontline approach and now involve decisions about using a time-limited option or continued therapy model. Other challenges exist on relapse, so it’s essential that providers understand the disease and patient factors that are critical when sequencing therapeutic agents. Join us in this Streaming National Broadcast that will help you meet the treatment needs of your patients with CLL/SLL both today and in the future.
Host: Peter G. Pappas, MD, FACP
Guest: Thomas F. Patterson, MD, FACP, FIDSA
Despite advances in diagnosis and treatment, as well as the dissemination of clinical practice guidelines, both the threat and burden of invasive fungal infections are increasing and underappreciated. Dr. Peter Pappas and Dr. Thomas Patterson, pioneers in this field, offer their perspectives on why this is the case and how a heightened awareness of invasive fungal infections is the key to improving your practice.
Host: Saad Z. Usmani, MD, MBA, FACP
Guest: Sikander Ailawadhi, MD
Guest: Amrita Krishnan, MD
Given the complexity of care for patients with multiple myeloma (MM) and the mounting clinical trial data, it is crucial to stay abreast of investigational agents and new data from current agents. Join Drs. Saad Usmani, Sikander Ailawadhi, and Amrita Krishnan as they explore new and emerging ways to close medical gaps in treatment and provide clinically applicable information to optimize outcomes for patients with MM. This enduring program will cover practical case illustrations, recent data released at the ASH annual meeting, and more!
Host: Sara W. Koblitz
Guest: Michael J. Thorpy, MD
While most clinicians are aware of a drug being either “approved” or “not approved” by the FDA, many are not familiar with the term “tentative approval.” Leading experts, attorney Sara Koblitz, JD, and Dr. Michael Thorpy, review the FDA approval process, explore how “tentative approval” is currently impacting treatment in the field of sleep medicine, and discuss how “non-drug” issues are related to delayed FDA approval. Review the latest safety and efficacy pivotal trial data associated with once-nightly sodium oxybate and find out if we’re truly on the cusp of a new awakening in sleep medicine.
Host: Martin Pollak, MD
Guest: Susanne Nicholas, MD, MPH, PhD
End-stage kidney disease (ESKD) is at least 3x higher among African Americans compared to Americans of European descent. Carriers of APOL1 variants with chronic kidney disease (CKD) are associated with more rapid disease progression and an increased risk of kidney failure. Join Drs. Martin Pollak and Susanne Nicholas as they discuss the epidemiology and possible mechanisms of APOL1 kidney disease, as well as recent clinical evidence for therapies in development that can potentially prevent rapid disease progression.
Host: Warner K. Huh, MD
Guest: Leigh Anne Cantrell, MD, MSPH
Guest: Mark H. Stoler, MD
Experts discuss the ACS and ASCCP CCV screening guidelines and review the benefits of primary screening and the latest data driven testing options. Is Pap cytology a thing of the past? Find out more about harmonization of guidelines from leading experts, Drs. Cantrell, Stoler and Huh. You might just transform your clinical practice.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Masja de Haas, MD, PhD
Program Chairman:
Roberto Romero, MD, DMedSci
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology
Neonatal alloimmune neutropenia (NAIN or NIN) is a neutrophil blood group antagonism similar to HDFN and FNAIT. Its presentation varies clinically and ranges from asymptomatic to severe manifestations such as sepsis and meningitis. Listen in as Drs. Masja de Haas and Lee Shulman discuss clinical clues that should catch your eye. Discover novel yet simple ways to be vigilant and make the right clinical calls.
Host: Andrea Singer, MD, FACP, CCD
Guest: Susan V. Bukata, MD, FAOA, FAAOS
Life-altering secondary fractures are a harsh reality, but Medicare studies show, and orthopedic surgeons agree, that knowledge has not translated into prevention. Why is there clinical inertia in providing preventative interventions related to secondary fragility fractures? Join Drs. Andrea Singer and Susan Bukata as they provide a cogent medical approach to preventing these fractures and a roadmap for when and how to use available therapies based on their mechanisms of action.
Host: William J. Gradishar, MD
Guest: Javier Cortes, MD, PhD
Guest: Hope S. Rugo, MD
New data for sequencing antibody-drug conjugates (ADCs) in HER2 metastatic breast cancer have hit the conference circuit. Listen as Drs. William Gradishar, Javier Cortés, and Hope Rugo dissect the data surrounding ADCs in different types of HER2 metastatic breast cancer. Make sure you’re up to date and offering your patients the best care.
Host: Floor J. Backes, MD
Follow along as Dr. Floortje Backes walks us through a patient case and demonstrates the shared decision-making process of selecting an appropriate maintenance treatment regimen for advanced ovarian cancer.
Host: Javed Butler, MD, MBA, MPH
Guest: Stefan D. Anker, MD, PhD
Guest: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA
Symptoms from iron deficiency can greatly affect the overall quality of life of our patients with heart failure. Recent clinical evidence from the IRONMAN trial explores the use of IV iron replacement in patients with chronic heart failure. Join Drs. Javed Butler, Stefan Anker, Piotr Ponikowski, and Robert Mentz as they discuss the clinical trial design and outcomes from IRONMAN compared to the current body of evidence for managing iron deficiency in this setting.
Host: Lee Shulman MD, FACOG, FACMG
Guest: Andrea S. Lukes, MD, MHSc, FACOG
Are you currently considering GnRH antagonists as first-line therapy, or are you waiting for patients to fail other endometriosis treatment approaches first? Drs. Andrea Lukes and Lee Shulman discuss how the advent of effective GnRH antagonists is evolving the care of endometriosis. Are you ready to provide patients with the clinical outcomes they seek while balancing the benefits of medical and surgical approaches?
Host: Jenny S. Sauk, MD
It is estimated that only 20% to 30% of patients with Crohn’s disease (CD) have a non-progressive or indolent course. While most patients with CD present with non-penetrating or non-stricturing disease, 50% of patients develop intestinal complications within 20 years of diagnosis. In this interactive CME activity, Dr. Sauk presents the case of a patient with CD, highlighting the importance of early recognition of disease complications and considerations for surgical management. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of inflammatory bowel disease (IBD) and learn more from an IBD expert faculty.
Host: Sushila R. Dalal, MD
The management of inflammatory bowel disease (IBD) remains challenging, owing to variable clinical presentations and ever-changing therapeutic options. In this interactive CME activity, Dr. Sushila Dalal presents the case of a newly diagnosed patient with IBD, highlighting the importance of prompt diagnosis and aggressive medical treatment. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of IBD and learn more from IBD expert faculty.
Host: Kara B. Markham, MD
What are the essential steps in managing hemolytic disease of the fetus and newborn (HDFN)? How soon after “the cord has been cut” does newborn care transfer from the maternal-fetal medicine specialist and ob-gyn to the pediatric team? At a recent satellite symposium of the American Academy of Pediatrics, Dr. James Bussel, Dr. Kara Markham, and Bethany Weathersby presented the latest data regarding current and emerging practice patterns and highlighted the critical need for improved understanding and multidisciplinary collaboration in the area of HDFN. Tune in to hear Dr. Markham summarize how diagnosis, care, and treatment have evolved—plus insights on how these might change the way you practice.
Host: Kevin J. Harrington, MBBS, PhD
Guest: Barbara Burtness, MD
Guest: Ari Rosenberg, MD
There is an unmet clinical need for more durable responses in many patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Advances in delineating the anti-apoptotic signaling mechanisms are guiding the development of novel therapeutic options for these patients. Join Drs. Kevin Harrington, Barbara Burtness, and Ari Rosenberg as they discuss challenges in treating patients with LA SCCHN and focus on the latest clinical data surrounding an antagonist of inhibitor of apoptosis proteins in this patient population.
Host: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Kamyar Kalantar‐Zadeh, MD
Guest: Pieter Martens, MD, PhD
Patients with heart failure are at increased risk for iron deficiency which leads to poor outcomes and quality of life. Several intravenous iron formulations are available to clinicians, yet iron deficiency remains undertreated. Join Dr. Giuseppe Rosano, Dr. Pieter Martens, and Dr. Kamyar Kalantar-Zadeh as they discuss differing iron formulations and the current body of evidence for managing iron deficiency in patients with heart failure.
Host: Richard S. Finn, MD
Guest: Peter R. Galle, MD
Combination immunotherapy (IO) is revolutionizing the management of advanced hepatocellular carcinoma (HCC). Listen in as Dr. Richard Finn and Dr. Peter Galle break down the most recent data around emerging strategies for using IO to treat your patients with HCC. What impact will these advances have on your clinical practice?
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: James B. Bussel, MD
Program Chairman:
As the platelet equivalent of hemolytic disease of the fetus and newborn, fetal and neonatal alloimmune thrombocytopenia (FNAIT) is an uncommon yet complex and life-threatening bleeding disorder that results from incompatibility between mother and baby for platelet-specific antigens. Despite relatively normal platelet function, in the setting of severe thrombocytopenia, intracranial hemorrhage is a consequence. Drs. Shulman and Bussel discuss advances in management strategies and concrete steps you can take to lower the risk and stop the progression of this disorder in your patients.
Host: Lee Shulman MD, FACOG, FACMG
Guest: Ayman Al-Hendy, MD
GnRH antagonists are revolutionizing the medical management of uterine fibroids. Drs. Al-Hendy and Shulman discuss how medical myomectomy with GnRH antagonists is revolutionizing care by bridging gaps during 3 different stages of patients’ lives.
Host: Yelena Janjigian, MD
Guest: Sam Klempner, MD
HER2 is an essential biomarker to be assessed in all patients with gastric/GEJ cancer. Its importance is not only related to its role as a therapeutic target for pathway inhibition, but also to its ability to anchor the application of non-HER2 pathway therapeutic strategies with direct and bystander impact in the tumor microenvironment. Join Drs. Janjigian and Klempner as they delve into historical and exciting emerging data that may well bring new hope to your patients with gastric/GEJ cancers.
Host: Marat Fudim, MD, MHS
Despite the use of guideline-directed medical therapy (GDMT), many heart failure (HF) patients may experience worsening symptoms and disease progression. There is now an FDA-approved device that works with GDMT and uses the baroreflex to improve HF-related physiological effects and clinical consequences. Tune in to keep up with baroreflex activation therapy, its mechanism of action, and the associated improved patient outcomes.
Host: Lee Shulman MD, FACOG, FACMG
Guest: Elizabeth Stewart, MD
Fertility preservation is a significant clinical concern for all women of reproductive age diagnosed with endometriosis or uterine fibroids (UF). Drs. Elizabeth Stewart and Lee Shulman discuss how the advent of GnRH antagonists is affecting how we approach these 2 conditions. Management trends are evolving beyond reflexive, prophylactic surgery, so are you ready to change with the times?
Host: Benjamin Levy, MD
Guest: Rebecca Heist, MD, MPH
Guest: Peter Bela Illei, MD
Antibody-drug conjugates (ADCs) have promising clinical data in the treatment of advanced non-small cell lung cancer. Listen in as Drs. Benjamin Levy, Rebecca Heist, and Peter Illei discuss current data on TROP2 ADCs and what this means for our patients.
Host: Maria Fleseriu, MD, FACE
Guest: Irina Bancos, MD
Cushing’s disease is complex, and individualized approaches require the consideration of many patient factors. You and your patient also need to know what to expect in terms of therapeutic response and speed of recovery. Tune in as Drs. Maria Fleseriu and Irina Bancos address these challenges and more!
Host: Aparna R. Parikh, MD
Guest: Dustin Deming, MD
Guest: Scott Kopetz, MD, PhD
In this chapterized panel discussion, Drs. Aparna Parikh, Dustin Deming, and Scott Kopetz take us through NCCN recommended guidelines and best practices for identifying biomarkers. Armed with this knowledge, you’ll be able to select systemic therapies more accurately for your patients with MSI-high disease, as well as patients with HER2-amplified CRC.
Host: Jyoti D. Patel, MD, FASCO
Join us as Dr. Jyoti Patel illustrates her approach to treating a 75-year-old patient who was recently diagnosed with stage IV NSCLC harboring a MET exon 14 skipping mutation—then put these tips to use in your own practice!
Host: Roger A. Goldberg, MD
Guest: Peter A. Campochiaro, MD
Can we apply the new, more durable treatments in diabetic macular edema and neovascular age-related macular degeneration to the treatment of our patients with diabetic retinopathy? Join Dr. Peter Campochiaro and Dr. Roger Goldberg as they discuss ways these new approaches could benefit even more patients.
Guest: Patrick Forde, MD
Guest: Jesús García-Foncillas, MD, PHD
Immune checkpoint inhibitors, or ICIs, have improved the prognosis for patients with many different types of cancer. Drs. Forde and García-Foncillas outline current biomarkers and the importance of testing to optimize patient outcomes. Your patients will thank you for tuning in!
Host: Javed Butler, MD, MBA, MPH
Guest: William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPE
Cardiac contractility modulation (CCM) is a novel, approved, implantable device that significantly improves heart failure symptoms, exercise tolerance, and quality of life while reducing the rate of heart failure hospitalizations. Find out why you should consider sending your patients with NYHA Class III heart failure who are not responding to guideline-directed medical therapy directly to an electrophysiologist for device implantation.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Kenneth J. Moise Jr., MD
Program Chairman:
How well do you understand the biology of hemolytic disease of the fetus and newborn (HDFN)? What about its connection to the FcRn receptor pathway and IgG? Drs. Lee Shulman and Ken Moise go beyond the basics taught in medical school immunology and look more closely at FcRn’s role in protecting IgG. With an improved understanding of these mechanisms, we can expand therapeutic targets beyond the fetus and newborn and finally put the needles away.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Linda Bradley, MD
Join Drs. Linda Bradley and Lee Shulman as they discuss factors contributing to disparities in care for patients with endometriosis and/or uterine fibroids. They offer practical tips to overcome the disproportionate disease burden that especially impacts women of color. Cut through the noise to clearly hear each patient’s voice. Your clinical impact may be profound.
Host: Theodora A. Potretzke, MD
Guest: Fouad T. Chebib, MD
This Expert Exchange webcast is designed to help improve clinicians’ understanding of the role radiologic imaging plays in the diagnosis and management of ADPKD.
Host: Paul Paik, MD
Guest: Catherine Shu, MD
Take a deep dive into current and ongoing clinical trials related to MET inhibitors and discover the key distinctions between these agents, such as dosing differences. Our experts also have recommendations on appropriate therapy selection for your patients with advanced NSCLC harboring MET exon 14 skipping mutations.
Host: Pam R. Taub, MD, FACC, FASPC
Guest: George L. Bakris, MD
Guest: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
The FIDELITY pooled analysis findings demonstrated benefits in cardiovascular and kidney outcomes when nonsteroidal mineralocorticoid receptor antagonists (MRAs) were added to the mix. Tune in to hear Drs. Pam Taub, Gerasimos Filippatos, and George Bakris discuss the risk factors of chronic kidney disease, the importance of measuring eGFR and UACR, and how finerenone improves outcomes.
Host: Charles P. Vega, MD
Guest: Paul G. Auwaerter, MD, MBA
Newer therapeutic options are now available to treat COVID-19. Don’t panic! Drs. Charles Vega and Paul Auwaerter are here to help you successfully integrate these therapeutics into your practice. Find out how to identify patients that are at risk for severe disease and select the appropriate treatment for the patient in front of you.
Host: Charles P. Vega, MD
Guest: David J. Cennimo, MD, FACP, FAAP, FIDSA
Clinicians treating patients in outpatient, urgent care, and emergent care settings who encounter patients with mild to moderate disease are tasked with providing optimal care to prevent disease progression. Drs. Charles Vega and David Cennimo take us through the spectrum of COVID-19 disease and identify available treatment options for your high-risk patients.
Host: Piotr Ponikowski, MD, PHD, FESC, FHFA
Guest: Adrian F. Hernandez, MD, MHS
Guest: Professor Andrew Sindone
Despite being an important and common comorbid condition in patients with heart failure, iron deficiency remains underdiagnosed and undertreated. Join Dr. Piotr Ponikowski, Dr. Andrew Sindone, and Dr. Adrian Hernandez as they discuss using guideline-directed medical therapy to overcome the morbidity, mortality, and very poor quality of life experienced by patients with heart failure and iron deficiency.
Host: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Peter van der Meer, MD, PhD
Iron deficiency in patients with heart failure remains underdiagnosed, undertreated, and commonly overlooked in non-anemic patients and has a significant impact on patient outcomes and quality of life. Join Dr. Robert Mentz and Dr. Peter van der Meer as they discuss approaches to identifying and treating iron deficiency in patients with heart failure and comorbidities such as diabetes.
Host: Courtney DiNardo, MD
Guest: Marina Y. Konopleva, MD, PhD
Developments over the last few years have brought dramatic changes to the treatment landscape of acute myeloid leukemia (AML). While new therapies mean more opportunities to individualize care, clinicians are also faced with new challenges and must quickly evaluate patients, order appropriate molecular tests, assess risk, and differentiate the efficacy, safety, and applicability of novel treatments and combinations. Join Drs. Courtney DiNardo and Marina Konopleva for a discussion of how to untangle the data to determine which treatment is right for each patient in the increasingly complex clinical setting of AML.
Host: Cem Akin, MD, PhD
Guest: Deepti Radia, MD
Indolent systemic mastocytosis is a rare disease often overlooked in the general healthcare setting. Drs. Deepti Radia and Cem Akin outline diagnostic criteria, signs and symptoms, and diagnostic tests to confirm diagnosis.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Kenneth J. Moise Jr., MD
Program Chairman:
Are you taking the right steps to consistently ensure all of your patients at risk of alloimmune disorders of pregnancy, specifically HDFN, receive a helping hand plus timely and appropriate clinical care? Despite having considerable clinical consequences, this area of medicine is not fully understood by many clinicians. Drs. Shulman and Moise provide expert insight on red blood cell alloimmunization, highlighting essential pathophysiology and current and evolving management strategies. Join us to learn new ways to approach this complicated and rare clinical condition.
Host: Courtney DiNardo, MD
Guest: Marina Y. Konopleva, MD, PhD
Developments over the last few years have brought dramatic changes to the treatment landscape of acute myeloid leukemia (AML). While new therapies mean more opportunities to individualize care, clinicians are also faced with new challenges and must quickly evaluate patients, order appropriate molecular tests, assess risk, and differentiate the efficacy, safety, and applicability of novel treatments and combinations. Join Drs. Courtney DiNardo and Marina Konopleva for a discussion of how to untangle the data to determine which treatment is right for each patient in the increasingly complex clinical setting of AML.
Host: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Peter van der Meer, MD, PhD
Iron deficiency in patients with heart failure remains underdiagnosed, undertreated, and commonly overlooked in non-anemic patients and has a significant impact on patient outcomes and quality of life. Join Dr. Robert Mentz and Dr. Peter van der Meer as they discuss approaches to identifying and treating iron deficiency in patients with heart failure and comorbidities such as diabetes.
Host: Robert L. Coleman, MD, FACOG, FACS
Guest: Kathleen Moore, MD, MS
The global burden of cervical cancer is immense, especially for patients who have failed first-line therapy. Second-line interventions have historically had low response rates of short duration. But the landscape is changing with new and emerging agents in late-stage clinical trials, including antibody-drug conjugates, immunotherapy regimens, and tumor-infiltrating lymphocyte therapies. Join Drs. Robert Coleman and Kathleen Moore as they discuss and distill the “need to know” findings about these more effective therapies—therapies destined to improve outcomes for patients whose cervical cancer has failed first-line therapy.
Host: Robert L. Coleman, MD, FACOG, FACS
Guest: Kathleen Moore, MD, MS
The global burden of cervical cancer is immense, especially for patients who have failed first-line therapy. Second-line interventions have historically had low response rates of short duration. But the landscape is changing with new and emerging agents in late-stage clinical trials, including antibody-drug conjugates, immunotherapy regimens, and tumor-infiltrating lymphocyte therapies. Join Drs. Robert Coleman and Kathleen Moore as they discuss and distill the “need to know” findings about these more effective therapies—therapies destined to improve outcomes for patients whose cervical cancer has failed first-line therapy.
Host: Christina Y. Weng, MD, MBA
Guest: Margaret A. Chang, MD, MS
What are the critical steps to implantation and refill of the PDS? Join Dr. Margaret Chang and Dr. Christina Weng to discover the nuances that retina surgeons need to know about to optimize success and minimize patient risk.
Host: Donna Ryan, MD
Guest: Juan Pablo Frías, MD
There are now multiple medical therapies available to facilitate weight loss in patients with type 2 diabetes (T2D). Learn who is the right patient, when these therapies should be started, and the right combinations and intensification strategies to sustain meaningful weight loss that can lower the risk of complications.
Host: Donna Ryan, MD
Guest: Juan Pablo Frías, MD
There are now multiple medical therapies available to facilitate weight loss in patients with type 2 diabetes (T2D). Learn who is the right patient, when these therapies should be started, and the right combinations and intensification strategies to sustain meaningful weight loss that can lower the risk of complications.
Host: Christina Y. Weng, MD, MBA
Guest: Margaret A. Chang, MD, MS
What are the critical steps to implantation and refill of the PDS? Join Dr. Margaret Chang and Dr. Christina Weng to discover the nuances that retina surgeons need to know about to optimize success and minimize patient risk.
Host: David Eichenbaum, MD
Guest: Mark R. Barakat, MD
Several novel treatment options are now available for DME, but do you know how which patients to treat with these agents to prolong durability and improve access? Join Dr. David Eichenbaum and Dr. Mark Barakat as they discuss patient management approaches based on the latest clinical data.
Guest: Neera Dahl, MD, PhD
Guest: Craig E. Gordon, MD
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
Host: David Eichenbaum, MD
Guest: Mark R. Barakat, MD
Several novel treatment options are now available for DME, but do you know how which patients to treat with these agents to prolong durability and improve access? Join Dr. David Eichenbaum and Dr. Mark Barakat as they discuss patient management approaches based on the latest clinical data.
Guest: Neera Dahl, MD, PhD
Guest: Craig E. Gordon, MD
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
Host: Donna Ryan, MD
Guest: Juan Pablo Frías, MD
Dropping 15% or more of body weight has a greater disease-modifying effect than any other glucose-lowering intervention. Join Drs. Donna Ryan and Juan Pablo Frias as they discuss implementing an upstream intervention to weight loss and newer drugs (GIP agonists, GLP-1 receptor agonists, SGLT2 inhibitors) to help your patients experience improved effects earlier and for a longer duration. Tune in to find out how the novel dual GIP and GLP-1 receptor antagonist tirzepatide could fit into your therapeutic strategies.
Host: Suzanne J. Baron, MD
Guest: Jonathan A. Bradlow, MD, FACC
Guest: Kendra J. Grubb, MD
Data are limited on the incidence and factors associated with structural valve deterioration (SVD) after transcatheter aortic valve replacement (TAVR) and surgery for severe aortic stenosis in patients of all risk levels. The lifetime management of these patients requires an understanding of bioprosthetic valve durability and failure. Tune in for new evidence evaluating the 5-year incidence, outcomes, and predictors of hemodynamic SVD in patients undergoing TAVR and surgery that will support best practices for treatment selection.
Host: John Kitchens, MD
Guest: SriniVas R. Sadda, MD
Whether you’re a medical or surgical retina specialist, the port delivery system (PDS) is a practice-changing treatment modality. How can you smoothly incorporate continuous anti-VEGF delivery technology into your clinical practice? Join Dr. SriniVas Sadda and Dr. John Kitchens as they discuss how the PDS fits into our treatment arsenal.
Host: Cem Akin, MD, PhD
Guest: Jason Gotlib, MD, MS
It could take up to 7 years for a patient to be accurately diagnosed with systemic mastocytosis. Drs. Jason Gotlib and Cem Akin take us through the guidelines, diagnostic criteria, signs and symptoms, and the most important diagnostic tests for high-suspicion patients.
Host: Suzanne J. Baron, MD
Guest: Jonathan A. Bradlow, MD, FACC
Guest: Kendra J. Grubb, MD
Data are limited on the incidence and factors associated with structural valve deterioration (SVD) after transcatheter aortic valve replacement (TAVR) and surgery for severe aortic stenosis in patients of all risk levels. The lifetime management of these patients requires an understanding of bioprosthetic valve durability and failure. Tune in for new evidence evaluating the 5-year incidence, outcomes, and predictors of hemodynamic SVD in patients undergoing TAVR and surgery that will support best practices for treatment selection.
Host: Cem Akin, MD, PhD
Guest: Jason Gotlib, MD, MS
It could take up to 7 years for a patient to be accurately diagnosed with systemic mastocytosis. Drs. Jason Gotlib and Cem Akin take us through the guidelines, diagnostic criteria, signs and symptoms, and the most important diagnostic tests for high-suspicion patients.
Host: John Kitchens, MD
Guest: SriniVas R. Sadda, MD
Whether you’re a medical or surgical retina specialist, the port delivery system (PDS) is a practice-changing treatment modality. How can you smoothly incorporate continuous anti-VEGF delivery technology into your clinical practice? Join Dr. SriniVas Sadda and Dr. John Kitchens as they discuss how the PDS fits into our treatment arsenal.
Host: Donna Ryan, MD
Guest: Juan Pablo Frías, MD
Dropping 15% or more of body weight has a greater disease-modifying effect than any other glucose-lowering intervention. Join Drs. Donna Ryan and Juan Pablo Frias as they discuss implementing an upstream intervention to weight loss and newer drugs (GIP agonists, GLP-1 receptor agonists, SGLT2 inhibitors) to help your patients experience improved effects earlier and for a longer duration. Tune in to find out how the novel dual GIP and GLP-1 receptor antagonist tirzepatide could fit into your therapeutic strategies.
Host: Charles P. Vega, MD
Guest: Rajeev Raghavan, MD, M.Ed, FASN
Clinicians have a critical need for up-to-date knowledge related to anemia of CKD. Provide better care for your patients by learning about the importance of assessing and treating while considering the burdens of the disease, advances in our understanding of the pathophysiology of the disease, ways to fill the unmet needs of treatment with ESAs, and the status of potential new therapies. Tune in to keep up!
Host: Charles P. Vega, MD
Guest: Rajeev Raghavan, MD, M.Ed, FASN
Clinicians have a critical need for up-to-date knowledge related to anemia of CKD. Provide better care for your patients by learning about the importance of assessing and treating while considering the burdens of the disease, advances in our understanding of the pathophysiology of the disease, ways to fill the unmet needs of treatment with ESAs, and the status of potential new therapies. Tune in to keep up!
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Patrick Rossignol, MD, PhD
In heart failure, the use of MRAs is often delayed despite being a crucial part of medical therapy. The evidence is clear that clinical inertia and the suboptimal use of these therapies leads to poorer outcomes for our patients. Join Dr. Ileana Piña and Dr. Patrick Rossignol as they discuss approaches to the clinical stigma surrounding the use of MRAs, as well as management strategies to better ensure the best medical therapy possible for our patients with heart failure.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Patrick Rossignol, MD, PhD
In heart failure, the use of MRAs is often delayed despite being a crucial part of medical therapy. The evidence is clear that clinical inertia and the suboptimal use of these therapies leads to poorer outcomes for our patients. Join Dr. Ileana Piña and Dr. Patrick Rossignol as they discuss approaches to the clinical stigma surrounding the use of MRAs, as well as management strategies to better ensure the best medical therapy possible for our patients with heart failure.
Host: Carl Danzig, MD
Guest: Arshad M. Khanani, MD, MA
With the availability of multiple novel treatment options, how do we decide which is best for each patient with neovascular age-related macular degeneration? Join Dr. Arshad Khanani and Dr. Carl Danzig as they discuss their approach to treatment based on the latest clinical evidence.
Host: Carl Danzig, MD
Guest: Arshad M. Khanani, MD, MA
With the availability of multiple novel treatment options, how do we decide which is best for each patient with neovascular age-related macular degeneration? Join Dr. Arshad Khanani and Dr. Carl Danzig as they discuss their approach to treatment based on the latest clinical evidence.
Host: Guillermo Garcia-Manero, MD
Guest: Rami Komrokji, MD
Lower-risk MDS is an acquired bone marrow disorder that manifests with symptomatic anemia. Over time, many of these patients become dependent on red cell transfusions. Erythropoiesis-stimulating agents (ESAs) are first-line treatment, but not all lower-risk MDS patients respond to ESA and many eventually become refractory to ESAs. Join Drs. Guillermo Garcia-Manero and Rami Komrokji as they discuss the diagnostic and prognostic imperatives associated with lower-risk MDS, when to initiate and move on from ESA therapy, and an approach for patients in whom ESAs are no longer effective.
Host: Guillermo Garcia-Manero, MD
Guest: Rami Komrokji, MD
Lower-risk MDS is an acquired bone marrow disorder that manifests with symptomatic anemia. Over time, many of these patients become dependent on red cell transfusions. Erythropoiesis-stimulating agents (ESAs) are first-line treatment, but not all lower-risk MDS patients respond to ESA and many eventually become refractory to ESAs. Join Drs. Guillermo Garcia-Manero and Rami Komrokji as they discuss the diagnostic and prognostic imperatives associated with lower-risk MDS, when to initiate and move on from ESA therapy, and an approach for patients in whom ESAs are no longer effective.
Host: Rami Komrokji, MD
Guest: Michael R. Savona, MD
Guest: Jamile Shammo, MD, FASCP, FACP
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms associated with cytopenias, suboptimal production of mature erythrocytes, and substantial risk for progression to acute myeloid leukemia.
The classification of MDS and MDS/myeloproliferative neoplasm (MPN) overlap syndromes continue to evolve, making them difficult for clinicians to define and raising important new considerations for diagnosis, assessment, risk stratification, and treatment. The presence of ring sideroblasts (RS) and mutations in the SF3B1 gene correlate with favorable outcomes and help define specific disease subtypes.
In this video-based educational activity, an interview-style expert faculty panel will provide their perspectives and insights on the latest trends and emerging research in low-risk MDS, including guideline-directed diagnostic workup, RS evaluation and SF3B1 testing and their implications, currently approved and novel emerging treatment strategies for managing lower risk MDS, and strategies to mitigate and manage treatment-related adverse events.
Host: Rami Komrokji, MD
Guest: Michael R. Savona, MD
Guest: Jamile Shammo, MD, FASCP, FACP
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms associated with cytopenias, suboptimal production of mature erythrocytes, and substantial risk for progression to acute myeloid leukemia.
The classification of MDS and MDS/myeloproliferative neoplasm (MPN) overlap syndromes continue to evolve, making them difficult for clinicians to define and raising important new considerations for diagnosis, assessment, risk stratification, and treatment. The presence of ring sideroblasts (RS) and mutations in the SF3B1 gene correlate with favorable outcomes and help define specific disease subtypes.
In this video-based educational activity, an interview-style expert faculty panel will provide their perspectives and insights on the latest trends and emerging research in low-risk MDS, including guideline-directed diagnostic workup, RS evaluation and SF3B1 testing and their implications, currently approved and novel emerging treatment strategies for managing lower risk MDS, and strategies to mitigate and manage treatment-related adverse events.
Host: Ayse Tuba Kendi, MD
Guest: A. Oliver Sartor, MD
Prostate cancer–specific antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical features predict different stages of PC progression, the application of imaging to guide treatment is still evolving but gaining substantial evidence for the targeting of PSMA. With clinical research shifting paradigms for the treatment of metastatic castration-resistant prostate cancer (mCRPC), novel treatment options require adoption and effective application into clinical practice. PSMA has become an appealing target for diagnostic agents for imaging and therapeutic agents to treat mCRPC. Radionuclide emitters are being used for both cell surface expression of PSMA and the tumor microenvironment, and research has proven the therapeutic efficacy of PSMA-directed radioligand therapy (RLT).
In this educational activity, two experts will examine the role and rationale for PSMA targeted therapies and diagnostics—jointly known as theragnostics—as a revolutionary new approach to treating patients with advanced prostate cancer and will evaluate clinical trial data for PSMA-targeted RLT.
Host: William Mencia, MD, FACEHP, CHCP
Guest: Julie Blatt, MD
Guest: Taizo Nakano, MD
PIK3CA-related overgrowth spectrum (PROS) refers to various clinical entities that share the same pathogenetic mechanism. These disorders are caused by somatic gain-of-function PIK3CA mutations. Diagnosis of PROS is often challenging and requires DNA sequencing of the affected tissue. PIK3CA genetic mutations vary greatly depending on the tissue being tested. PROS is not considered an inherited disease.
The road to a diagnosis of a rare disease can be a long, winding process. Because of its rarity, a wide spectrum of symptoms, and disease heterogeneity, patients may feel alone and as though they are the only ones with the disease. Management of PROS currently involves symptomatic treatment of its manifestations; an unmet need exists for targeted, systemic therapies.
Currently, there is no cure for PROS. This educational activity will assist the interprofessional care team to better understand, apply, and interpret advances in current and emerging evidence that will help bridge the gap toward faster adoption into patient care.
Host: Jason D. Bloom, MD, FACS
Guest: Carolyn I. Jacob, MD, FAAD
The injection of botulinum toxin type A products can diminish unwanted facial wrinkles and improve appearance. Do you fully understand how to use these products? Tune in as Dr. Jason Bloom and Dr. Carolyn Jacob take us through the pharmacologic similarities, differences, and duration of effect for the 4 FDA-approved neuromodulators and demonstrate specific injection techniques for the masseter, platysma bands, “bunny lines,” and the glabellar complex.
Host: Jason D. Bloom, MD, FACS
Guest: Carolyn I. Jacob, MD, FAAD
The injection of botulinum toxin type A products can diminish unwanted facial wrinkles and improve appearance. Do you fully understand how to use these products? Tune in as Dr. Jason Bloom and Dr. Carolyn Jacob take us through the pharmacologic similarities, differences, and duration of effect for the 4 FDA-approved neuromodulators and demonstrate specific injection techniques for the masseter, platysma bands, “bunny lines,” and the glabellar complex.
Host: Mikhail Kosiborod, MD
Optimizing GDMT for patients with heart failure and concomitant kidney dysfunction and/or diabetes continues to be a challenge despite the overwhelming clinical evidence and recent updates to the guidelines for heart failure management. Recent evidence from clinical trials with SGLT2 inhibitors and mineralocorticoid receptor antagonists and the use of novel potassium binders provide new therapeutic opportunities for these patients. This activity will review the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes.
Host: Mikhail Kosiborod, MD
Optimizing GDMT for patients with heart failure and concomitant kidney dysfunction and/or diabetes continues to be a challenge despite the overwhelming clinical evidence and recent updates to the guidelines for heart failure management. Recent evidence from clinical trials with SGLT2 inhibitors and mineralocorticoid receptor antagonists and the use of novel potassium binders provide new therapeutic opportunities for these patients. This activity will review the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes.
Host: John J. Russell, MD
Guest: Vallerie V. Mclaughlin, MD
Join Dr. John Russell as he speaks about diagnosing and treating pulmonary arterial hypertension using the latest pharmacologic and medical management strategies with Dr. Valerie McLaughlin, Director of the Pulmonary Hypertension Program at the University of Michigan.
Host: John J. Russell, MD
Guest: Vallerie V. Mclaughlin, MD
Join Dr. John Russell as he speaks about diagnosing and treating pulmonary arterial hypertension using the latest pharmacologic and medical management strategies with Dr. Valerie McLaughlin, Director of the Pulmonary Hypertension Program at the University of Michigan.
Host: Shanu Modi, MD
Guest: Sara A. Hurvitz, MD, FACP
This Expert Exchange webcast is designed to help improve clinicians’ ability to implement appropriate treatment strategies for patients with HER2+ breast cancer.
Host: Shanu Modi, MD
This Clinical Case Challenge is designed to help improve clinical decision making for providers caring for patients with HER2+ breast cancer.
Host: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
Guest: Javier Morales, MD, FACP, FACE
Guest: Angela Yee-Moon Wang, MD, FACP, FACE
Diabetic nephropathy is one of the leading causes of end-stage renal disease (ESRD) and is associated with mortality and morbidity worldwide. Recent data on the use of nonsteroidal MRAs were presented at the European Society of Cardiology and other major meetings and were simultaneously published in major journals. Join our experts to explore these data and find out how you can better prevent the deterioration of renal function and improve cardiovascular outcomes in your patients across the spectrum of renal decline.
Host: Dixon W. Wilde, PhD, FAHA
Guest: Jean M. Elwing, MD
Many pulmonary arterial hypertension (PAH) patients remain undiscovered, undiagnosed, and underserved. The reasons for this are many-fold, but central to the treatment of these patients is a need to make PAH care more accessible, affordable, and attractive. The COVID-19 pandemic has further exacerbated the need to connect with not only undiscovered PAH patients, but even those currently under physician care. That’s why this program explores myriad aspects of finding means to discover, connect with, and manage the disease of these underserved PAH patients in our general population. Key explorations brought to light in the program include the burdens many patients and physicians face with the financial costs to care, the prejudices many experience or perceive, and the lack of education and awareness of patients and healthcare providers alike. Part of the solution to these modern-day issues centers on the education of physicians, reducing medical and ancillary costs to patients, and making the most of the developing practices of telemedicine.
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Guest: Narjust Duma, MD
Guest: Janani Reisenauer, MD
Guest: Colleen Channick, MD, FCCP, DAABIP
A multidisciplinary panel including a medical oncologist, a thoracic surgeon, and an interventional pulmonologist will discuss the role of lung cancer teams in their thoracic oncology practices. The panelists will review their management of patients with lung cancer during the COVID-19 pandemic, including the impact of delayed procedures and telemedicine on patient outcomes.
Host: Mark Socinski, MD
Guest: Jennifer Marie Suga, MD, MPH
There are new targeted therapies that are now approved for the treatment of advanced non-small cell lung cancer. Dr. Mark Socinski & Dr. Marie Suga discuss evolving diagnostic approaches and best practices for selecting the right therapy for patients with NSCLC.
Host: Susan O’Brien, MD
Guest: Timothy Call, MD
The process of matching the most optimal first-line therapy to patients with CLL has recently undergone a paradigm shift. Along with a widening focus on targeted agents, untangling key patient- and disease-centric parameters adds complexity to this shared decision. Join Drs. Susan O’Brien and Timothy Call as they offer clarity to this first-line decision process—a clarity that you can readily take into the clinic.
Host: Jacob D. Soumerai, MD
Guest: Andrew H. Lipsky, MD
The landscape of treatment for CLL is rapidly evolving, with promising results from trials examining chemotherapy-free regimens in the frontline setting. While these targeted approaches utilizing BTK or BCL-2 inhibitors have largely displaced chemoimmunotherapy in frontline management of CLL, there remains a clinically significant fraction of patients who will require subsequent therapy after developing drug intolerance or progressive disease. Join Drs. Andrew Lipsky and Jacob Soumerai as they strategize which targeted therapeutic options for relapsed/refractory CLL likely offer each individual patient the safest and most effective clinical outcome.
Host: Ian W. Flinn, MD, PhD
Guest: William Wierda, MD
Preventing or mitigating adverse events (AEs) when utilizing small molecule inhibitors of BTK and Bcl-2 in the management of CLL is critical to improving patient outcomes. Coupling each agent’s unique side-effect profile with the appropriate patient makes the decisions even more complex. Join Drs. Ian Flinn and William Wierda as they deep dive into these issues and offer actionable guidance backed by key clinical trials.
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Guest: Narjust Duma, MD
Guest: Andreas Rimner, MD
Two internationally known medical and radiation oncologists will discuss ongoing and recent clinical trials and offer their perspectives on how they will impact thoracic oncology practice. The panelists will also discuss current guidelines for managing patients with advanced lung cancer and emphasize the role of tissue and blood biomarkers.
Host: Monique Hartley-Brown, MD, MMSc
Guest: Shonali Midha, MD
Significant progress has been made with induction and initial treatment of multiple myeloma, leading to longer and deeper remissions for patients. Yet, how do you decide which regimen is best? Hear how Dr. Monique Hartley-Brown and Dr. Shonali Midha navigate the treatment of their newly diagnosed patients and what factors they consider when selecting a regimen.
Host: Jennifer Caudle, DO
Guest: Alireza Atri, MD, PhD
Guest: Sharon J. Sha, MD, MS
Alzheimer’s disease (AD) is a progressive, irreversible, neurodegenerative disease that significantly impacts the lives of patients and their families, as well as society. AD is typically diagnosed later in the disease course, limiting time for psychoeducation, interventional strategies, and planning. Additionally, this delayed diagnosis leads to inefficient or unnecessary care, as well as higher costs, and causes harm to individuals and society. That is why detecting AD early is critically important.
In the second part of this two-episode series, expert faculty will answer some of your questions pertaining to the early detection of AD.
If you haven’t viewed the first part of this series, you can view it here.
Guest: Amrita Krishnan, MD
Guest: Morie Gertz, MD, MACP
Patients with multiple myeloma inevitably experience disease relapse, which is challenging. Rapid therapeutic advances have heralded an increasing number of efficacious targeted strategies and combination therapies for patients after a first relapse or in those with heavily pretreated disease. However, selecting the optimal regimen requires a individualized approach. Hear how Dr. Amrita Krishnan and Dr. Morie Gertz translate the evolving clinical data into their clinical practices and what factors influence their choices to improve durable responses and outcomes for patients with relapsed/refractory multiple myeloma.
Host: Shaji K. Kumar, MD
Guest: María-Victoria Mateos, MD, PhD
A plethora of new data for multiple myeloma were presented at ASCO 2022. Hear Dr. Shaji Kuman and Dr. Maria-Victoria Mateos discuss the most relevant findings and which emerging strategies look promising for patients.
Guest: Amrita Krishnan, MD
Guest: Cesar Rodriquez Valdes, MD
There is an unmet clinical need for more durable responses in patients with multiple myeloma because of their inevitable relapses. Advances in our ability to delineate the molecular pathobiology of the disease are guiding impressive new therapeutic options for this patient population. Join Dr. Cesar Rodriguez Valdes and Dr. Amrita Krishnan as they discuss the latest data around emerging agents targeting BCL-2 and BCMA for multiple myeloma and the investigational targets on the horizon.
Guest: Caitlin Costello, MD
Guest: Ravi Vij, MD
Frontline management of patients with newly diagnosed multiple myeloma is complicated by a multitude of current and newer agents, and navigating the guidelines can be confusing. Tune in as Drs. Caitlin Costello and Ravi Vij provide insight into the newer agents and different administration modalities so that you can address your patients’ questions.
Host: Dixon W. Wilde, PhD, FAHA
Guest: Vallerie V. Mclaughlin, MD
In the management of the pulmonary arterial hypertension (PAH) patient, the use of risk assessment algorithms has become de rigueur for the regular determination of disease progression and the effectiveness of treatment. However, based on the registries, from which the modern risk assessment models have been developed, it’s clear that the majority of patients fall into the intermediate-risk category. And yet, within this broad category, there’s a spectrum of disease severity, medical treatment need, and survivorship. Using risk assessment effectively in the modern era will rely on a rethinking of how to use risk assessment and adjusting disease management strategies appropriately. This program explores new ideas in the use and application of risk assessment protocols and the impact these have on the use of multimodal, combination therapy and lung transplantation.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Nanette F. Santoro, MD
Tune out the noise and get to the heart of managing menopause and associated vasomotor symptoms. This program provides highlights from the 2022 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting. Join Drs. Nanette Santoro and Lee Shulman as they dive into the latest research, which could alter your current practice patterns and help your patients cool off.
Host: Ayman Al-Hendy, MD
Despite its profound impact, endometriosis remains critically undermanaged. This program provides highlights from a live symposium at the annual meeting for obstetrics and gynecology professionals and is based on patient & provider surveys. Join Dr. Ayman Al-Hendy to explore management gaps, the role of GnRH antagonists in addressing deficits, and the latest research, which he presented with Drs. Andrea Lukes and Lee Shulman—you might just alter your current practice patterns.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Adrian F. Hernandez, MD, MHS
Recent clinical trial data and subsequent approval of novel therapies have expanded the treatment armamentarium. These advances have the potential to improve long-term patient outcomes, but also make the choice of therapy more complex. This activity aims to educate clinicians managing patients with HFrEF already on guideline-directed medical therapy (GDMT) who continue to be at high risk of rehospitalization to recognize the clinical characteristics of worsening heart failure and to select appropriate HF treatment strategies including novel classes of agents in heart failure.
Host: Mitchell D. Creinin, MD
In-office delivery of sexual and reproductive healthcare (SRH) services was markedly restricted for 2 years during the COVID-19 pandemic. Now, in-office access to these services has begun to improve. What have we learned since 2020 that can prepare us for future periods of reduced access? Join Dr. Mitchell Creinin as he discusses SRH service strategies initiated during the pandemic that remain useful even in times of full in-office access.
Host: Eric Edell, MD, FCCP
Host: Septimiu Murgu, MD, FCCP
Guest: Narjust Duma, MD
Guest: Christopher Hartley, MD
Guest: Jeffrey Mueller, DO
Expert pathologists and a medical oncologist will discuss current guidelines and their own practices regarding the role of liquid biopsy and comprehensive genetic and PD-L1 testing in the management of advanced lung cancer. The panelists will also explore various strategies for optimizing the quantity and quality of cytology and small volume biopsy specimens.
Host: Javed Butler, MD, MBA, MPH
Guest: Pam R. Taub, MD, FACC, FASPC
Guest: Marc S. Sabatine, MD, MPH
Two lipid experts will 1) provide an overview of the landscape of nonstatin, LDL-C-lowering therapy, 2) explain current guideline recommendations, 3) describe the evidence with ezetimibe and PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease (ASCVD), 4) discuss cardiovascular risk reduction with PCSK9 inhibitors in a variety of very high risk ASCVD patient populations, and 5) emphasize the need to incorporate PCSK9 inhibition early in acute coronary syndrome patients to facilitate best patient outcomes.
Host: Luis Paz-Ares, MD, PhD
Guest: Kristen Marrone, MD
In the first-line management of non-small cell lung cancer, the use of immune checkpoint inhibitors (ICI) as monotherapy, as dual ICI, in combination with chemotherapy, or not at all is broadly dependent on which biomarkers are identified. While the choice of therapy is generally based on the level of expression of 1 or more biomarkers (eg, PD-L1, TMB), other factors often complicate this decision. Join us as Drs. Luis Paz-Ares and Kristen Marrone tackle these complexities by providing both foundational and clinical guidance to help you help your patients.
Host: Elizabeth Smyth, MD
Guest: Jaffer Ajani, MD
HER2 expression is a crucial biomarker when selecting treatment for patients with advanced gastric and gastroesophageal junction (GEJ) cancers. Until recently, there were limited therapeutic options. Join this lively conversation to enhance your knowledge related to emerging data and optimal treatment selection for patients with HER2-positive gastric and GEJ cancers.
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Guest: Nichole Tanner, MD, MS, FCCP
Guest: Fabien Maldonado, MD, FCCP
Two internationally known interventional pulmonologists will discuss current guidelines and their own experiences regarding sampling of lung lesions and mediastinal adenopathy. Specifically, the panelists will discuss the pros and cons of various diagnostic strategies and sampling techniques, including transcutaneous and bronchoscopic biopsies. This interactive webinar will offer the opportunity for learners to ask questions prior to and during the event. Learning is augmented by a few follow-up quizzes weeks after the webinar, a strategy proven to improve knowledge gain and retention.
Host: Jennifer Caudle, DO
Guest: Alireza Atri, MD, PhD
Guest: Brad Dickerson, MD
Guest: Sharon J. Sha, MD, MS
Alzheimer’s Disease (AD) is a progressive disease that presents challenges when it comes to the early diagnosis and treatment of patients. That’s why this two-part series will help answer your specific questions while providing expert insights into these challenges.
In this first activity, a panel of esteemed faculty will examine the case of a patient who was diagnosed early with mild cognitive impairment (MCI) due to AD, prior to dementia. Using this patient case, faculty will delve into both the importance of early identification of AD and how to detect it early. The panel will then discuss the pathobiology of AD and potential treatments in development to target this pathology. Finally, the panel will explore current treatment options, including the appropriate use of anti-amyloid monoclonal antibody (mAb) treatment. Throughout this activity, we will gather questions from clinicians like you who care for patients living with dementia, and then in part two of this series, we will answer some of the questions generated from this first activity.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Charles P. Vega, MD
We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A pragmatic approach that addresses residual cardiovascular (CV) risk across a variety of risk factors and that goes beyond LDL-C lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients require review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.
Host: Jeffery D. Dunn, PharmD, MBA
Guest: Gary M. Owens, MD
Guest: Anita L. Nelson, MD
Are you ready to see what is on the horizon to more effectively navigate vasomotor symptoms (VMS)? Join Drs. Dunn, Owens, and Nelson as they discuss highlights from a symposium held at AMCP 2022 featuring the latest data on the impact of menopause and evolving treatments options. They provide guidance, context, and recommendations for the medical management of VMS beyond estrogen. The nonhormonal treatment options that are currently being studied represent a new horizon for both patients and payers.
Host: Jennifer Caudle, DO
Guest: April W. Armstrong, MD, MPH
Guest: Allan Gibofsky, MD, JD, MACR, FACP, FCLM
There's good news for patients and clinicians dealing with the challenges of psoriasis or psoriatic arthritis (PsA). Novel and emerging therapies exist that can help improve symptoms, and slow or prevent disease progression. In this fast-paced, clinical discussion, you'll hear from two leading experts who will share recent evidence and highlights from the American Academy of Dermatology (AAD) Annual Meeting that support using novel biologic and targeted synthetic agents for psoriasis and PsA. As part of the discussion, they also examine a patient case illustrating how you can optimize treatment plans, integrate the latest guideline recommendations in your practice, and encourage shared decision making with your patients.
Host: Richard Elion, MD
Sexual histories are a vital part of ensuring a patient’s well-being. Nonetheless, many providers are uncomfortable taking a sexual history for an individual who may be at increased risk for acquiring HIV. The ability to offer a preventative medication for HIV acquisition is a cornerstone for informed consent for sexual health. Join Dr. Richard Elion as he takes us through a patient-clinician dialogue demonstrating how to take a sexual history that is complete, respectful, and nonjudgmental.
Host: Sagar Lonial, MD
Guest: Noopur Raje, MD
Two newly approved BCMA-directed CAR T cell therapies, idecabtagene vicleucel and ciltacabtagene autoleucel, are providing patients with the prospect of deep and durable remissions. Maximizing the potential of CAR T cell therapy can provide improved length and quality of life for patients with multiply relapsed multiple myeloma. Join us as Dr. Sagar Lonial and Dr. Noopur Raje discuss the available treatment options, current applications of the clinical data, and strategies to improve care for your patients with multiple myeloma who may be candidates for CAR T cell therapy.
Host: Christie M. Ballantyne, MD
Guest: Gregory Pokrywka MD, FACP, FNLA, FASPC, NCMP
Guest: Joseph Saseen, PharmD, BCPS, BCACP, CLS
Guest: Karol Watson, MD, PhD
Managing patients with established CVD presents challenges in our practice every day. These patients may have had a prior stroke or MI and are at a very high risk of future life-threatening CV events. Join our expert faculty to hear the latest data on new and emerging statin adjuncts presented in a highly relevant and clinically applicable format. Barriers to the optimal management of ASCVD risk in many patient types (ethnicity/race/sex) will be addressed, and solutions to effectively manage such challenges in your everyday clinical practice will be provided.
Host: Lyudmila Bazhenova, MD
Guest: Benjamin Levy, MD
HER2-targeted therapies have demonstrated substantial survival benefits for patients with HER2-positive breast cancer. So can we use those agents for HER2-positive NSCLC? Join Dr. Lyudmila Bazhenova and Dr. Benjamin Levy as they discuss the latest data around emerging agents for HER2-positive NSCLC and the best way to identify these mutations in clinical practice.
Host: Anthony Mato, MD, MSCE
During the past 10 years, BTK inhibitors are increasingly replacing chemotherapy-based regimens, especially in patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Current clinical practice is continuous long-term administration of covalent, irreversible BTK inhibitors, which can be complicated by side effects or the development of drug resistance. Resistance mutations and intolerance contribute to therapy interruption or discontinuation and abrogate clinical benefits associated with continued covalent BTK inhibitor therapy, leading to subsequent care that is suboptimal due to a dearth of effective treatment options (as reflected in lower progression-free survival, overall survival, or response duration). Non-covalent, reversible BTK inhibitors do not bind to C481, therefore providing a potentially effective option to patients with B cell malignancies that have developed resistance to covalent BTK inhibitors. Preliminary clinical studies have suggested that non-covalent BTK inhibitors are effective and well-tolerated.
This educational activity will assist hematology-oncology professionals develop management plans designed to overcome these challenges and offer patients the full benefit of BTK inhibitor therapy. We will discuss the clinical implications of BTK inhibitor selectivity profiles and safety differences; the integration of BTK inhibitors into the management of different B-cell cancer patient populations; and the proactive adaptation of treatment plans to …
Host: Amer Zeidan, MBBS
Guest: Amy E. DeZern, MD, MHS
MDS is a very heterogenous clonal bone marrow disorder with a high risk for anemia and progression into acute myeloid leukemia. Dr. Amer Zeidan and Dr. Amy DeZern discuss how to appropriately monitor and treat patients with higher-risk MDS.
Host: Richard S. Isaacson, MD
Guest: Michael Weiner, MD
Are you familiar with available and developing tools for assessing Alzheimer’s disease (AD)? Correctly using these tools can lead to a vital earlier diagnosis which can improve outcomes for our patients. Tune in to hear Dr. Richard Isaacson and Dr. Michael Weiner take us through some of these assessment tools and they ways in which they can help us reach a true diagnosis of AD.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Stephanie Martin, DO
How ready are you to go beyond simply ordering CBCs and recognizing anemia? Join Drs. Martin and Shulman as they discuss the latest developments in oral and IV iron therapies. Learn how you may take a more active role in managing iron deficiency anemia, focusing on abnormal uterine bleeding.
Participating in this activity will ensure that you are prepared to address the goals with your patients by improving access and adherence to efficacious and convenient therapies.
Host: Ahmad Masri, MD, MS
Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
—Breaking News—Commentary on HCM-related Late-Breaking Abstracts presented at ACC.22 in April has been added to the start of the program. The rest of the program will cover the following topics: Why do we need new therapies in hypertrophic cardiomyopathy (HCM), and will newer and emerging cardiac myosin inhibitors improve the standard of care for patients with HCM? What differences can we expect regarding patient outcomes and quality of life with these new therapies? Join Dr. Ahmad Masri and Dr. Deepak Bhatt as they explore how newer cardiac myosin inhibitors go beyond traditional medical management (that only addresses the macro-pathophysiology and disease symptoms) to actually treat HCM at the cellular level.
Host: Andrew M. Brunner, MD
Guest: Amy E. DeZern, MD, MHS
New and novel therapeutics for the treatment myelodysplastic syndrome (MDS) are in development. What are these agents, and how do they work? Listen in as Dr. Andrew Brunner and Dr. Amy DeZern discuss ongoing clinical trials, current data from those trials, and the future potential for tailoring treatment plans.
Since the completion of this activity, the U.S. Food and Drug Administration has lifted the partial clinical hold placed on studies evaluating the investigational agent magrolimab in combination with azacytidine for the treatment of MDS and AML.
https://clinicaltrials.gov/ct2/results?cond=&term=Magrolimab+&cntry=&state=&city=&dist=
Host: Larry Anderson, MD, PhD
Guest: Thomas G. Martin, MD
Patients with multiple myeloma (MM) whose disease has relapsed multiple times have historically poor outcomes. CAR T cell therapy is a novel therapeutic option for those patients and can provide prolonged responses and improved outcomes. However, the treatment is complex, and careful planning is needed to effectively incorporate these treatments into practice. Drs. Thomas Martin and Larry Anderson discuss CAR T cell therapies for MM with a focus on patient selection, accessibility of treatment, and management of patients after administration.
Host: Mikhail Kosiborod, MD
Guest: Austin G. Stack, MBBCh, MD, MSc, FASN, FRCPI
RAASi therapy is a critical component of heart failure management; however, concern about patients developing hyperkalemia often leads to clinical delay and suboptimal dosing. This is especially evident in our patients with chronic kidney disease. So how can we simultaneously maintain optimal therapy and manage hyperkalemia? Join Dr. Mikhail Kosiborod and Dr. Austin Stack as they discuss a patient case and make sure you’re staying up to date with the evolving data, guidelines, and practices.
Host: Neilanjan Nandi, MD
Guest: David T. Rubin, MD
The proliferation of new classes of therapies for ulcerative colitis is affecting how we decide which treatments are most appropriate for our patients who are first- or second-line non-responders. This creates not only new challenges, but also new opportunities for all community gastroenterologists. Dr. Neil Nandi and Dr. David Rubin walk us through a case to highlight some of these challenges.
Since the completion of this activity, results from the ELEVATE UC 52 study, a yearlong phase 3 trial of etrasimod in moderate to severe ulcerative colitis, were announced. Etrasimod is an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator that showed positive 12- and 52-week results compared to placebo. Patients achieved statistically significant improvements in the co-primary endpoint of clinical remission at weeks 12 and 52 when compared to placebo. Statistically significant improvements were also attained in all key secondary endpoints at both 12 and 52 weeks. We will provide more data as the full results are published and presented in the future.
Host: Neal Bhatia, MD
Guest: Jeffrey Sugarman, MD, PhD
Drs. Neal Bhatia and Jeff Sugarman discuss how the new formulation of benzoyl peroxide can change our treatment armamentarium for rosacea. Find out how microencapsulation technology stabilizes BPO and improves outcomes for patients.
Host: Adrienne W. Scott, MD
Guest: Rajendra Apte, MD, PhD
Guest: Jennifer I. Lim, MD, FARVO
A main goal in the treatment of diabetic retinopathy is to intervene early enough to prevent vision loss. New data are giving us new tools for our armamentarium and helping us define what constitutes “early”—and if there’s such a thing as “too early.” Join us to take a closer look at the data surrounding the management of NPDR and CI-DME with good vision and hear our panelist of experts explain how the data translate into clinical care.
Host: Rachel Caskey, MD, MAPP
Guest: Gwendolyn Ramirez
Vaccine hesitancy is a very challenging, and often tiring topic, for clinicians to address. Join Dr. Rachel Caskey in an engaging clinician-patient dialogue as she uses a dynamic and presumptive approach to overcome common vaccination challenges. What communication pearl will you use with your patients?
Host: George I. Papakostas, MD
Host: Larry Culpepper, MD, MPH
This Expert Exchange webcast is designed to help clinicians achieve better outcomes in patients with MDD who have an inadequate initial treatment response.
Host: Eugene E. Wright, Jr., MD
Guest: Jolanta Małyszko, MD, PhD
Guest: María José Soler, MD, PhD
Achieving optimal outcomes when treating patients with chronic kidney disease (CKD) in type 2 diabetes (T2D) remains a challenge due to the multidisciplinary response needed to prevent progressive renal dysfunction. Low screening rates and underdiagnosis impede early interventions. On the other hand, early diagnosis and regular screening of CKD in T2D set the stage for clinicians to optimize drug therapy to prevent progression to end-stage renal disease while aggressively managing comorbid T2D and other CKD risk factors.
Host: Sergio Schwartzman, MD
Guest: April W. Armstrong, MD, MPH
Guest: Philip J. Mease, MD, MACR
Integrating routine assessments of psoriatic arthritis (PsA)-related structural progression has proven challenging in clinical practice. Join Drs. Sergio Schwartzman, Philip Mease, and April Armstrong as they discuss evidence that frequent monitoring of PsA structural progression permits earlier intervention with effective therapies as well as provides indications for when to switch to another class of agent. They also address which therapeutic agents have been shown to impact PsA structural progression in clinical trials and provide insight into how best to incorporate collaborative treatment strategies across disciplines. These practices are likely to improve outcomes for patients with PsA, so be sure to stay informed.
Host: Javed Butler, MD, MBA, MPH
Guest: Stefan D. Anker, MD, PhD
The DIAMOND trial recently released topline results, adding to the growing clinical evidence for the use of potassium binders in the management of hyperkalemia in patients with heart failure. So what do the data mean for our patients? Join Dr. Stefan Anker and Dr. Javed Butler as they discuss the value of these results and make sure you’re staying up to date with the evolving data, guidelines, and practices.
Host: David J. Portman, MD
Guest: Patty Cason, RN, MS, FNP-BC
Guest: David L. Eisenberg, MD, MPH, FACOG
Are you ready for the contraceptive revolution? Are you applying the latest information on contraceptive efficacy, recent clinical trial data, and sexual satisfaction when counseling your patients on contraceptive options? Join Dr. David Portman, Dr. David Eisenberg, and Ms. Patty Cason as they discuss the novel mechanisms of action of cutting-edge, non-hormonal contraceptive options, such as the vaginal pH modulator (VPM). Participating in this activity will ensure that you are prepared to discuss sexual and reproductive goals with your patients and confirm that your patients’ goals are being met.
Host: Javed Butler, MD, MBA, MPH
Guest: Shelley Zieroth, MD
Have you started using newly approved therapies when caring for your patients with heart failure with reduced ejection fraction (HFrEF)? Tune in to hear Drs. Javed Butler and Shelley Zieroth discuss strategies you can use to determine the best treatment approaches for your most challenging patients. A 3D mechanism of action animation is included to help you understand the workings of novel classes of agents in heart failure. Make sure you get with the guidelines, because guideline-directed medical therapy really does work.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Ayman Al-Hendy, MD
Surgery has long been the default choice when managing uterine fibroids and endometriosis. However, over the past few years, reliable and durable medical interventions have emerged, notably GnRH antagonist therapy. Clinical trial data for GnRH antagonists highlight both their safety and efficacy for a broad demographic of patients. Join Drs. Lee Shulman and Ayman Al-Hendy as they discuss the “how” and the “why” of a paradigm shift that is occurring, changing our focus from surgery to first-line medical intervention for uterine fibroids and endometriosis.
Host: Kristen Whitaker, MD, MS
Guest: Ricki Fairley, BA, MBA
Guest: Sara M. Tolaney, MD, MPH
For patients with recurrent unresectable or metastatic triple negative breast cancer (TNBC), standard systemic therapy has largely consisted of chemotherapy, though the outlook has improved recently following FDA approval of several targeted therapies and immunotherapeutic options. The management of TNBC remains quite challenging for clinicians, particularly in light of persistent disparities in TNBC care that disproportionately impact specific patient populations (eg, women of minoritized populations). Racial disparities specific to TNBC include a higher incidence, more advanced stage at diagnosis, and increased mortality among black women versus white women in the United States.
This web-based, on-demand, activity will review health disparities and inequities in TNBC and how they impact care, along with the latest evidence for current and emerging antibody-drug conjugates and immunotherapeutic agents, to assist oncology professionals in delivering impartial care to all patients.
Host: Miguel A. Escobar, MD
Guest: Cindy Leissinger, MD
Guest: Guy Young, MD
Hemophilia A is an X-linked genetic disorder characterized by a deficiency in normal factor VIII resulting in an increased risk of bleeding. Repeated bleeds, notably in the joints, lead to chronic pain and loss of function. Joint damage can be prevented, at least in part, with prophylactic factor VIII replacement. Although factor VIII can be replaced, its intravenous administration is burdensome, which may impair adherence. Furthermore, about 30% of patients treated with factor VIII will develop inhibitors—neutralizing alloantibodies to factor VIII—making factor VIII replacement ineffective. Although patients with inhibitors can be treated with bypassing agents, these agents are expensive and less predictable than factor VIII.
However, there is now another option for both patients with and without inhibitors: bispecific antibody non–factor replacement prophylaxis. It is important for the interprofessional care team to be aware of how this treatment compares with traditional prophylactic agents, its safety and efficacy data, and how to appropriately incorporate prophylaxis therapy based on the latest real-world clinical data.
In this educational activity, an expert faculty will review and provide their interprofessional perspectives on currently approved prophylaxis therapy in hemophilia A, including the benefits of prophylaxis and adherence, real-world experience, and patient quality of life factors.
Host: Matthew S. Davids, MMSc, MD
Many CLL treatments cause a high risk for tumor lysis syndrome (TLS), an oncologic emergency due to the release of intracellular contents of tumor cells characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. These electrolyte imbalances may be severe enough to cause acute renal failure, cardiac arrhythmias, seizures, loss of muscle control, and even death. In addition, neutropenia is a common side effect associated with CLL therapies, which increases the risk for infection and can disrupt or delay treatment, ultimately affecting patient outcomes.
A greater understanding of assessment and management of TLS and neutropenia is critical for reducing the likelihood of life-threatening complications in patients with CLL, which allows patients to continue to receive treatment.
AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent educational series on preventing and managing tumor lysis syndrome and neutropenia in CLL.
Host: John J. Russell, MD
Guest: R. Scott Turner, MD, PhD
Alzheimer’s disease (AD) is an irreversible, age-related, neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. It is the most common cause of dementia worldwide and its’ prevalence continues to grow in part because of the aging world population. AD is characterized classically by two hallmark pathologies: β-amyloid plaque deposition and neurofibrillary tangles of hyperphosphorylated tau. Diagnosis is based upon clinical presentation fulfilling several criteria including fluid and imaging biomarkers. Until recently, current therapies were limited to delaying cognitive decline in some patients, but not treating the underlying causes of the disease nor halting the progression of the disease. This program discusses recent advances in our understanding of the clinical evaluation for early and accurate diagnosis, newly approved and emerging disease-modifying therapies, as well as non-pharmacological strategies for the management of patients with AD.
Host: Jayanth Sridhar, MD
Guest: Avni P. Finn, MD, MBA
Are you aware of the latest data that adds to our understanding of the management of diabetic retinopathy (DR)? Listen in as Dr. Avni Finn and Dr. Jay Sridhar discuss what those data are and the impact they have on the early referral and timely treatment of patients with DR. Make sure you’re properly using all of the resources in your armamentarium to save your patients’ sight.
Host: Mark Socinski, MD
Guest: Benjamin Levy, MD
With the availability of more immunotherapies for the management of first-line metastatic NSCLC, PD-L1 status takes on greater importance in determining which approach is best for each patient. Follow along as Dr. Mark Socinski and Dr. Benjamin Levy discuss the factors they use when considering either an immuno-monotherapy or immunotherapy plus chemotherapy approach, and how they monitor for and manage immunotherapy-related adverse events.
Host: Jonathan C. Routh, MD, MPH, FAAP
Guest: Benjamin M. Whittam, MD, MS, FAAP, FACS
This Expert Exchange webcast is designed to enhance clinicians’ awareness of advances in the pharmacotherapeutic armamentarium for treating NDO in the pediatric population.
View the Advances in the Treatment of Neurogenic Detrusor Overactivity Clinical Compendium here: https://cdn.reachmd.com/uploads/clinicalcompendium_ndo_v2_final.pdf
Guest: David H. Ilson, MD, PhD
Guest: Jaffer Ajani, MD
This Expert Exchange webcast is designed to help improve clinicians’ ability to implement appropriate treatment HER2 strategies for patients with gastric cancer.
Host: Ilene Weitz, MD
Guest: Jamile Shammo, MD, FASCP, FACP
In a “how I do it” clinical commentary, Dr. Jamile Shammo and Dr. Ilene Weitz share their real-world experience in the diagnosis and management of PNH in special patient populations. This case-based activity includes clinical scenarios and treatment strategies to improve patient outcomes.
Host: Jennifer Caudle, DO
Guest: Kevin Black, MD
Hallucinations and delusions cause a significant number of hospitalizations and nursing home admissions for our patients with Parkinson’s Disease. Listen to Dr Kevin Black share his approach to timely diagnosis and evidence-based management that can improve the daily lives of these patients and their caregivers.
Kevin Black, MDProfessor of Psychiatry, Neurology, Radiology, and Neurobiology
Washington University in St Louis School of Medicine
St Louis, Missouri
Host: Peter Libby, MD
Guest: Lawrence A. Leiter, MD
Guest: Prof. Kausik Ray, MBChB, MD, MPhil
This CME Roundtable highlights key takeaways and late-breaking data shared at a symposium held at the AHA annual meeting. Hear updated management strategies, new data, and guidelines to help you manage patients with established ASCVD who are at an increased risk of myocardial infarction, stroke, and death.
Host: Adam M. Brufsky, MD, PhD
Host: Nina Thomas, MD
Interstitial lung disease (ILD) is a heterogeneous group of diseases that produce inflammation and fibrosis of the parenchyma, affecting the alveolar, interstitial, and vascular spaces. Drug-induced (DI) ILD is associated with a range of novel targeted therapies for the treatment of multiple cancer types, including immune checkpoint inhibitors, CDK 4/6 inhibitors, EGFR tyrosine kinase inhibitors, HER2 targeted therapies, and mechanistic target of rapamycin inhibitors.
Although management of low-grade or asymptomatic ILD with corticosteroid treatment and/or treatment interruption may slow or reverse ILD progression, higher-grade/symptomatic ILD requires permanent discontinuation of therapy. Therefore, it is critical that the interprofessional care team is prepared to monitor for and detect anti-cancer therapy–induced ILD. This educational activity will review the latest evidence and strategies for the early detection of medication-induced ILD and pneumonitis and appropriate management strategies to overcome these treatment challenges in patients who receive select anti-cancer therapies. Expert thought leaders will present relevant information about cancer therapy–induced ILD and pneumonitis and how to integrate the latest advances into real-world clinical practice regarding differential diagnosis, hallmark signs/symptoms, recommended management strategies, implications of patient/caregiver education, and the essentials of team-based management to optimize patient outcomes.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Andrea S. Lukes, MD, MHSc, FACOG
By 50 years of age, 70% to 80% of women are affected by uterine fibroids, and nearly 10% of women are affected by endometriosis. Clinical trial data demonstrate that GnRH antagonist therapy can dramatically impact pain and bleeding and improve results across all EHP-30 domains. Join Drs. Lee Shulman and Andrea Lukes as they dive into these data and offer strategies to help you better incorporate patient-centric medical management for uterine fibroids and endometriosis into your clinical practice.
Host: Clete A. Kushida, MD, PhD
Guest: Lois E. Krahn, MD
Tune in to hear about new treatments for patients with narcolepsy. Data were recently presented at the American College of Chest Physicians Annual Meeting, and Drs. Clete Kushida and Lois Krahn are breaking it down for you: they examine the evolving treatment landscape and dive into the latest research on currently available and emerging pharmacologic options including the expanding range of oxybate therapies. Join us and find out why it’s such an exciting time to be caring for patients with narcolepsy.
Host: Daniel P. Petrylak, MD
Guest: Arlene O. Siefker-Radtke, MD
It's critical that we select and sequence appropriate therapeutics to provide our patients with the best possible outcomes. Dr. Petrylak and Dr. Siefker-Radtke provide a rundown of multiple disease factors to consider, evolving clinical trial data, and the various therapeutic options available in the second and subsequent lines of therapy for patients with locally advanced or metastatic urothelial carcinoma. With so many new treatment options now available and a cure becoming a real possibility, we invite you to tune in to find out if your treatment strategies are on target.
Host: Peter Rossing, DMSc, MD
Guest: Gerasimos Filippatos, MD, FESC, FHFA
Guest: Matthew R. Weir, MD
Achieving optimal outcomes in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) remains a challenge, and treating physicians need to embrace multidisciplinary components when managing progression to CKD.
In this discussion, Drs. Gerasimos Filippatos, Peter Rossing, and Matthew Weir review the unmet needs of patients with CKD and T2D. They also explore the role of mineralocorticoid receptor antagonists (MRAs) in the treatment spectrum and review recent findings from clinical trials. Tune in to ensure you’re doing all you can for each of your patients.
Host: Mark Socinski, MD
Guest: Justin Gainor
With an expanding arena of available selective RET inhibitors and more data being released on emerging therapies, the landscape for patients with RET-positive metastatic NSCLC is evolving rapidly. Join Drs. Mark Socinski and Justin Gainor as they review the importance of molecular testing in every patient, as well as when to initiate the use of selective RET-inhibitors across multiple lines of therapy. Did we mention you should be testing every patient? Tune in to make sure you’re identifying everyone who can benefit from these newer therapies.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Marco Metra, MD
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
In the management of patients with heart failure, foundational therapy is critical to improving patient outcomes. Are you up to date on the latest recommendations concerning MRAs, ACEI/ARBs/ARNI, beta-blockers, and SGLT2 inhibitors? Recent updates to the ESC/HFA guidelines, heart failure clinical trials, and the COVID-19 pandemic have impacted the way we manage our patients, so tune in to keep up with the latest developments.
Our experts, Drs. Ileana Piña, Javed Butler, Marco Metra, and Giuseppe Rosano, discuss the ESC/HFA guideline updates and how these changes impact the clinical considerations for managing recurrent hyperkalemia and the recommended foundational therapy for patients with heart failure.
Host: Lauren Ritterhouse, MD ,PhD
Guest: Pasi Antero Jänne, MD, PhD
Guest: Kanwal Raghav, MD
HER3 is the new marker on the block, but is it diagnostic, predictive, or prognostic? Hear from the experts, Drs. Lauren Ritterhouse, Pasi Jänne, and Kanwal Raghav, as they explore the role of HER3 in oncogenesis and resistance to EGFR TKIs. Find out how we can now target HER3 signaling in metastatic solid tumors through the use of emerging HER3-targeted therapies along with novel and exciting antibody-drug conjugate studies and strategies.
Host: Mikhail Kosiborod, MD
Guest: Javed Butler, MD, MBA, MPH
Guest: Matthew R. Weir, MD
Renin-angiotensin-aldosterone system inhibition (RAASi) is the foundation of guideline-directed medical therapy (GDMT) for heart failure patients. However, due to practice gaps, a significant proportion of the population requiring its use do not experience the benefits of RAASi therapy, which is especially true for patients with comorbid conditions. Hyperkalemia is a common adverse effect of RAASi therapy that needs to be anticipated and mediated so that the optimal dosing of necessary medications can occur. Maximizing GDMT in the face of hyperkalemia remains a key clinical challenge that, if not handled properly, can result in increased morbidity and mortality.
In this activity, Drs. Javed Butler, Mikhail Kosiborod, and Matthew Weir review a patient case and discuss different treatment approaches to optimize GDMT while managing hyperkalemia. Tune in to make sure you’re doing all you can to improve outcomes for your patients with heart failure and comorbid conditions.
Host: Joël Guigay, MD, PhD
Guest: Kevin J. Harrington, MD
Formulating individualized treatment plans for patients with recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN) is increasingly essential and increasingly complex. Newer regimens have become the standard of care because of their efficacy in overall survival and reduced toxicities. So how do we deploy them now that they’re in our treatment armamentarium?
Join Drs. Joël Guigay and Kevin Harrington as they explore the role of IO as the standard of care in SCCHN and discuss the potential of taxanes to reduce dependence on fluorouracil-based chemotherapeutic regimens. Tune in to make sure you’re meeting the needs of your patients’ with SCCHN.
Guest: Peter Goadsby, MD, PhD, DSc
Guest: Kathleen B. Mullin, MD
Women with migraine have unique needs that often remain undermanaged. Have you taken a critical look at the standard of care and how current treatment strategies have recently shifted? Groundbreaking research on the calcitonin gene-related peptide (CGRP) pathway has led to the development of new medications that act on the specific cascade of inflammatory response associated with migraine. Also called gepants, the CGRP receptor antagonists confer clinical benefit to patients who seek better control of their migraines.
Tune in to this Women’s Health 2021 program to hear our experts, Drs. Peter Goadsby and Kathleen Mullin, discuss the diagnosis of migraine with a focus on the recent evolution of acute and preventive treatment strategies and the role of gepants. Are you doing all you can to ensure that your patients’ needs are optimally addressed?
Host: Misako Nagasaka, MD, PhD
One area of recent progress in the treatment of non–small cell lung cancer (NSCLC) is the development of HER2 targeted therapies for the rare, emerging genetic variant, ERBB2 (HER2) mutations. In fact, the NCCN lists ERBB2 (HER2) mutations as an emerging biomarker to identify novel therapies for patients with metastatic NSCLC. The HER2-directed antibody-drug conjugates (ADC) ado-trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan-nxki are now listed as available targeted agents with activity against HER2 mutations. ADCs with other targets such as Trop-2 and HER3 are now also under investigation and showing promise in NSCLC. ADCs have the potential to increase treatment choices for patients with mNSCLC.
For practicing clinicians, this evolution of HER2-directed therapy and ADCs will add to the complexity of NSCLC treatment. This activity will review the emerging role and potential application of ADCs in mNSCLC, including HER2 as a target in NSCLC, biomarker testing, HER2-, HER3-, and TROP2-targeted ADCs, available clinical data on safety and efficacy, evidence-based guideline recommendations, and how newer targeted agents may fit into the treatment paradigm for patients with mNSCLC.
Host: Jennifer Caudle, DO
Guest: Drew Weissman, MD, PhD
mRNA vaccines are one of the latest developments in medicine, but researchers have been evaluating mRNA technology for years. One of those researchers, Dr. Dr. Drew Weissman, Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania, joins Dr. Jennifer Caudle to talk about his role in the research and development of mRNA vaccines as well as what’s on the horizon for them.
Host: Mark Socinski, MD
Guest: Edward B. Garon, MD, MS
In the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC), when is an EGFR TKI not enough? Answer: When you don’t have all of the information. Digging deeper into the specific EGFR mutations has led to advances in the dual blockade of VEGF and EGFR in the frontline setting. Join Drs. Mark Socinski and Edward Garon as they discuss the evolving role of EGFR and VEGF blockade based on clinical trial data. Find out how you can have an immediate impact on your patients by making targeted treatment decisions based on specific oncogenic driver mutations in NSCLC. Be sure to keep up with our experts because making the right choice is more critical than ever.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Erica E. Marsh MD, MSCI, FACOG
Hear from Dr. Erica Marsh and Dr. Lee Shulman as they discuss the burden, prevalence, and treatment of uterine fibroids and endometriosis and the disproportionate impact these conditions have on vulnerable populations. Learn how to prioritize early diagnosis and treatment to improve outcomes for your patients; as well as evaluating barriers to proper diagnosis and treatment
Our experts offer strategies to guide discussions beyond surgical treatment approaches to include pharmacotherapeutic options such as GnRH agonists and new oral GnRH antagonists. Open communication with patients allows them to carefully consider symptom severity, risks, and fertility preferences to optimize treatment outcomes and patient satisfaction. Tune in to make sure that you’re really doing all you can for your patients.
Host: Anita H. Clayton, MD
Guest: Nancy Byatt, DO
Guest: Jennifer L. Payne, MD
In this panel discussion, Drs. Anita Clayton, Jennifer Payne, and Nancy Byatt walk us through two clinical cases of postpartum depression. Listen in as they discuss optimal strategies to screen, diagnosis, and treat patients, as well as go over the newer class of medications specifically targeted at treating PPD.
Host: Mark Socinski, MD
Guest: John V. Heymach, MD, PhD
FLAURA and RELAY have changed the landscape of treatment in EGFR-mutant advanced non-small cell lung cancer (NSCLC). But how do know which patients will benefit from these important advances in our knowledge of treating these cancers in the first and subsequent lines of therapy? Join Drs. Mark Socinski and John Heymach as they examine a patient case and discuss the “art” of treatment selection and sequencing of therapy. They also dive into recent advances in the dual blockade of antiangiogenics and TKIs in the frontline setting. Tune in to keep up!
Host: Anita H. Clayton, MD
Listen in as Dr. Anita Clayton takes us through the importance of screening for postpartum depression (PPD) and reaching an early diagnosis in the perinatal and postnatal stages of pregnancy. This Women’s Health 2021 lecture also covers the exciting new agents that are targeted specifically for PPD. Find out how they compare to the traditional antidepressants and how they can improve the quality of life for your patients with PPD.
Host: Anita L. Nelson, MD
In this Women’s Health 2021 lecture, Dr. Anita Nelson discusses why uterine fibroids are such a high priority for both women and their clinicians. Listen in as she shares strategies to engage patients in discussions about their fibroid symptoms and their preferences for treatment. Dr. Nelson also evaluates the latest evidence on the mechanisms of action, safety, and efficacy of the newer class of therapies that are now available and can improve the quality of life for women with fibroids.
Host: Anita L. Nelson, MD
How confident are you in determining which of your patients with endometriosis are suitable candidates for medical intervention? Do you ask about each patient’s goals and preferences? Have you heard about the paradigm shift occurring in the medical management of endometriosis?
While medical management of endometriosis is often a secondary consideration to surgery, it should often be the first line of treatment. Join Dr. Anita Nelson as she discusses long-standing and novel medical strategies for managing endometriosis. Find out how you can use shared decision-making strategies to help you provide more options to your patients. Join us and take an important first step that can improve outcomes and quality of life for your patients while enabling them to make educated decisions about their immediate and long-term treatment.
Host: Gregg C. Fonarow, MD
Guest: Andrew J. S. Coats, MD
Rapid initiation and up-titration of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy is critical in the management of heart failure, especially given the prevalence of comorbid conditions, such as recurrent hyperkalemia, in these patients. To improve patient outcomes, it is crucial that physicians avoid any unnecessary halting or dose reductions to these medications.
In this discussion, Drs. Coats and Fonarow review updates to the ESC/HFA guidelines and explain how these changes affect patient care. Find out how to maintain optimal RAASi therapy for your patients with heart failure in the face of their challenging comorbidities.
Host: Roger S. McIntyre, MD, FRCPC
Guest: Charles L. Raison, MD
This patient-provider role play webcast is designed to provide clinicians with effective communication strategies for discussing long-acting injectable antipsychotics with patients in a variety of scenarios.
Host: Roger S. McIntyre, MD, FRCPC
Guest: Martha Sajatovic, MD
This Expert Exchange webcast is designed to help clinicians determine the appropriate time to initiate LAI therapy in patients with bipolar disorder, and how to discuss that treatment decision with patients.
Host: Jeffrey S. Weber, MD, PhD
Approximately half of metastatic cutaneous melanomas carry mutations in BRAF, leading to more aggressive disease. For patients with BRAF V600–activating mutations, treatment options now include the use of combination targeted therapy with BRAF and MEK inhibitors, and combination targeted therapy and immunotherapy. However, even with guideline recommendations, the optimal treatment selection and sequencing is unclear, and additional combination strategies continue to be studied in clinical trials.
In this activity, expert faculty will review and evaluate combination strategies for the treatment of BRAF V600–activating mutation–positive metastatic melanoma, including considerations for treatment selection, sequencing, and management of associated toxicities.
Guest: Phil Lieberman, MD
Host: Jennifer Caudle, DO
Are you familiar with the role of serum tryptase testing in diagnosing idiopathic anaphylaxis and mastocytosis? What role does serum tryptase play in the ongoing management of patients who have anaphylactic reactions to insect venom, and are there different considerations when a patient has a known trigger? Expert faculty Dr. Phil Lieberman shares his insights on serum tryptase testing in clinical practice and its importance in assessing mast cell disorders and anaphylaxis. This moderated discussion is enhanced with animation, key takeaways, and support slides to provide an engaging learning experience.
Serum tryptase plays an important diagnostic role in the setting of mast cell activation resulting from a variety of causes, including mastocytosis and anaphylaxis. Emergency medicine specialists, allergists, and primary care providers serve as the first-line responders to patients experiencing the effects of mast cell activation. The measurement of tryptase levels helps confirm diagnoses and inform management decisions for these life-threatening disorders. To help physicians provide optimal evaluation and management, it is essential that they be knowledgeable regarding the appropriate use of tryptase testing in these clinical settings. This education enables multidisciplinary clinicians to identify patients at risk of mast cell activation due to a variety of causes and employ ...
Host: Keith C. Ferdinand, MD
Guest: Marco Metra, MD
There is a substantial gap between the guideline recommendations for treatment and the real-world prescribing patterns of RAASi therapy. This disconnect results in worse cardiorenal outcomes and higher mortality in patients receiving suboptimal dosing. This is particularly true in patients with CKD who develop hyperkalemia, which constitutes the major barrier to optimal therapy.
In this activity, Drs. Ferdinand and Metra discuss how best to manage comorbidities, optimize RAASi therapy, and improve the long-term care for our patients with heart failure.
Host: Michael E. Wechsler, MD, MMSc
Guest: Eileen Wang, MD, MPH
In this session, National Jewish Health faculty experts will discuss a new paradigm of severe asthma pathophysiology and potential treatment targets that may impact patients with non-allergic and non-eosinophilic as well as eosinophilic severe asthma. This session will explore new understanding of the immunology of severe asthma, new potential targets for treatment, and emerging data on novel therapies that may improve outcomes for your patients with severe asthma.
Guest: Garth W. Garrison, MD
The diagnosis and management of chronic cough can be challenging. Only an estimated 50% of patients with chronic cough are accurately diagnosed. Recent advances in the understanding and management of refractory chronic cough, have led to the development of novel therapies and ongoing clinical studies. In this two-part educational curriculum, pulmonary experts will discuss the prevalence, unmet clinical needs, and impact of chronic cough in patients who do not find relief from recommended management strategies. They will also review the clinical trial data and mechanisms of action of emerging therapies for patients with refractory chronic cough; and finally, summarize the current guidelines and emerging treatment strategies for the management of patients with chronic cough.
Host: Scott Kopetz, MD, PhD
Guest: Rona Yaeger, MD
Advances in the diagnosis and treatment of mCRC enable personalized care based on the molecular profile of the tumor to achieve improved outcomes. About 5% to 15% of mCRC patients have a mutation in the proto-oncogene BRAF. BRAF is part of an essential cell signaling pathway, mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK). The BRAF V600E mutation induces constitutive activation of BRAF, leading to increased cell growth and proliferation downstream. Patients with the V600E mutation have a 2-fold increased risk for mortality compared to patients with wild-type BRAF, suggesting this gene mutation may act not only as a prognostic biomarker but also as a predictive biomarker. Understanding the current research regarding the consequences of the V600E mutation and testing for it can help guide treatment decision-making in patients with BRAF V600E–mutated mCRC.
This web-based, on-demand activity will feature an expert panel discussion on the latest trends and emerging research in the treatment of BRAF-mutated mCRC. Expert faculty will review and provide their interprofessional perspectives on testing patients for BRAF mutations, recent and emerging data for combination therapies, appropriate treatment selection, and side effect management.
Host: Andrea Singer, MD, FACP, CCD
Guest: Paul A. Anderson, MD
Guest: Susan V. Bukata, MD, FAOA, FAAOS
While there’s growing awareness among orthopedic surgeons that osteoporosis is the underlying cause of fractures, there is often a disconnect between this recognition and action in the form of treatment to prevent subsequent fractures. In this discussion, Drs. Andrea Singer, Paul Anderson, and Susan Bukata address the pathophysiology of osteoporosis and the need to identify patients at risk for additional fractures. Osteoporosis treatment (including pharmacotherapy) can play a critical role in preventing future fractures, but physicians must first recognize that fracture is a sentinel event and treat it as a call to action.
Host: Johann de Bono, MD, PhD
Guest: Alicia K. Morgans, MD, MPH
Prostate cancer is the second most common cancer in incidence and the fifth most frequent cause of cancer-related mortality in men worldwide. With the broader availability of PSA screenings, the incidence of disease is only rising.
This lively discussion focused on prostate cancer is designed to help you keep pace in GU cancers. You will enhance your knowledge and skills related to targeted therapy in patients with metastatic castrate-resistant prostate cancer, discover relevant biomarkers in prostate cancer, follow a patient case example, and hear about the latest clinical trial data presented at ASCO and ESMO 2021.
The prostate cancer landscape is rapidly evolving, so tune in to find out what changes you can make in your daily practice today.
Guest: Cem Akin, MD, PhD
Host: Jennifer Caudle, DO
What is the risk of anaphylaxis following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19)? Are you familiar with the role of serum tryptase testing in patients with a suspected anaphylactic reaction? Expert faculty, Dr. Cem Akin, discusses serum tryptase testing and its importance in assessing anaphylaxis in response to COVID-19 vaccination. This moderated discussion is enhanced with animation, key takeaways, and support slides to provide an engaging learning experience.
Serum tryptase plays an important diagnostic role in the setting of mast cell activation resulting from a variety of causes, including mastocytosis and SARS-CoV-2 vaccination. Emergency medicine specialists, allergists, and primary care providers serve as the first-line responders to patients experiencing the effects of mast cell activation. The measurement of tryptase levels helps confirm diagnoses and inform management decisions for these life-threatening disorders. This education enables multidisciplinary clinicians to identify patients at risk of mast cell activation due to a variety of causes and employ appropriate use of tryptase testing across acute and follow-up care settings.
Host: Mikhail Kosiborod, MD
Guest: Ewa A. Jankowska, MD, PhD, FESC
Guest: Phil McEwan, PhD
Assessing iron deficiency is a crucial aspect of heart failure (HF) that warrants close clinical consideration, especially because it remains underdiagnosed and undertreated.
In this expert panel discussion, we examine data from AFFIRM-HF supporting the importance of correcting iron deficiency in patients with HF. Find out how treating iron deficiency can change the natural history of heart disease, lead to cost savings, and improve patients’ lives.
Guest: Steven Fishbane, MD
Guest: Shayan Shirazian, MD
Host: Jennifer Caudle, DO
At least 25% of patients with chronic kidney disease (CKD), and between 50% to 86% of patients with CKD on dialysis suffer from CKD-associated pruritus (CKD-aP). The itch can substantially interfere with sleep and quality of life and has been linked with depression, fatigue, and isolation. There are at least 4 pathways that have been hypothesized as possible etiologies of CKD-aP, leading to a wide range of potential therapeutic strategies for the itch. Difelikefalin is the first agent FDA-approved specifically for the treatment of moderate-to-severe pruritus in CKD patients undergoing dialysis; it is a peripheral kappa-opioid receptor agonist that targets the opioid dysregulation theory. It is imperative that all clinicians involved in the care of patients with CKD routinely inquire about pruritus and adequately treat their patients for CKD-aP. This case-based program will apply the foundational information presented in the first program of this 2-part series to real-world patients.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Rapid initiation and up-titration of guideline-directed medical therapy (GDMT) is critical to achieve optimal patient outcomes in heart failure. This is particularly important in patients with multiple comorbidities and in pivotal situations to avoid stopping or lowering the dose of any of the four critical medicines that these patients must receive.
Drs. Javed Butler, Ileana Piña, and Giuseppe Rosano will recap the data and the views that were presented at a symposium held in conjunction with the Heart Failure Society of America’s 2021 annual scientific meeting.
Host: Robert J. Chilton, DO
Guest: John R. Nelson, MD, FACC, FNLA, FASNC
Join Drs. Chilton and Nelson as they discuss recent omega-3 fatty acid (OM-3) outcomes trial results and how to apply those results along with evidence-based guidelines to reduce ASCVD risk. Tune in to hear about the use of OM-3s including dietary supplement OM-3s that are readily available in pharmacies and online, so you can keep your patients informed!
Host: Ricardo Franco, MD
Guest: Catherine A. Chappell, MD MSc
With alarming increases in the incidence of maternal HCV, your obstetrics and gynecology (OB/GYN) practice plays a critical role in screening of all pregnant patients and engaging HCV-infected women who otherwise may not seek medical care. This educational activity will provide practical tactics for implementing Centers for Disease Control and Prevention (CDC) screening guidelines at the practice level, insights for destigmatizing behavioral risk inquiries and harm-reduction discussions, current recommendations for postpartum HCV treatment, and evolving perspectives on HCV treatment during pregnancy.
Host: Ricardo Franco, MD
Guest: David L. Wyles, MD
The COVID-19 pandemic has taken a disproportional toll on already vulnerable persons, yet substance use, psychosocial comorbidities, and preexisting disparities in access to care may translate to an even greater adverse impact among persons with chronic HCV. This educational activity offers up-to-date information on the impact of COVID-19 on the normal and HCV-infected liver, practical strategies for optimizing telehealth-delivered HCV care, and other recommendations for engaging vulnerable populations in HCV care during times of reduced service capacity.
Host: Louis Kuritzky, MD
Guest: Karl Doghramji, MD, FAASM, DFAPA
Guest: Julie Flygare, JD
Guest: Phyllis C. Zee, MD, PhD
Excessive sleepiness is a common, highly impactful problem not commonly reported and frequently misdiagnosed by physicians. While prevalence reports of narcolepsy vary, patients often do not seek medical advice for their symptoms or, if they do, they receive inaccurate diagnoses. Because of this, it’s possible that more than 1 in 2000 people are living with narcolepsy. It may even take 10 to 15 years to be diagnosed, during which time these patients are impaired. What signs and symptoms are both clinicians and patients missing?
Tune in to hear a patient, Julie Flygare, JD, recount her bizarre symptoms and receive clinical tips on how to improve your identification of overlooked sleep disorders and narcolepsy. Drs. Zee, Doghramji, and Kuritzky provide their clinical insight and expertise on this serious medical condition that continues to be grossly misdiagnosed, underdiagnosed, and undermanaged. By improving your ability to detect, accurately diagnose, and appropriately manage narcolepsy, you can improve the quality of life and health outcomes for your patients. Find out what subtle signs and red flags you need to be on the lookout for and what exciting therapies are now available for these patients.
Guest: Madhukar H. Trivedi, MD
Guest: Steven Shoptaw, PhD
Join Drs. Madhukar Trivedi and Steven Shoptaw as they discuss the evolving landscape of pharmacologic intervention for methamphetamine use disorder. Their focus will be on evidence from the ADAPT-2 clinical trial supporting the combination of extended release naltrexone and high dose bupropion to reduce methamphetamine use for patients with moderate to severe methamphetamine addiction. These important data from ADAPT-2 offer a significant therapeutic advance for methamphetamine use disorder that can be taken into the clinic.
Host: Paul Nyirjesy, MD
The global burden of acute vulvovaginal candidiasis (VVC) and the substantial morbidity and poor quality of life associated with recurrent disease (RVVC) requires improved solutions and quality of care for affected women. Join Dr. Paul Nyirjesy as he dissects the barriers to managing VVC and RVVC in your clinical practice and provides both diagnostic and therapeutic guidance inclusive of newly emerging and novel agents. These agents have unique qualities that may well represent a significant step forward in how you manage this challenging infection.
Host: David L. Eisenberg, MD, MPH, FACOG
Many women prefer to use a nonhormonal contraceptive. They also want the freedom to self-administer on demand and want assurances that the contraceptive is safe, effective, and has received FDA approval. One such contraceptive is a self-administered, hormone-free gel that functions as a vaginal pH modulator. Join Dr. David Eisenberg as he describes the evolution of this vaginal pH modulator and the clinical trials leading to FDA approval. Even more significant is patient acceptance, which was remarkably high for this contraceptive. In fact, approximately 9 out of 10 women participating in the clinical trials indicated they would continue using the vaginal pH modulator and also recommend this novel method to their friends.
Host: Brooke M. Faught, DNP, WHNP-BC,NCMP, IF
Our patients express a number of misperceptions about combined hormonal non-LARC contraceptives such as the contraceptive patch, vaginal rings, and oral contraceptive pills. How well do you explain the advantages and disadvantages of these different options to your patients? How often have you prescribed what appeared to be a good contraceptive method for your patients only to have them be dissatisfied and become nonadherent?
Join Dr. Brooke Faught in this Women’s Health 2021 lecture as she tackles these issues and offers insights into how to discuss the full range of combined hormonal non-LARC contraceptive options with your patients using shared decision-making strategies. Remember, each patient’s needs, goals, and cultural background are important factors in a patient-centric approach to the choice of contraception.
Guest: Gregory Pokrywka MD, FACP, FNLA, FASPC, NCMP
Guest: Karol Watson, MD, PhD
Join us to discover optimal ways to identify women at risk or with atherosclerotic cardiovascular disease (ASCVD). In this Women’s Health 2021 lecture, our experts, Dr. Gregory Pokrywka and Dr. Karol Watson, dive deeper into evidence-based approaches to assess and manage ASCVD in women. They discuss topics from lifestyle modifications to recent clinical trial data on the use of omega-3 fatty acids for ASCVD event reduction.
Guest: Steven Fishbane, MD
Guest: Shayan Shirazian, MD
Host: Jennifer Caudle, DO
At least 25% of patients with chronic kidney disease (CKD) and between 50% to 86% of patients with CKD on dialysis suffer from CKD-associated pruritus (CKD-aP). The itch can substantially interfere with sleep and quality of life, and has been linked with depression, fatigue, and isolation. There are at least 4 pathways that have been hypothesized as possible etiologies of CKD-aP, leading to a wide range of potential therapeutic strategies for the itch. Difelikefalin is the first agent FDA-approved specifically for the treatment of moderate-to-severe pruritus in CKD patients undergoing dialysis; it is a peripheral kappa-opioid receptor agonist that targets the opioid dysregulation theory. It is imperative that all clinicians involved in the care of patients with CKD routinely inquire about pruritus and adequately treat their patients for CKD-aP. This first program will review the epidemiology, consequences, evaluation, pathophysiology and available and emerging treatments for CKD-aP; a second case-based program will apply the information to real-world patients.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Gregg C. Fonarow, MD
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Recent guideline updates and publications are leading to changes in care in patients with heart failure with reduced ejection fraction (HFrEF). What clinical evidence is driving recent changes to guideline directed medical therapy (GDMT) in HFrEF, and what real-world data exists that may impact the landscape of care and patient outcomes?
Host: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
The COVID-19 pandemic has had an unprecedented impact on the entire global population. COVID-19 fears have not only disrupted the regular care of patients with heart failure, but also clinical trials and their participation rates.
These studies are critical for determining the safety and efficacy of new drugs and innovative treatments. When the pandemic started, some clinical trials shut down permanently while others are finally, albeit slowly, resuming. This has created a delay in the research pipeline that may hinder how quickly new heart failure medications come to market in the next few years.
Join us as our experts—Drs. Deepak Bhatt, Javed Butler, and Giuseppe Rosano—discuss the impact of COVID-19 on patient care and the implications for clinical trial data moving forward.
Host: Ricardo Franco, MD
Guest: Charles P. Vega, MD
Armed with Centers for Disease Control and Prevention (CDC) guidelines for HCV universal screening and risk-based testing — and an understanding of the simplicity of prescribing and managing direct-acting antiviral (DAA) therapies — primary care providers (PCPs) will be well equipped to step up and provide comprehensive HCV care and cure. This educational activity offers practical tips and tactics to prepare PCPs for their central role in eliminating HCV.
Host: Jay Raman, MD, FACS
Guest: Oguz Akin, MD
Guest: Robert J. Motzer, MD
Guest: Elizabeth Plimack, MD, MS
Immune checkpoint inhibitor/tyrosine kinase inhibitor combination therapy has forged to the front-line for the management of metastatic RCC and recurrent RCC, but how do clinicians select the ideal treatment regimen for their patients? How does patient risk status influence the decision-making process? This virtual tumor board features a multidisciplinary expert panel presenting a favorable-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize outcomes in this patient population. Faculty additionally cover the importance of incorporating the patient perspective into treatment decisions.
After viewing the activity, visit the Related tab for supplemental resources.
Host: Jennifer Caudle, DO
Guest: Mikkael A. Sekeres, MD, MS
Guest: Sara M. Tinsley, PhD, ARNP, AOCNP
Please note: This activity is no longer available for continuing education credit.
There is a lack of available therapeutic options for the management of patients with myeloid malignancies, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). Novel therapeutic approaches are being evaluated, particularly those that target the NEDD8-activating enzyme (NAE). Evaluating the rationale for NAE inhibition, assessing emerging safety and efficacy data on use of NAE inhibitors in myeloid malignancies, and developing strategies based on the evolving implications of this research will allow for greater understanding of their potential impact on management and health outcomes of patients with MDS, CMML, and AML.
Guest: Arlene B. Chapman, MD
Guest: Michel Chonchol, MD
This Expert Exchange webcast aims to improve clinicians’ awareness of emerging agents in the treatment of patients with ADPKD.
Host: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Peter van der Meer, MD, PhD
Iron deficiency is an extremely common comorbidity for 50% to 70% of our patients with heart failure in both the acute and chronic settings. It’s associated with poor exercise capacity, poor quality of life, and increased morbidity and mortality. In hospitalized patients with acute heart failure, iron deficiency is often present independent of anemia.
With that in mind, join Drs. Robert Mentz and Peter van der Meer as they discuss the impact of iron deficiency on patients with heart failure. Find out why it’s time to shift our perception of iron deficiency from a marker of disease outcome to a treatment target.
Host: George L. Bakris, MD
Guest: Rajiv Agarwal, MBBS, MD, FASN, BRCU
Guest: Bertram Pit, MD
Two HOT LINE sessions presented at the ESC Congress 2021 may change the way you manage your patients with diabetes and CKD as you work to prevent their progression to ESRD and improve their cardiovascular outcomes. Drs. Rajiv Agarwal, George Bakris, and Bertram Pitt review data from the FIGARO-DKD trial and the FIDELITY Analysis to explore the evolving role of mineralocorticoid receptor antagonists (MRAs) as part of the overall treatment plan for patients with diabetes and CKD. Don’t miss this potentially practice-changing session!
Host: Arjun V. Balar, MD
Guest: Daniel P. Petrylak, MD
Bladder cancer is the sixth most common malignancy in the United States. Many of these patients present with multiple comorbidities which creates a considerable challenge for clinicians when determining an appropriate treatment plan. Until recently, platinum-based chemotherapy was the only viable systemic therapy option for patients with locally advanced or metastatic urothelial cancer (mUC); however, the majority of these patients eventually relapse and need subsequent lines of therapy. Patients are then left with limited treatment options and often poor outcomes, contributing to a largely unmet need that prompted investigation into new and promising therapeutic options.
This chapterized activity is designed to update clinicians who treat locally advanced or metastatic urothelial cancer on new clinical trials and the treatment guidelines that align with the identified unmet need of subsequent treatment options for this patient population. Drs. Arjun Balar and Daniel Petrylak focus on enhancing the knowledge and skills of clinicians through case-based content to demonstrate individualized patient treatment plans and enable participants to further incorporate changes into their clinical practice. Join us to find out why the future is bright for our patients with mUC.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Michelle Y. Owens, MD
OB-GYN clinicians can improve how they communicate with their patients about hemolytic disease of the fetus and newborn or HDFN. Strategies include encouraging patients to talk about their feelings when learning about this condition and communicating with them in terms that are not overly complex. In this program, Drs. Lee Shulman and Michelle Owens discuss how to break things down for the patient in front of you and explain how to use a read-back approach. This tactic ensures that your patient has absorbed what was discussed and also allows you to identify gaps in her understanding that can be addressed with further counseling.
Host: Jay Raman, MD, FACS
Guest: Oguz Akin, MD
Guest: Robert J. Motzer, MD
Guest: Elizabeth Plimack, MD, MS
Did you know that the current 5-year survival rate for patients diagnosed with metastatic RCC is only 12% despite advances in molecular research over the past decade? Are you familiar with recent treatment guidelines and clinical trial data showcasing the benefits of treating poor- and intermediate-risk ccRCC patients with immuno-oncology/tyrosine kinase inhibitor combination therapy? This virtual tumor board features a multidisciplinary expert panel presenting a poor-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize patient outcomes. Faculty additionally cover the importance of incorporating the patient perspective and adverse event profiles into treatment decisions.
After viewing the activity, visit the Related tab for supplemental resources.
Host: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
It is well understood that RAASi therapy is critical in the management of patients with heart failure. However, hyperkalemia is common in these patients, and its presence often leads to suboptimal RAASi dosing, which in turn results in poorer patient outcomes. Join Drs. Javed Butler and Giuseppe Rosano as they look at a case presentation and discuss the hows and whys of optimal RAASi dosing in patients with heart failure and recurrent hyperkalemia.
Host: George L. Bakris, MD
Guest: Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
Guest: Robert Toto, MD
When treating patients with heart failure and chronic kidney disease, RAASi therapy should be continued if at all possible. One thing to keep in mind is that an elevation in serum creatinine does not always represent acute kidney injury. In this activity, Drs. George Bakris, Biykem Bozkurt, and Robert Toto examine a case study and discuss transient changes in serum creatinine with hyperkalemia. Join us to find out how and why you should avoid RAAS blockade interruption in these patients.
Guest: Maria E. Arcila, MD
Guest: Alexander Drilon, MD
Capitalizing on the advances in identification of oncogenic driver mutations, genetic testing, and therapeutic approaches that target actionable mutations, targeted therapy is the current standard of care in NSCLC. The use of molecular testing and targeted therapies has yielded remarkable and practice-changing improvements for patients harboring these actionable mutations.
The current availability of multiple targeted agents, such as second- and third-generation ALK and ROS1 tyrosine kinase inhibitors, some of which are approved for use both in first-line and subsequent lines of therapy, coupled with the presence of concomitant actionable mutations, can make selection of the appropriate targeted treatment for eligible patients complicated.
This web-based, on-demand activity will feature an expert panel that will provide their interprofessional perspectives on the latest trends and emerging research regarding biomarker testing and evidence-based biomarker-guided targeted therapy for patients with NSCLC with ROS1 and ALK rearrangements.
Guest: Cheryl Pirozzi, MD, MS
Guest: Charlie Strange, MD
Alpha-1 antitrypsin deficiency (AATD) is a common yet underdiagnosed genetic disorder. Led by 2 AATD experts, this activity will address the most current information on the screening, diagnosis, and treatment of this potentially fatal disorder. AATD primarily affects the lungs and liver and requires a multidisciplinary care approach. Faculty will review patients who are at risk for AATD, its clinical manifestations (including similarities with COPD), and possible consequences to the lung and liver. Current treatment involves augmentation therapy with IV administration of AAT; there are ongoing investigations into other potential treatments. Patient cases will help clinicians apply the foundational information to clinical practice.
Guest: Michel Chonchol, MD
Guest: Frederic Rahbari-Oskoui, MD, MS
This Expert Exchange webcast aims to improve clinicians’ ability to manage patients diagnosed with ADPKD.
Guest: Garth W. Garrison, MD
Guest: Prema Menon, MD, PhD
The diagnosis and management of chronic cough can be challenging. In fact, only an estimated 50 percent of patients with chronic cough are accurately diagnosed. Recent advances in the understanding and management of refractory chronic cough have led to the development of novel therapies and ongoing clinical studies. In this two-part educational curriculum, pulmonary experts will discuss the prevalence, unmet clinical needs, and impact of chronic cough in patients who do not find relief from recommended management strategies. They will also review the clinical trial data and mechanisms of action of emerging therapies for patients with refractory chronic cough and summarize the current guidelines and emerging treatment strategies for the management of patients with chronic cough.
Guest: Matthew B. Lanktree, MD, PhD
Guest: Neera Dahl, MD, PhD
This Expert Exchange webcast aims to improve clinicians’ ability to properly monitor disease progression and make treatment decisions based on prognostic indicators.
Guest: Arlene B. Chapman, MD
Guest: Matthew B. Lanktree, MD, PhD
This Expert Exchange webcast aims to improve clinicians’ ability to detect and diagnose ADPKD in at-risk patients.
Host: Carl C. Awh, MD
Guest: Peter A. Campochiaro, MD
The quest for durable VEGF-suppression in neovascular AMD and diabetic macular edema has led to significant advances in the operating room for surgical retina specialists. What are these new methods, and what do surgeons need to know to ensure a successful procedure? Listen to pro tips from Drs. Carl Awh and Peter Campochiaro and see demonstrations of the new techniques. How will your patients benefit from the introduction of durable VEGF suppression into clinical practice?
Host: Diana Do, MD
Guest: Nancy M. Holekamp, MD
Guest: Carl Regillo, MD
One of the biggest challenges with anti-VEGF therapy is the burden of continued and frequent treatment. Fortunately, new options are on the horizon in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) that can safely reduce treatment burden while improving vision. So what are these strategies, and what is the latest evidence for their use?
Join us as leading experts, Diana Do, Nancy Holekamp, and Carl Regillo, discuss several new strategies to improve VEGF suppression in nAMD and DME. Hear about unique mechanisms of action, the most recent clinical evidence supporting the use of these developments, and their potential applications in clinical practice.
Host: Ezra Cohen, MD
Guest: Barbara Burtness, MD
Head and neck squamous cell carcinomas (HNSCC) represent a significant healthcare burden due to associated morbidity and mortality. Most patients survive less than a year after diagnosis and report a poor quality of life. Tune in to this chapterized content as two leading experts, Drs. Ezra Cohen and Barbara Burtness, discuss recent clinical trial data and strategies to improve sequencing and treatment selection. Find out how checkpoint inhibitors are shifting the treatment landscape of HNSCC and what this means for your patients.
Host: Joseph Saseen, PharmD, BCPS, BCACP, CLS
Guest: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Drs. Cheeley and Saseen will discuss the biological effects of OM-3s and their mechanisms of action and review all recent major clinical trials. Faculty will share practical information for pharmacists on the use of icosapent ethyl vs. generic OM-3s and dietary supplements for ASCVD management.
Upon completion of this activity you will be directed to the activity’s sponsor, Postgraduate Healthcare Education, LLC (PHE) to claim your ACPE credits. Once there you will click, ‘Take Exam’ to claim your credits.
Host: Cassandra B. Donnelly, DO
Guest: Charles P. Vega, MD
Post-exposure influenza prophylaxis should be a top-of-mind discussion with patients receiving an influenza diagnosis. Unfortunately, it remains an underused means to reduce secondary infections in at-risk households. Join Drs. Cassandra Donnelly and Charles Vega as they examine an extended patient case and offer practical strategies to overcome common clinical barriers surrounding post-exposure influenza prophylaxis, including how to match the right patient with the right antiviral treatment.
Host: Clete A. Kushida, MD, PhD
Guest: Michael J. Thorpy, MD
While gaps in care remain, the future is bright for patients with narcolepsy. Data from cutting-edge clinical trials were recently presented at 2021 Virtual Sleep, the 35th Annual Meeting of the Associated Professional Sleep Societies, and Drs. Clete Kushida and Michael Thorpy are ready to break it down for you. Join them as they examine the main barriers to timely diagnosis and treatment and then dive into the latest research on currently available and emerging pharmacologic therapies. Tune in to stay up to date on the latest progress and research on the management of patients with narcolepsy.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Kenneth J. Moise, Jr., MD
Guest: Christopher Robinson, MD
Hemolytic disease of the fetus and newborn (HDFN) is a rare disease that occurs due to the incompatibility between fetal and maternal red cell antigens. HDFN can lead to both short- and long-term consequences, including potentially fatal outcomes. In order to better prevent these associated issues, the timely evaluation, recognition, and treatment of HDFN are critical.
Listen in as three leading experts, Drs. Lee Shulman, Kenneth Moise, and Christopher Robinson, join together to discuss new epidemiologic evidence, the underlying pathophysiology of HDFN, health equity, and evolving management strategies you can implement to improve your clinical practice.
Guest: John Ryan, MD, MB, BCh, BAO, MRCPI, FACC, FAHA
John Ryan, MD discusses screening protocols, diagnostic and treatment algorithms, clinical trial evidence, and the vital role of multidisciplinary teams for the management of patients with CTD-PAH in this four-chapter series.
Host: Kristi K. Orbaugh, MSN, NP, AOCN®
Guest: Val R. Adams, PharmD, FCCP, BCOP, FHOPA
Guest: Theresa W. Gillespie, PhD, MA, RN, FAAN
Endocrine therapy is currently the cornerstone of treatment for advanced hormone receptor–positive (HR+) breast cancer in both pre- and postmenopausal patients. However, not all advanced HR+ breast cancers respond to first-line endocrine therapy, and those that do respond eventually relapse. Agents that target critical pathways involved in resistance to endocrine therapy, such as cyclin-dependent kinase (CDK) 4/6 inhibitors, have been approved by the US Food & Drug Administration (FDA) for the treatment of HR+/human epidermal growth factor receptor 2–negative (HER2−) advanced/metastatic breast cancer. Now, CDK 4/6 inhibitors are being investigated for the treatment of early stage HR+, HER2- breast cancer.
This web-based, on-demand, activity will feature interprofessional perspectives and expert insights on the latest emerging evidence for CDK 4/6 inhibitors in the adjuvant setting for early breast cancer. The faculty panel will also provide their perspectives and best practice recommendations for improving adherence and side effect management. Case-based discussion will provide practical approaches for integrating CDK 4/6 inhibitors into real-world clinical practice for the treatment of early stage HR+, HER2- breast cancer.
Since the date of this activity’s recording, an exciting and practice changing advancement has occurred with the Food and Drug Administration’s (FDA) recent approval of abemaciclib with endocrine ...
Guest: Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Guest: Leslie Cho, MD
More than 15 professional societies now recommend the use of icosapent ethyl to treat atherosclerotic cardiovascular disease (ASCVD), but clinical questions about the use of omega-3 fatty acids remain. Dr. Leslie Cho and Dr. Erin Michos discuss the role of DHA and EPA and whether all omega-3 fatty acids are the same. But what about EPA plasma levels, incidence of atrial fibrillation, and differences between the STRENGTH and REDUCE-IT trials? Tune in to get these answers and more!
Host: Paul P. Doghramji, MD, FAAFP
Guest: Nina Delaney Wagner-Johnston, MD
Guest: Seema A. Bhat, MD
Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy associated with different cytogenetic, immunophenotypic, and morphological profiles. This diversity has resulted in varying clinical courses and responses to therapy and underscores the importance of individualizing therapy. The availability of targeted therapies has dramatically transformed the CLL therapeutic landscape, providing options for personalized treatments within both the newly diagnosed and relapsed/refractory (R/R) settings.
In this educational activity, faculty members review current efficacy and safety data for targeted therapies approved for patients with treatment-naïve or R/R CLL, as well as emerging strategies for treatment. They evaluate clinical trial data, along with patient- and disease-related factors, that allow for the individualization of therapy selection and sequencing of therapy in first and second lines of therapy and beyond.
Host: George L. Bakris, MD
Guest: Biff F. Palmer, MD
In this case-based activity, Drs. George Bakris and Biff Palmer discuss the benefits of RAAS inhibitors in the patient diagnosed with diabetes, hypertension, and chronic kidney disease. They review the importance of titrating RAAS inhibitors to the highest tolerated recommended dose and identify obstacles to optimizing the dosing of these therapies in patients with comorbidities. They also discuss the use of potassium binders for the management of hyperkalemia as an alternative to discontinuing RAASi therapy.
Host: Hector O. Chapa, MD, FACOG
Guest: Marc S. Sabatine, MD, MPH
Cholesterol guidelines recommend nonstatin, LDL-C-lowering therapies in very high risk ASCVD patients if LDL-C goals are not achieved (ESC/EAS dyslipidemia guideline) or if LDL-C is above a specific threshold of 70 mg/dL (AHA/ACC cholesterol guideline). Unfortunately, a substantial number of patients with ASCVD do not achieve LDL-C targets, and nonstatin, LDL-C-lowering therapies are underutilized. Therefore, patients such as those who have experienced an acute coronary syndrome (ACS) remain at increased risk for another major cardiovascular event. Patients with a recent ACS are especially vulnerable to a recurrent cardiovascular event. Nonstatin, LDL-C-lowering therapy with PCSK9 inhibitors and ezetimibe has demonstrated reductions in cardiovascular risk after an ACS. PCSK9 inhibitors have demonstrated robust LDL-C lowering to very low LDL-C levels, with no increase in adverse safety events and with additional cardiovascular risk reduction. Analyses of cardiovascular outcome trial data with PCSK9 inhibition have indicated particularly potent cardiovascular risk reduction in patients with a recent ACS; utilizing PCSK9 inhibitors in these patients enables clinicians to greatly improve their patients’ clinical outcomes. Significant LDL-C reductions, rapid LDL-C goal attainment, and safety have been observed in very early (in-hospital) use of PCSK9 inhibitors. In this educational initiative, lipid expert Dr. Marc Sabatine will discuss guideline ...
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Anna-Barbara Moscicki, MD
Updated cervical cancer screening guidelines were published by both the American Society for Colposcopy and Cervical Pathology (ASCCP) and the American Cancer Society (ACS). Dr. Lee Shulman leads a discussion with Dr. Anna-Barbara Moscicki on the recent guidelines, the range of cervical cancer screening tests, and the impact on risk stratification and patient management.
Host: Cassandra B. Donnelly, DO
Guest: Charles P. Vega, MD
Antiviral agents are underutilized against influenza in clinical practice, a failure that places many patients, especially those with comorbidities, at high risk for influenza-associated complications. Join Drs. Cassandra Donnelly and Charles Vega as they explore management strategies for patients with symptomatic influenza, compare and contrast clinical applications for the available antiviral agents, and reflect upon the increasing use of these agents as post-exposure influenza prophylaxis.
Guest: Kevan C. Herold, MD
Guest: Andrea Steck, MD
Guest: Anette Gabriele Ziegler, MD
Experts in the immunopathology of type 1 diabetes review data showing that clinical presentation is preceded by an asymptomatic phase, characterized by the presence of one or more islet autoantibodies. Screening children for islet autoantibodies during the two preclinical stages can identify those with multiple autoantibodies and high-risk antibody phenotypes who may be candidates for preventive interventions before developing dysglycemia or the clinical onset of type 1 diabetes.
Guest: Javier Cortes, MD, PhD
Guest: Sara A. Hurvitz, MD, FACP
While HER2+ breast cancers are traditionally associated with a poor prognosis, the development of HER2-directed treatment strategies has led to substantial and durable survival improvements, even in patients with metastatic disease. Nonetheless, a percentage of these patients will not respond to certain therapies, and many may become resistant within a year of treatment.
In this chapterized activity, Dr. Javier Cortes and Dr. Sara Hurvitz discuss optimal therapy selection based on individual patient characteristics as well as strategies to manage potential adverse events associated with current treatment options for HER2+ metastatic breast cancer.
Host: Paul W. Armstrong, MD
Guest: Justin Ezekowitz, MD, MBBCh, MSc
Is it possible to reduce the nearly 60% one-month rehospitalization rates in patients with worsening heart failure? Dr. Paul Armstrong and Dr. Justin Ezekowitz discuss new therapeutic combinations including soluble guanylate cyclase (sGC) stimulators, as well as the practical applications of new evidence that was presented at the 2021 annual ACC meeting that may change how physicians approach treating their patients with worsening heart failure. Don’t miss out on new information about how sGC stimulators may benefit your patients.
Host: Adnan Subei, DO
Guest: Robert Bermel, MD
Guest: Claire Riley, MD
The emergence of COVID-19 has created an unprecedented medical emergency that both raises new questions and presents updated information each day. This issue is even more pressing for patients with conditions such as multiple sclerosis (MS) who have altered immune systems from both chronic illness and disease modifying therapies (DMTs). While the advent of vaccines has revived hope for a return to normal life, vaccination is not always straightforward for those on or planning to start immunosuppressive therapies such as MS DMT. In this activity, Drs. Claire Riley and Robert Bermel discuss guidance outlined by the National Multiple Sclerosis Society (NMSS) and approaches to implementing these considerations in routine practice.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Jeffrey T. Jensen, MD, MPH
The effort to reduce the estrogen concentration in combination oral contraceptives (COCs) and strike the right balance between efficacy and safety appears to be never-ending. However, a recently FDA-approved estetrol/drospirenone COC formulation offers some unique properties not seen in current COC formulations. Join us as Dr. Jeffrey Jensen and Dr. Lee Shulman discuss if this estetrol/drospirenone COC formulation will allow physicians to better address these efficacy and safety issues.
Guest: Jimmy T. Lee, MD
Guest: Arlene B. Chapman, MD
This Expert Exchange webcast aims to better define the importance radiological imaging plays in the management of patients with autosomal dominant polycystic kidney disease (ADPKD).
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Lincoln Nadauld, MD, PhD
Current cancer screening methods like mammograms, colonoscopies, and CT scans are all effective in detecting cancers, but they don’t always detect cancers as early as we’d like them to, resulting in missed and delayed diagnoses. Could new technology like multicancer early detection (MCED) be the answer to addressing current unmet needs in cancer screening? Find out with Dr. Charles Turck and Dr. Lincoln Nadauld, an oncologist and the Vice President and Chief of Precision Health and Academics at Intermountain Healthcare.
Host: Paul Paik, MD
Guest: Joshua K. Sabari, MD
For the 3% to 4% of patients with non-small cell lung cancer (NSCLC) who harbor a MET exon 14 skipping mutation, the prognosis is grave. MET gene dysregulation may also play a role in the emergence of resistance to EGFR TKI therapy in patients with EGFR-mutated NSCLC, further complicating treatment. Join our case discussion as Dr. Paul Paik and Dr. Josh Sabari highlight the importance of identifying MET gene aberrations in patients with NSCLC.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
There is clinical trial-supported evidence for the use of renin-angiotensin-aldosterone system inhibitors (RAASi) in patients with heart failure and reduced ejection fraction. RAASi therapy improves both morbidity and mortality outcomes, and its use is now recommended in published guidelines. However, the achievement of target dosing is often limited or interrupted due to the development of hyperkalemia.
In this case-based activity, Drs. Javed Butler and Ileana Piña discuss the importance of optimizing RAASi therapy in patients with heart failure and how the use of potassium binders can help accomplish this goal. They will also review the risks and benefits of potassium binders, in addition to both short- and long-term use of these agents in the treatment of patients with heart failure.
Guest: D. Ross Camidge, MD, PhD
The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF V600E mutations has led to an improvement in overall survival and progression-free survival in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatment. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) note, “For patients with recurrent and metastatic disease, the NCCN Guidelines recommend that histologic subtype should be determined before therapy so that the best treatment can be selected. In addition, biomarker testing for genetic alterations (ie, oncogenic driver events) is recommended in patients with NSCLC, because targeted therapy has been shown to decrease tumor burden, decrease symptoms, and dramatically improve the quality of life for patients with specific genetic alterations. The number of available targeted agents is increasing.” (Ettinger et al, 2020.)
Approximately 5% of patients with NSCLC have ALK gene rearrangements. One of the most noteworthy areas of progress is the development of effective ALK-targeting therapies to treat NSCLC, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib. Because of the fast pace of developments in this area, it may be difficult for clinicians to remain up-to-date on ...
Host: Loretta J. Nastoupil, MD
Guest: John P. Leonard, MD
Recent clinical trial evidence supports the use of available and emerging options in relapsing/refractory follicular lymphoma. In this case-based activity, Dr. Loretta Nastoupil and Dr. John Leonard discuss the importance of testing for EZH2 mutations in follicular lymphoma, choosing the appropriate treatment option for each patient, and how to minimize risk to improve patient outcomes.
Host: David L. Eisenberg, MD, MPH, FACOG
Guest: David J. Portman, MD
A new form of contraception based on vaginal pH modulation is available. In this activity, Dr. Eisenberg reviews the risks and benefits of the hormone-free, user-controlled gel, and Dr. Portman provides his perspective on clinical trial results within the context of the “creeping Pearl Index.”
Guest: Christie M. Ballantyne, MD
Host: John J. Russell, MD
According to the Consensus Statement published by the European Atherosclerosis Society, more than 90% (and maybe as high as 99%) of individuals with FH in the US have not been properly diagnosed due to gaps in screening, recognition and classification of FH. If not identified and aggressively treated from an early age, individuals with FH have a 20-fold increased life time risk of heart disease compared to the general population. However, with optimal treatment, an affected individual’s lifetime risk of cardiovascular disease approaches the risk found in the general population. Although the clinical symptoms are not as pronounced in cases of heterozygous FH, both homozygous (HoFH) and heterozygous FH (HeFH) patients still have an elevated risk of developing coronary heart disease at some point in their life. Early diagnosis and treatment for both HoFH and HeFH can significantly reduce the risk of coronary heart disease or delay its onset. Both homozygous and heterozygous FH are serious conditions that require special attention and treatment.
Host: Loretta J. Nastoupil, MD
Guest: Gilles Salles, MD
Follicular lymphoma (FL) is an incurable neoplasm that is frequently associated with relapse and refractory (R/R) disease. In this activity, Drs. Loretta Nastoupil and Gilles Salles will review the role of EZH2 modulation in FL and explain the role that EZH2 inhibition can play in R/R disease. They will also discuss the many available oral therapeutic options and emerging therapies on the horizon, recent data from those clinical trials, and where these therapies will fit into clinical practice.
Guest: Kevan C. Herold, MD
Guest: Stephen Gitelman, MD
Experts in the immunopathology of type 1 diabetes consider the potential role of monoclonal antibodies, disease modifying agents, and other agents to prevent or delay the onset of clinical disease. Particular emphasis will be placed on the CD3 cell surface marker and anti-CD3 monoclonal antibodies, which has been shown to slow progression to clinical type 1 diabetes in high risk persons.
Host: Michael Miller, MD, FACC, FAHA, FNLA
Guest: Brian Olshansky, MD, FACCP, FAHA, FHRS, FESC
In 2019, the REDUCE-IT trial studying eicosapentaenoic acid (EPA), a purified form of omega-3 fatty acid, was published and demonstrated a dramatic 25% reduction in major cardiovascular events. In 2020, the STRENGTH trial that used a carboxylic acid formulation of combined EPA and docosahexaenoic acid (DHA), was surprisingly neutral and the study was halted for futility. A recent post hoc analysis of the STRENGTH study failed to show a difference in the primary endpoint in the highest tertile group receiving the EPA/DHA carboxylic acid treatment. Why did these two major omega-3 clinical trials studying patients with elevated triglyceride levels have disparate results? What does this mean for our patients? Join two experts, Drs. Michael Miller and Brian Olshansky, as they assess the different trials and offer their perspective on the clinical and scientific implications of the results.
Host: Linda Bradley, MD
In this activity, Dr. Linda Bradley reviews risk factors for uterine fibroids, the use of TVS,
Host: Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Guest: James A. Underberg, MD
Guest: Nathan D. Wong, PhD, MPH
This activity is presented by outstanding educators in the field of lipidology and preventive cardiology. Join Drs. Erin D. Michos, James A. Underberg, and Nathan D. Wong for a deep dive into these hot topics: new pathways to manage high risk in ASCVD, differential biological effects of omega-3 fatty acids, and practical considerations to manage ASCVD risk.
Host: Nanette F. Santoro, MD
In this activity, Dr. Nanette F. Santoro explains risk factors for vasomotor symptoms, reviews current medical options for this bothersome problem, and describes the mechanism of action of a new class of nonhormonal agents: selective neurokinin-3 receptor antagonists.
Host: Christina Y. Weng, MD, MBA
Guest: Arshad M. Khanani, MD, MA
Diabetic macular edema (DME) remains undertreated in the real world. New targeted agents are in development for DME that seek to broaden current treatment approaches while improving upon the durability of VEGF suppression. These new treatments that go beyond the current standard of care may help reduce treatment burdens and ultimately improve vision outcomes in DME. Join our two experts, Dr. Christina Weng and Dr. Arshad Khanani, as they discuss these emerging agents, their mechanisms of action, and the latest available data.
Host: Paul Paik, MD
Guest: Viola Zhu, MD
Dysregulation of MET signaling has been widely described in oncogenic processes. While all 3 types of MET dysregulation (amplification, overexpression, and gene mutations) have been documented in non-small cell lung cancer (NSCLC), MET exon 14 skipping alterations are a primary oncogenic driver in approximately 3% to 4% of these patients, often with a poor outcome. Join us as Dr. Paul Paik and Dr. Viola Zhu discuss the importance of testing patients for MET gene aberrations and their relevance in the management of NSCLC, especially as related to recently approved and emerging therapies for patients harboring a MET gene aberration.
Host: Loretta J. Nastoupil, MD
Guest: Matthew J. Matasar, MD
The epigenetic modulator EZH2 is known to play a crucial role in mediating the lymphomagenesis of follicular lymphoma (FL), and the inhibition of EZH2 in the relapsing/refractory disease setting has shown efficacy. In this activity, Drs. Matasar and Nastoupil discuss the role of EZH2 in the pathobiology of FL, emphasize the need to test for mutations in EZH2 in FL, and explore the potential of targeting EZH2 in different settings of FL treatment.
Host: Vivian Fonseca, MD, FRCP
Guest: Rishi P. Singh, MD
Diabetic macular edema and diabetic retinopathy are 2 of the most common vision complications associated with diabetes. Moreover, diabetic retinopathy is the leading cause of vision loss among adults. We know that screening works, and we have effective treatments, so why do we continue to see high rates of vision loss? Listen as our experts, Dr. Vivian Fonseca and Dr. Rishi Singh, navigate persisting disparities to determine which populations are most vulnerable, the barriers they face, and the potential for emerging strategies to improve screening and vision outcomes for all patients.
Host: Julien Taieb, MD, PhD
Guest: Scott Kopetz, MD, PhD
BRAF mCRC is a very aggressive subset of colon cancer and, until recently, treatment options have been very limited. With a new standard of care on the rise, a critical challenge remains: How will emerging regimens be utilized in daily clinical practice?
Join us as 2 experts, Dr. Scott Kopetz and Dr. Julien Taieb, examine strategies to enhance the personalized management of patients with BRAF V600E-mutated mCRC.
Host: Susan L Samson, MD, PhD, FRCPC, FACE
Guest: Kevin C.J. Yuen, MD
Acromegaly is a rare disorder caused by excess growth hormone production and is associated with increased morbidity and mortality. Delays in the diagnosis and initiation of therapy or the provision of suboptimal therapy often negatively impact the quality of life of these patients. Join us for this expert interview with Dr. Susan Samson and Dr. Kevin Yuen who offer insights to help you overcome the complex medical challenges often faced when managing patients with acromegaly, including strategies to apply the latest guidelines and the 2020 consensus statement into clinical practice.
Host: Daniel Catenacci, MD
Guest: Yelena Janjigian, MD
Do you face clinical challenges when managing patients with advanced HER2-positive gastric cancer? You’re not alone. Advanced gastroesophageal cancers remain among the most difficult cancers for clinicians to manage. One of the many challenges to optimizing patient outcomes is a relative lack of familiarity with practice standards regarding HER2-positive disease. While HER2 is an oncogenic driver in gastroesophageal cancers, it does not appear to act as a predictive biomarker in quite the same way as it does in breast cancer. However, there are ways to fully optimize anti-HER2 therapy in gastroesophageal cancers. Join us as Dr. Daniel Catenacci and Dr. Yelena Janjigian demystify HER2-positive gastroesophageal cancers and provide insights for the integration of personalized therapeutic approaches for these patients.
Guest: James Lewis II, PharmD, FIDSA
Guest: George Thompson III, MD, FIDSA
Have you ever wondered what went wrong in the management of invasive fungal infections? Through a storytelling approach Dr. James Lewis & Dr. George Thompson discuss a clinical story and identify where medical misses may have occurred. Supportive evidence will be provided on how care should have been provided and strategies for clinicians to apply in their practice.
Guest: Carlos del Rio, MD
Guest: Angela Rasmussen, PhD
With cases of COVID-19 surpassing 51 million worldwide, the rush to develop a vaccine capable of slowing the pandemic and lessening the morbidity and mortality of SARS-CoV-2 is underway. Several COVID-19 vaccines are now being studied in phase 3 trials, and clinicians would benefit from a review of these ongoing efforts, particularly the status of vaccines close to approval. This podcast will provide clinicians a review of up-to-date safety and efficacy information on vaccine candidates in late-stage development, and steps to prioritize patients who would benefit most from vaccination once available.
Host: Hector O. Chapa, MD, FACOG
Guest: Colin Quinn, MD
Guest: Matthew Wicklund, MD
Dr. Colin Quinn and Dr. Matthew Wicklund discuss the genetic and pathophysiologic underpinnings of limb girdle muscular dystrophy, as well as the use of appropriate diagnostic tests for accurate identification of LGMD.
Host: Richard T. Penson, MD, MRCP
Guest: Ana Oaknin, MD
Therapeutic choices for many women with advanced endometrial cancer are being driven by our understanding of the mismatch repair (deficient/proficient) and microsatellite (instable/stable) status of their tumors. Join us as Dr. Richard Penson and Dr. Ana Oaknin discuss the global perspective surrounding the recent emergence of immunotherapy agents in the management of recurrent or metastatic endometrial cancer. Find out how to manage the toxicities of these newer therapies and discover just how critical a role molecular testing plays in selecting which patients receive a particular therapeutic strategy.
Host: Matthew R. Weir, MD
Guest: Gates B. Colbert, MD, FASN
Guest: Robert Toto, MD
Hyperkalemia (HK) is a major impediment to optimizing RAASi therapy in various patient populations. Fortunately, newer treatments are now available to mitigate this adverse effect. In this chapterized activity, Drs. Colbert, Toto, and Weir discuss strategies to manage a patient with chronic kidney disease (CKD) and resistant hypertension. Find out who is at risk for HK and explore the use of a potassium binder as both a short- and long-term solution.
Host: Richard T. Penson, MD, MRCP
Guest: Nicoletta Colombo, MD
Guest: Christine Ghione
Therapeutic options are changing for many patients with advanced endometrial cancer. Join us as Dr. Richard Penson and Dr. Nicoletta Colombo discuss new immunotherapeutic approaches and the importance of a patient’s tumor genomic profile when determining which interventional strategy, they receive. Also hear from Ms. Christine Ghione, a patient advocate, who provides a firsthand perspective of shared decision-making and how the process may be improved.
Since the production of this activity, the FDA has approved the use of dostarlimab for the treatment of patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR, as determined by an FDA-approved test. Visit the FDA statement dated 22 April 2021 to learn more.
Host: Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Guest: Joseph Lim, MD
Guest: Danny Chu, MD
Guest: Jian Q. Zhang, DNP, MS, FNP-BC, NEA-BC, FAAN
Experts in chronic hepatitis B within Asian communities discuss prevention, screening and management options to reduce the number of new cases and the risk of progression to cirrhosis, hepatic failure, and hepatocellular carcinoma. Experts also will consider the integration of Western and Eastern Medicine approaches to treatment and how cultural perceptions and community stigmatization of persons of Asian descent with chronic HBV infection can create barriers to diagnosis and care.
Guest: David Eichenbaum, MD
Guest: Charles Wykoff, MD, PhD
Current challenges in the treatment of neovascular retinal disease include the tremendous burden of treatment and suboptimal response to treatment in many cases. Strides have been made recently toward therapies that deliver increased efficacy vs traditional first-line therapies, a decreased treatment burden, or both. To achieve these ends, next-generation treatment strategies target multiple angiogenic cellular pathways at once. In this activity, experts in retinal disease treatment use custom animations to discuss the mechanisms of action of various novel treatment strategies. The latest clinical trial data for faricimab and OPT-302, two molecules currently in phase 3 clinical trials for the treatment of retinal disease, are also presented.
Host: Jennifer Caudle, DO
Guest: Crystal Proud, MD
Guest: Edward Clinton Smith, MD
Dr. Crystal Proud and Dr. Edward Smith discuss the relationship of DMD genetics and pathophysiology and explain the importance of early diagnosis of Duchenne Muscular Dystrophy and the challenges associated with making this diagnosis.
Guest: Kevan C. Herold, MD
Guest: Chantal Mathieu, MD, PhD
Experts in the immunopathology of type 1 diabetes discuss the epidemiology, non-genetic and genetic risk factors, and progression from preclinical to clinical stages of this disease. The discussion will emphasize the breakdown of immune tolerance that precedes type 1 diabetes and the subsequent pathogenetic role of islet autoantibodies responsible for its clinical manifestations.
Host: Robert Mocharnuk, MD
Guest: Johann de Bono, MD, PhD
Guest: Neeraj Agarwal, MD
During recent years, advances in the understanding of the underlying genetic events and biology in prostate cancer development, including the DDR and MMR pathway alterations, have yielded new avenues for clinical exploration. Prostate cancers with deleterious aberrations in DNA damage repair (DDR) genes, including homologous recombination repair, such as mutations in BRCA1/2 and ATM, are associated with response to poly (adenosine diphosphate–ribose) polymerase (PARP) inhibition.
PARP inhibitors are now gaining FDA approvals for the treatment of patients with mCRPC, and ongoing clinical trials are evaluating these PARP inhibitors as monotherapy or in combination with other treatments such as androgen pathway inhibitors. The National Comprehensive Cancer Network (NCCN®) is now recommending germline testing and molecular biomarker analysis, including tumor testing for HRR mutations, and to consider tumor testing for MSI or dMMR for metastatic disease. PARP inhibitors for the treatment of mCRPC in patients harboring germline and somatic BRCA/ATM mutations, and in combination with androgen pathway inhibition, are poised to propel the management of mCRPC toward a more personalized approach.
In this activity, expert faculty will review, discuss, and provide their expert insights on recent and emerging practice-changing advancements with PARP inhibitors for the treatment of mCRPC, with a ...
Host: Paul Paik, MD
Guest: Jyoti D. Patel, MD, FASCO
Lung cancer remains the most common cancer in the United States and Europe and second most common in Japan. Of patients with non-small cell lung cancer (NSCLC), approximately 3% to 4% have tumors that harbor MET gene aberrations including MET exon 14 skipping mutations. These patients have an even worse prognosis than others with NSCLC, and early diagnosis and targeted therapies are essential. Join us as Dr. Paul Paik and Dr. Jyoti Patel discuss the value that liquid biopsy brings to patients with NSCLC, specifically those with MET exon 14 skipping mutations.
Guest: Robert Gottlieb, MD, PhD, FACC
Guest: Marilyn Bulloch, PharmD, BCPS, FCCM
Guest: Tesha Seabra, MSN, RN
Host: Mimi Secor, DNP, FNP-BC, FAANP
Neutralizing monoclonal antibodies (mAbs) first received emergency use authorization (EUA) in November 2020 for treating at-risk patients with COVID-19, and the field has continued to evolve since that time. This presentation provides an update in the latest evidence showing reduced severe illness and hospitalization in patients treated with neutralizing mAbs. This presentation will also answer your questions from multidisciplinary expert perspectives in identifying EUA-appropriate patients and administering outpatient infusion therapies: Robert Gottlieb, MD, PhD; Marilyn Bulloch, PharmD, BCPS, FCCM; and Tesha Seabra, MSN, RN.
Host: Joseph F. Goldberg, MD, MS
Guest: Larry Culpepper, MD, MPH
Guest: Andrew A. Nierenberg, MD
Bipolar depression remains a burden for patients living with bipolar I disorder. Therefore, faculty experts came together on World Bipolar Day in a call to action to the healthcare community to improve the diagnosis and treatment of bipolar I depression. In this 60-minute activity previously aired as a live broadcast, faculty review the diagnosis and treatment of a patient case, discussing the utility of tools in diagnosis and strategies to overcome common clinical challenges. An overview of treatments recommended for bipolar I depression is also provided.
Host: Neil Bressler, MD
Hear the world-renowned Dr. Neil Bressler discuss the important role you can play in saving vision when wet AMD strikes.
###### Scroll down to download our Wet AMD handout, so you can share it with your patients! The handout includes a QR code where patients can access this video.
Guest: Monica L. Baskin, PhD
Guest: Josep M. Llovet, MD, PhD
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. Patients with advanced disease at diagnosis typically are not candidates for potentially curative treatment options, such as resection, liver transplantation, or ablation. Additionally, liver cirrhosis and hepatic dysfunction often complicate treatment. Advances in the understanding of the molecular pathogenesis of HCC have broadened the potential for effective molecular targeted therapies, and advances in immune checkpoint inhibitor therapy are now transforming the way clinicians treat HCC.
Of particular concern, HCC incidence and mortality rates have risen among American Indian/Alaska Native, Hispanic, and black populations in the United States in recent years. Incidence of HCC is also expected to increase in older populations due to hepatitis C, a risk factor for development of HCC, among other comorbid conditions such as cirrhosis, obesity, diabetes, and non-alcoholic steatohepatitis, which are also on the rise. Screening and surveillance of these conditions that contribute to the development of HCC occur less often in many Hispanic and black populations, which can delay diagnosis and leave them ineligible for curative resection or transplantation due to advanced disease, leading to worse prognosis.
In this activity, the expert faculty will review health disparities, inequities, and ...
Host: Michael S. Ip, MD
Guest: Christina Y. Weng, MD, MBA
For patients with retinal vascular disease, time is vision. But there are key components that can help you diagnose early neovascular age-related macular degeneration and retinal vein occlusion before permanent vision loss occurs. Drs. Michael Ip and Christina Weng discuss warning signs, risk factors for progression, and the steps you can take to ensure early diagnosis and improved outcomes for your patients.
Host: Shannon L. Meeks, MD
Guest: Jonathan C. Roberts, MD
Dr. Shannon Meeks and Dr. Jonathan Roberts give an overview of the treatments used for the management of hemophilia A and discuss the safety and efficacy of these treatments. Using a patient case, they illustrate the pharmacovigilance process and explain how to implement this important reporting structure into everyday practice.
Host: Diana Shechtman, OD, FAAO
Guest: Mark T. Dunbar, OD, FAAO
Early diagnosis and early treatment of age-related macular degeneration (AMD) and retinal vein occlusion (RVO) can be critical to preserving a patient’s vision. How can optometrists, who are on the frontlines of eye care, diagnose and refer patients early in the disease process to ensure the best visual outcomes for patients? Join the discussion with Dr. Dunbar and Dr. Shechtman to find out more about how time is vision for these patients.
Host: Diana Do, MD
Guest: Julia Haller, MD
Guest: Rishi P. Singh, MD
Age-related macular degeneration (AMD) is the most common cause of blindness in adults over the age of 50 years. Anti-VEGF therapy has markedly improved vision outcomes in patients with neovascular AMD, but what else can we do to maximize long-term vision in these patients? Drs. Do, Haller, and Singh discuss the key role of fluid in the treatment of wet AMD, dosing interval data from clinical trials, and the importance of patient expectations when selecting therapy.
Host: Adrienne W. Scott, MD
Guest: Peter A. Campochiaro, MD
Guest: Rahul N. Khurana, MD
Retinal vein occlusion (RVO) can lead to macular edema, which is the main cause of vision loss. Accordingly, retina specialists know that time is vision and prompt intervention is critical to good outcomes in patients with RVO.
Join our discussion with Drs. Campochiaro, Khurana, and Scott to discover strategies to use with your patients before and during treatment and throughout maintenance to improve visual acuity while minimizing side effects.
Host: Shannon L. Meeks, MD
Guest: Cindy Leissinger, MD
Pharmacovigilance begins after clinical trials end and new therapies enter everyday practice. Due to the rarity of hemophilia, participation in clinical trials has necessarily been small, and so monitoring the safety of new hemophilia treatments is especially important. Continued surveillance of adverse drug reactions (ADRs) after approval is a responsibility that falls on all members of the care team.
Dr. Shannon Meeks and Dr. Cindy Leissinger discuss the importance of safety surveillance and monitoring for novel hemophilia A therapeutics. To give a better understanding of pharmacovigilance, this activity includes animation that breaks down the process and illustrates where your ADR reports go and what happens next.
Host: Javed Butler, MD, MBA, MPH
Guest: Paul W. Armstrong, MD
Finding the optimal treatment strategy for patients with worsening heart failure with reduced ejection fraction (HFrEF) can be challenging, and long-term outcomes are poor. Can newer therapies and novel mechanisms of action finally help close the treatment gap for these patients? Join Drs. Javed Butler and Paul Armstrong as they explore these new mechanisms of action and provide practical insights into incorporating newly approved therapies into an overall HFrEF treatment plan.
Host: Peter K. Kaiser, MD
Guest: Dante J. Pieramici, MD
Correctly identifying retinal diseases early on is essential in preserving your patients’ vision. How do physicians distinguish key pathological features to identify early neovascular age-related macular degeneration (AMD) and retinal vein occlusion (RVO) before macular edema leads to permanent vision loss?
In this activity, Drs. Kaiser and Pieramici discuss these key pathologies in AMD and RVO and when further evaluation with advanced imaging is necessary—for these patients, time is vision.
Host: Emily Chew, MD
Guest: Neil Bressler, MD
Guest: Joseph M. Coney, MD
Guest: Steven Ferrucci, OD, FAAO
Approximately 2 million individuals in the United States are living with age-related macular degeneration (AMD), and another 1.6 million are living with retinal vein occlusion (RVO). These numbers are increasing daily due to an aging population and prevalence of risk factors. There have been many advances in treatment, but what else can you be doing to prevent vision loss in your patients?
In this activity, Dr. Emily Chew speaks with Drs. Neil Bressler, Joseph Coney, and Steven Ferrucci to examine the evidence around early diagnosis, referral, and treatment of AMD and RVO and the impact of these diseases on patients’ lives.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Barbara Dehn
Physicians continue to seek the safest and most effective formulations for combined hormonal contraceptives (CHCs). The goal is to ensure that the patient’s chosen option optimizes the many benefits of estrogen but also reduces its adverse events—particularly those that are cardiovascular and thromboembolic in nature. Lower estrogen concentrations do not always mean better; sometimes better means better. But just like in a game of beach limbo, we have to ask: How low can you go?
Join us as Dr. Lee Shulman and Barbara Dehn, a nurse practitioner with vast contraception counseling and prescribing experience, discuss the dynamics of a new, lower-strength estrogen with the potential for use in combined oral contraceptives.
Host: Joel L. Cohen, MD
The differences between biostimulators and dermal fillers are simple yet critically important to their safe and successful use. With the help of 2D animation, Dr. Joel Cohen presents different techniques to optimize results in patients and minimize the risk of adverse effects.
Host: Floor J. Backes, MD
Guest: Robert L. Coleman, MD, FACOG, FACS
Does immunotherapy play a role in improving quality of life and survival for patients with ovarian cancer? Learn how experts are determining immunotherapy’s place in the treatment plan during the PARP era and what’s on the horizon.
Host: Neilanjan Nandi, MD
Guest: Sunanda Kane, MD, MSPH, AGAF
Follow Dr. Sunanda Kane and Dr. Neil Nandi as they explore a personalized and proactive treat-to-target strategy to achieve long-term remission in this clinical case scenario of a patient with IBD. Would you make the same decisions?
Host: Federico Cappuzzo
Guest: Professor Solange Peters
Guest: Professor Yi-Long Wu
Are dMMR and MSI-H both markers that will soon replace or work in conjunction with PD-L1 when determining immunotherapy for patients with metastatic NSCLC? Accurate testing and treatment selection is critical in identifying patients who will benefit from these therapies. Dr. Federico Cappuzzo, Dr. Solange Peters, and Professor Yi-Long Wu discuss emerging data from the recent WCLC, ESMO, and ASCO virtual conferences and offer their international and regional perspectives on the evolving use of immunotherapies in advanced NSCLC.
Host: Edward J. Mayeaux, Jr., MD, DABFP, FAAFP
Guest: Paul P. Doghramji, MD, FAAFP
Adherence to CDC vaccination recommendations is a public health issue and a topic of great concern for clinicians. According to the World Health Organization, vaccines ultimately reduce the burden of infectious disease and have the potential to save 2 to 3 million lives a year worldwide independent of their impact on morbidity. Join us as Drs. E.J. Mayeaux and Paul Doghramji discuss the challenges we’re all facing to overcome vaccine hesitancy and improve vaccine uptake, especially during the COVID-19 pandemic.
Host: Peter Schmid, FRCP, MD, PhD
Guest: Javier Cortes, MD, PhD
Our understanding of the biology of triple-negative breast cancer (TNBC) is leading to the development of more targeted therapies. Dr. Peter Schmid and Dr. Javier Cortés discuss the role of immunotherapies in the treatment of metastatic TNBC and how to determine if your patient is eligible for combination immunotherapies.
Host: Joel L. Cohen, MD
Guest: Jason D. Bloom, MD
Dr. Joel Cohen and Dr. Jason Bloom discuss the importance of neuromodulator selection and accurate dosing for the glabella and upper face. Dr. Bloom takes us through a patient demonstration of optimal injection techniques and dosing while addressing strategies to minimize the risk for adverse events.
Host: Charles E. Geyer, Jr., MD, FACP
Guest: Hope S. Rugo, MD
Although outcomes have improved for women with HER2-positive early-stage breast cancer, patients who do not have a pathologic complete response after neoadjuvant therapy are at an increased risk for recurrence and need further improvements in therapy options.
In this activity, Drs. Charles Geyer and Hope Rugo discuss how the management of HER2-positive early-stage breast cancer has evolved, the continued quest to reduce the burden of therapy on patients—and how subcutaneous approaches are achieving this—and other challenges in the treatment continuum.
Host: Neilanjan Nandi, MD
Guest: Russell D. Cohen, MD, FACG, AGAF
New and emerging therapeutic targets will add to the existing portfolio of available biologics and small molecule therapies available in IBD. Join Dr. Russel Cohen and Dr. Neil Nandi as they explore the role of these targets in addressing the various unique IBD phenotypes that lead to loss of response over time, as well as provide practical insights into selecting the right therapy at the right time for your patient.
Host: Neilanjan Nandi, MD
Guest: Gary R. Lichtenstein, MD, FACG, FACP, AGAF
Achieving remission and long-term success in IBD is greatly dependent on developing a treatment plan that incorporates therapies that induce mucosal healing, reduce inflammation, and that do not possess broad immunosuppressive properties. Join Dr. Gary Lichtenstein and Dr. Neil Nandi as they break down their therapeutic recommendations and patient care approaches. Learn how to develop treatment plans that incorporate early, more aggressive use of targeted therapies and to select the right treatment for the right patient.
Host: Patricia K. Coyle, MD
Guest: Jiwon Oh, MD
Treatment goals for patients with multiple sclerosis continue to be refined as more and better disease-modifying drugs emerge from clinical trials and we accrue findings from real-world data. Nonetheless, the decision to match a patient with a particular drug agent has become more complex as we strive to achieve our treat-to-target goals and optimize patient outcomes.
Drs. Coyle and Oh discuss how clinicians can best approach the medical management of patients with multiple sclerosis, both in the short and long term. The goal is to apply best clinical evidence while personalizing a patient’s therapy, thus offering the patient as normal a life as possible.
Host: Neilanjan Nandi, MD
Guest: Miguel Regueiro, MD, AGAF
Treat-to-target is the current standard for the management of IBD, and as such it is imperative to understand what those targets are, what strategies will help you achieve them, and the importance of integrating a patient-focused therapeutic plan. Join Dr. Miguel Regueiro and Dr. Neil Nandi as they explore practical approaches to defining therapeutic success and provide listeners with solutions and recommendations to ultimately improve long-term IBD patient outcomes.
To view and download the Crohn's and Colitis Foundation's appeal letters referenced in this program, click here!
Host: Patricia K. Coyle, MD
Guest: Mitzi Joi Williams, MD
While we are witnessing an impressive expansion in the multiple sclerosis treatment landscape, we cannot lose sight of the fact that a critical component of care is the incorporation of best clinical evidence into the personalized management of each patient.
Join us as Drs. Coyle and Williams discuss how bringing shared decision-making into the management of multiple sclerosis can help us to not only achieve our treat-to-target goals, but also improve patient outcomes and satisfaction.
Host: Azeem Latib, MD
Guest: Sarah Kohnstamm, MD, FACC
New guidelines on valvular heart disease from the American Heart Association and the American College of Cardiology have recently been published. In this activity, Dr. Latib and Dr. Kohnstamm discuss the etiology of aortic stenosis, as well as apply the new ACC/AHA guidelines to clinical practice.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Andrew M. Kaunitz, MD, FACOG
The estrogen component of combined oral contraceptives in part helps to suppress FSH and folliculogenesis, stabilizes the endometrium, minimizes unscheduled bleeding, and supports progestin activity. Nonetheless, there are downsides to estrogen, including an increased risk for cardiovascular and thromboembolic adverse events such as pulmonary embolism and deep vein thrombosis.
Join Drs. Lee Shulman and Andrew Kaunitz as they envision a better oral contraceptive—one formulated with a high NEST activity estrogen that has less potential to increase the risk of thromboembolic events while maintaining good cycle control.
Host: John J. Russell, MD
Guest: Steven W. Pipe, MD
Hemophilia A and hemophilia B are congenital X-linked bleeding disorders caused by deficiency of coagulation factor VIII (FVIII) and IX (FIX). While the life expectancy of patients with hemophilia has dramatically increased over the past several decades, the hemophilia population still faces unique challenges that require appropriate use of effective strategies. The preferred treatment option for patients with hemophilia is replacement therapy. Prophylaxis with standard recombinant factor requires regular intravenous infusion at least two (FIX) to three (FVIII) times a week. Recombinant FVIII and FIX products with an extended half-life are currently available and newer strategies are on the horizon. With reported mean half-life extensions of 1.5–1.8 times that of standard products for FVIII and 3–5 times that of standard products for FIX, these therapies have the potential to address and individualize the needs of patients.
Click here to access patient information on hemophilia from the CDC.
Guest: Joseph Mikhael, MD
A 15-minute synopsis of the top hematology research in multiple myeloma presented at the 2020 ASH Annual Meeting. Learn about potential practice-changing data placed in a real-world context by a myeloma expert. This activity is an opportunity to stay up to date on the rapidly evolving myeloma landscape and to enhance your management and care strategies for patients with multiple myeloma.
Host: Joel L. Cohen, MD
Guest: Carolyn I. Jacob, MD, FAAD
What does the future hold for aesthetics? The 4 four available neuromodulators share a similar mechanism of action and efficacy profiles, but they each have their own unique characteristics, and now an emerging agent is about to enter the scene. Dr. Joel Cohen and Dr. Carolyn Jacob discuss the subtle differences among neuromodulators and the importance of dosing for duration, specifically for the glabella and upper face. They also explore potential adverse events and strategies to minimize your patients’ risks.
Host: Andrew Alexis, MD, MPH
Guest: Linda Stein Gold, MD
Depression, anxiety, failure to thrive, unemployment, low self-esteem, and suicidal ideation. What could possibly be contributing to all of these consequences? The culprit is acne—didn’t expect that, did you? Hear from dermatologists Dr. Andrew Alexis and Dr. Linda Stein Gold as they discuss the proper assessment of acne, its location—particularly beyond the face—and the differences to keep in mind when assessing skin of color. Faculty also examine the role that selective retinoid therapies play in treating acne and preventing the development of both the physical and psychological scars associated with this condition.
Host: Leslie Citrome, MD, MPH
Guest: Christoph U. Correll, MD
Dr. Leslie Citrome and Dr. Christoph Correll discuss the clinical trial data of current and emerging antipsychotic therapy for bipolar I disorder and schizophrenia. They provide insight on how to apply this clinical data into everyday practice and explore the best strategies to improve patient-centric issues for people coping with these illnesses.
Host: Mimi Secor, DNP, FNP-BC, FAANP
Guest: Karen Bloch, MD, MPH, FIDSA, FACP
Guest: Jarrod W. Kile, RPh, BCPS
Hear from a multidisciplinary, interprofessional panel of experts on COVID-19 infusion therapies with virus-neutralizing monoclonal antibodies (mAbs). This activity features a clinical discussion of the Emergency Use Authorization criteria and data from real-world use of mAbs in ambulatory patients. Learn how this treatment reduces the chance of patients with COVID-19 developing severe illness and what could be done to effectively implement the outpatient delivery of mAbs to patients with COVID-19 in your practice.
Guest: Richard Channick, MD
Guest: Vallerie Mclaughlin, MD
Pulmonary Arterial Hypertension is a progressive disease and is associated with poor clinical outcomes. This first live webinar provides an in-depth discussion of the new thresholds for the diagnosis of PAH, and differential diagnostic considerations, along with the emerging data on the optimal management of patients with PAH. This activity provides a case discussion on the clinical application and effective strategies to integrate the emerging data into treatment regimens to improve outcomes for individuals with this highly complex disease.
Host: Jennifer W. Carlisle, MD
Guest: Suresh S. Ramalingam, MD
Targeted therapy has revolutionized the treatment of advanced non–small-cell lung cancer (NSCLC) across a broad range of molecular aberrations. The epidermal growth factor receptor (EGFR), a member of the HER/ErbB family of membrane-bound proteins, was one of the first successful targets in lung cancer, and HER2, another member of the HER/ErbB family, is a valid target in breast and gastric cancers. Yet developing effective HER2-targeted therapy for patients with NSCLC has been difficult, leading some to underestimate the potential of HER2 as a target in NSCLC. Fortunately, recent data suggest that a novel antibody-drug conjugate (ADC) has clinically meaningful activity in HER2-mutated, metastatic NSCLC, and this agent, trastuzumab deruxtecan, has been granted “breakthrough therapy” designation for this use. As important as this finding is, it adds to the volume of data being generated in lung cancer every day, and many oncologists report feeling overwhelmed by lung cancer advances. This situation is only exacerbated as the COVID-19 pandemic taxes healthcare professionals and systems alike. Oncologists, therefore, need education about the latest advances in the targeted treatment of NSCLC with HER2 aberrations, delivered in a format and location that makes the education timely, succinct, and accessible to close these gaps.
Host: Jennifer Caudle, DO
Guest: Andrew D. Badley, MD, FRCP(C), FACP, FIDSA
Guest: Chad Worz, PharmD, BCGP, FASCP
The United States is one of the hardest hit countries with SARS-CoV-2 with many more deaths expected in early 2021. Outpatient infusion treatment with neutralizing monoclonal antibodies (nAbs) is an important treatment option for some patients. This 30-minute ReachMD program helps you recognize appropriate patients for nAb-therapy and presents the most recent evidence on ambulatory options. Get expert perspectives from a physician and pharmacist as they present compelling case studies. This broadcast replay includes a pre-read summarizing key clinical trial information.
Guest: Janet B. McGill, MD, MA, FACE, FACP
Host: John J. Russell, MD
Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease and end-stage renal disease, accounting for almost 50 percent of all patients starting renal replacement therapy worldwide. At least half of the patients with T2DM will develop diabetic kidney disease (DKD). DKD is the single strongest predictor of morbidity and premature mortality in patients with diabetes. Even mild increases in albuminuria or GFR decline are associated with an increased risk of cardiovascular diseases and CV death, along with increased health-care costs. Therefore, kidney protection is a critical target in T2DM. Join us as we take a look at new therapeutic agents for the prevention of DKD development and progression.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Anita L. Nelson, MD
Although oral contraceptives were first introduced approximately 60 years ago, we continue our efforts today to identify new estrogens and progestins that improve cycle control while minimizing adverse events.
Today’s dialogue focuses on the evolution of estrogen in contraception, including newly combined oral contraceptives. Drs. Lee Shulman and Anita Nelson also discuss contraception innovations using E4 that are currently under investigation.
Host: Gregory Lewis, MD
Guest: Michael Böhm, MD, FESC
Guest: Josep Comin-Colet, MD, PhD
Do you know that as many as 70% of patients hospitalized with heart failure are iron deficient? This condition is associated with reduced functional capacity, reduced quality of life, and adverse outcomes. Come and explore the new data from the AFFIRM-AHF trial on repletion of iron deficiency in this population and discover the effect of iron on hospitalization rates. What practical steps should you be taking to improve the health of your patients with heart failure?
Guest: Marwan Noel Sabbagh, MD, FAAN, CCRI
Host: Alireza Atri, MD, PhD
Once an Alzheimer’s disease diagnosis is made, the next challenge is treatment. Dr. Alizera Atri and Dr. Marwan Sabbagh discuss the current standard of care, the clinical pipeline for Alzheimer’s disease, and the role of amyloid-beta-targeted antibodies.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Mira Irons, MD
Guest: Shannon Curtis
Following the approval of the first COVID-19 vaccine, mass-vaccination has made approving a vaccine difficult. How are the Food and Drug Administration and the Centers for Disease Control deciding on which vaccinations to authorize? Dr. Mira Irons and Shannon Curtis of the American Medical Association join Dr. Charles Turck to discuss authorization processes and recommendations for COVID-19 vaccines.
Host: Richard S. Isaacson, MD
Guest: Marc E. Agronin, MD
Despite decades of research, there are only a handful of FDA-approved drugs available for patients with Alzheimer’s disease (AD). Fortunately, several promising agents for the treatment of AD are in the late stages of development
Join us as Dr. Richard Isaacson and Dr. Marc Agronin take a deeper dive into the important guidelines and advances surrounding the treatment of Alzheimer’s disease.
Guest: Yohann Loriot, MD, PhD
Guest: Robert J. Motzer, MD
Advances in immune checkpoint inhibitor therapy are transforming the way clinicians treat and manage metastatic UC and RCC. Given the approval of immune checkpoint inhibitors for the treatment of metastatic UC and RCC in recent years, and more emerging evidence, it can be challenging to understand how to best incorporate these therapies into current treatment strategies.
This activity will review the latest clinical advances, emerging data, and guideline recommendations for immunotherapy for the treatment of advanced renal cell carcinoma and urothelial carcinoma.
Guest: Richard S. Finn, MD
Guest: Amit Singal, MD, MS
Guest: Mark Yarchoan, MD
In this web-based CME activity, experts discuss recent developments in the treatment of hepatocellular carcinoma (HCC). Do not miss this opportunity to learn more about new and emerging combination strategies and receive practical guidance on their integration into clinical practice.
You will hear first-hand from an experienced patient with HCC who will share his personal journey and offer a novel perspective for healthcare professionals.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Corey S. Cutler, MD, MPH, FRCPC
Guest: Doris M. Ponce, MD
Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation and is a major cause of morbidity and mortality. Although systemic corticosteroids are traditional first-line treatment for aGVHD, about half of patients are refractory to therapy. So what options are available for the treatment of steroid-refractory aGVHD?
Host: Robert A. Hauser, MD, MBA, FAAN
Guest: Stuart H. Isaacson, MD
Please note: This activity is no longer available for continuing education credit.
This Expert Exchange activity is designed to make clinicians aware of the potential for emerging pharmacotherapies in treating patients with Parkinson’s disease.
You can access the Clinical Compendium for Novel Therapies to Manage OFF Episodes in Patients with Parkinson’s Disease by clicking the link here.
Host: Pradeep Y. Ramulu, MD, PhD
Guest: E. Randy Craven, MD
Guest: Mark T. Dunbar, OD, FAAO
Glaucoma is a major public health problem in this country and can severely affect the well-being and quality of life of patients with the disease. Within the last five years, there have been several important advances in the pharmacologic and surgical management of glaucoma that clinicians need to know about.
In this program, we examine these innovations and their potential to improve your patients’ clinical outcomes.
Host: Mikhail Kosiborod, MD
Despite evidence and guideline recommendations, renin-angiotensin-aldosterone system inhibitor (RAASi) therapy tends to be used suboptimally among patients with heart failure (HF), particularly in patients with chronic kidney disease (CKD). What are the real-world factors that influence RAASi treatment decisions in patients with HF who have or are at risk for hyperkalemia? Hear about how the CARE HK in HF study is being designed to explore the real-world data surrounding this question and its associated impact on outcomes.
Host: Pradeep Y. Ramulu, MD, PhD
Guest: Ian Benjamin Gaddie, OD, FAAO
Glaucoma is a major public health problem in the US with an estimated 3 million Americans diagnosed with the disease and as many as 120,000 who are blind as a result. Fortunately, treatments to slow the progression of glaucoma are becoming more and more available.
In this activity, Drs. Pradeep Ramulu and Ian Gaddie review what role these newer innovations play in improving outcomes for patients with glaucoma as well as the benefits and risks associated with these modalities.
Host: Sandra G. Adams, MD, MS, FCCP
Guest: Anju T Peters, MD, MSCI, FAAAAI
Selection among therapies for severe asthma can be challenging, but there are 'treatable traits' clinicians can use to better predict which patients will have a favorable response.
Personalized management strategies for patients with severe asthma should consider patient history, lifestyle, triggers, comorbidities, symptoms, and patient technique, compliance, and education, as these three patient cases show.
Host: Stacy Kahn, MD
Inflammatory bowel disease in pediatric patients is not as uncommon as you may think. Dr. Stacy Kahn, Assistant Professor of Pediatrics at Boston Children’s Hospital, shares her experience with healthy diet plans, preparing families for transition, and more.
Published August 7, 2020
Host: Lorraine Dugoff
Most pregnant women make the decision to undergo some form prenatal aneuploidy testing—either a blood analyte-based test or the newer noninvasive prenatal testing (NIPT). NIPT is a highly accurate screening test that can be performed early during pregnancy and provides the woman and her clinician with important information regarding the genetic health of the fetus.
This patient-clinician connection activity will demonstrate counseling strategies for discussing NIPT with patients. One vignette will focus on a patient considering NIPT; the second will focus on discussing the NIPT results, encompassing “negative,” positive,” and “no-call/indeterminate” outcomes.
Guest: Anita Afzali MD, MPH, FACG, AGAF
The management of IBD remains challenging, owing to variable clinical presentations and ever-changing therapeutic options. In this interactive CME activity, Dr. Anita Afzali presents the case of a newly diagnosed patient with IBD, highlighting the importance of prompt diagnosis and aggressive medical treatment. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of IBD and learn more from IBD expert faculty.
Guest: David P. Hudesman, MD
It is estimated that only 20% to 30% of patients with Crohn’s disease (CD) have a non-progressive or indolent course. While most patients with CD present with non-penetrating or non-stricturing disease, 50% of patients develop intestinal complications within 20 years of diagnosis. In this interactive CME activity, Dr. Hudesman presents the case of a patient with CD, highlighting the importance of early recognition of disease complications and considerations for surgical management. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of inflammatory bowel disease (IBD) and learn more from an IBD expert faculty.
Guest: Peter A. Lio, MD
Guest: Mark Boguniewicz, MD
Guest: Eric Simpson, MD, MCR
Please note: This activity is no longer available for continuing education credit.
Tune in as a multidisciplinary panel discusses a clinician's question about the appropriateness of combining two biologics in a very young child with several atopic diseases.
Guest: Peter A. Lio, MD
Guest: Mark Boguniewicz, MD
Guest: Eric Simpson, MD, MCR
Please note: This activity is no longer available for continuing education credit.
A multidisiplinary panel is presented with a highly allergic, extremely refractory patient with atopic dermatitis. Her dermatologist wants to take the next step and start her on a biologic, but she's worried about the patient's occular history and dupilumab's conjunctivitis risk. Find out what the experts have to say about this doctor's dilemma.
Guest: Peter A. Lio, MD
Guest: Mark Boguniewicz, MD
Guest: Eric Simpson, MD, MCR
Please note: This activity is no longer available for continuing education credit.
Infants have the highest incidence of atopic dermatitis in the US but the fewest treatment options. This is a case a doctor submitted about a baby who is refractory to multiple oral and topical treatments. A multidisciplinary panel discusses how they would approach the baby's treatment, emerging options for this vulnerable patient population, and if anything can be done now to prevent progression of the atopic march later.
Host: Anne O'Donnell, MD
Guest: Patrick Flume, MD
Please note: This activity is no longer available for continuing education credit.
Nontuberculous mycobacteria lung disease (NTM-LD) is a relatively uncommon condition, although its prevalence is rising. In this interactive CME activity, Drs. Anne O’Donnell and Patrick Flume review two patient cases to demonstrate how clinicians can maintain a greater index of suspicion for the diagnosis of NTM-LD to enable timely and effective therapy. The management of NTM-LD remains challenging, owing to the need for long-term treatment, the potential for drug-related toxicities and patient nonadherence. These factors underscore the importance of specialty referral for the successful management of NTM-LD.
Host: Anne O'Donnell, MD
Guest: Robert "Brinkley" Sewell
Please note: This activity is no longer available for continuing education credit.
The successful management of nontuberculous mycobacteria lung disease (NTM-LD) remains challenging owing to the need for long-term treatment, the ongoing risks of adverse drug reactions, and the potential for nonadherence. These factors underscore the importance of specialty referral and shared decision making in the successful management of NTM-LD, as Dr. Anne O’Donnell and her patient Brinkley exemplify.
Host: Joseph K. Han, MD
Please note: This activity is no longer available for continuing education credit.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and negatively impacts quality of life. The good news is that biologic therapies targeting type 2 inflammatory pathways provide additional treatment options for CRSwNP. However, clinicians not only need to accurately diagnose nasal polyps in patients but also recognize the role of the underlying pathology to incorporate biologic agents into treatment regimens when appropriate, as Dr. Joseph K. Han explains.
Host: Reynold A. Panettieri, Jr., MD
Guest: Michael Wechsler, MD
Guest: Jonathan Corren, MD
Please note: This activity is no longer available for continuing education credit.
The management of severe asthma has changed drastically after the introduction of biologics. However, their introduction comes with many questions, such as, When should they be used and in whom? This Care Team ForumSM brings pulmonologists and an allergist/immunologist in dialogue with a patient about the immunologic underpinning of asthma pathology and how it relates to identifying patients appropriate for step-up care with biologics.
Host: Peter A. Lio, MD
Guest: Eric Simpson, MD, MCR
Guest: Mark Boguniewicz, MD
Please note: This activity is no longer available for continuing education credit.
“I begged my doctor for something else – there had to be something else,” Pam.
For over 50 years, Pam suffered with uncontrolled moderate-to-severe atopic dermatitis (AD). She experienced the evolution of treatment strategies over the course of the several decades, trying everything from topicals to off-label targeted systemic agents. She was willing to try anything to make the unbearable itch go away. In this roundtable discussion, we brought Pam and her dermatologist to discuss AD with a multidisciplinary physician panel. Together they weigh in on experimental and newly approved therapies, management strategies, impact on quality-of-life, and shared decision-making techniques, all supplemented by Pam’s unfiltered, down-to-earth reality check of what life with AD and all these drugs really feels like.
Host: Shira Johnson, MD
Guest: Amy L. Olson, MD, MSPH
Guest: Jeffrey Swigris, DO, MS
Guest: Katherine Rosen, RN, MSN, ANP-C
Please note: This activity is no longer available for continuing education credit.
This discussion highlights the challenges associated with progressive-fibrosing ILD diagnosis, explains management differences for connective tissue disease-associated ILD, and reviews therapeutic options for the management of PF-ILD.
Host: Shira Johnson, MD
Guest: Amy L. Olson, MD, MSPH
Guest: Jeffrey Swigris, DO, MS
Guest: Katherine Rosen, RN, MSN, ANP-C
Please note: This activity is no longer available for continuing education credit.
This discussion highlights the diagnosis of and treatment approach for interstitial pneumonia with autoimmune features (IPAF).
Host: Eric H. Kraut, MD
Hemophilia A is a rare bleeding disorder caused by deficiency of clotting factor VIII. The current standard of care for patients with severe hemophilia A centers on replacement therapy with factor VIII concentrate, either on demand when bleeding occurs or prophylactically (replacement therapy). Potential complications from replacement therapy include the development of inhibitory antibodies that attack the clotting factor in approximately one-fourth of patients, viral infections from human clotting factors, and bleeding in joints and muscles resulting from treatment delays. According to treatment guidelines from the Medical and Scientific Advisory Council (MASAC), “Inhibitor development is the most severe complication of treatment for patients with inherited hemophilia A.” In addition, the high cost and frequency of infusing factor VIII concentrates can increase the potential for side effects, thereby negatively affecting patient quality of life.
Fortunately, several unique agents have been newly approved or are currently under development. These agents promise to reduce morbidity and improve quality of life for patients. Clinicians will be challenged to integrate these new agents into their clinical practices.
AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when ...
Host: Leora Horn, MD, MSc
Please note: This activity is no longer available for continuing education credit.
Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with a poor prognosis. The recent addition of immunotherapy to the treatment landscape has changed the standard of care for ES-SCLC. In this interactive activity an expert will guide you through the latest evidence on checkpoint inhibitors for the management of ES-SCLC and offer expert insight into effectively and safely incorporating immunotherapy into your practice to improve patient outcomes.
Host: Chrysalyne D. Schmults, MD, MSCE (Chair)
Guest: Omid Hamid, MD
Guest: Anokhi Jambusaria, MD, MSCE, FAAD
Please note: This activity is no longer available for continuing education credit.
Available treatment options for cutaneous squamous cell carcinoma (cSCC) are expanding and involving more interdisciplinary dialogue. This slides/audio presentation features 3 clinical case scenarios with feedback and commentary by a medical oncologist, surgeon, and dermatologist exploring topics in immunotherapy, Mohs surgery, and complex patient presentations.
Host: Patricia K. Coyle, MD
Guest: Clyde E. Markowitz, MD
Please note: This activity is no longer available for continuing education credit.
Multiple sclerosis (MS) is one of the leading causes of disability worldwide. As the treatment armamentarium continues to grow, patient involvement in the development of an effective treatment strategy is becoming increasingly important. In this Clinical ExchangesSMactivity, leading MS specialists discuss issues of diagnosing MS, initiating treatment, and switching therapies, all in the context of practical shared decision-making techniques demonstrated by their own patients.
Host: Chrysalyne D. Schmults, MD, MSCE (Chair)
Guest: Omid Hamid, MD
Guest: Anokhi Jambusaria, MD, MSCE, FAAD
Please note: This activity is no longer available for continuing education credit.
The recent approval of the first immunotherapeutic agent for cutaneous squamous cell carcinoma (cSCC) is changing the way healthcare providers treat patients with inoperable cSCC. In this roundtable discussion, a cSCC survivor draws upon his experience with the cancer when surgery and chemotherapy failed him, as our multidisciplinary faculty panel focus on how to optimally select patients with cSCC for treatment with immunotherapy.
Guest: Bincy P. Abraham, MD, MS
Guest: Jason Ken Hou, MD, MS, FACG
Guest: Siddharth Singh, MD
As the most common extraintestinal complication from IBD, iron deficiency anemia (IDA) can take a heavy toll on your patients’ quality of life. This activity will review those impacts, in addition to discussing the different therapies and resources that are available to both you and your IBD patients.
Host: Matt Birnholz, MD
Guest: Joshua D. Lee MD, MSc
Opioid use disorder is a growing problem in the United States. Every day we hear about the rampant increase in the misuse of prescription analgesics, the easy accessibility of opioids, and the skyrocketing opioid overdoses that demonstrate the need for healthcare providers to not only understand more about these drugs, but also offer meaningful treatments.
Guest: Robert A. Baldor, MD
Guest: Chadwick R. Johr, MD
This innovative, 45-minute, case-based CME activity features two prominent faculty covering important, timely issues and data related to the detection of autoimmune (AI) disorders. Using case studies, the faculty will explore diagnosis and management strategies to maximize patient care. In addition to the analysis of AI cases, key topics will be covered, including:
- Evaluation for suspected RA
- Combination serological assessment
- 14-3-3eta as a marker for joint damage
- Autoantibodies in SLE diagnosis and classification
- ANA IFA and subserologies
- Diagnosis of RA, Sjögren’s, Lupus, and Systemic Sclerosis
Guest: Robert A. Baldor, MD
Guest: Chadwick R. Johr, MD
This innovative, 30-minute, online activity features a Video Expert Dialogue with two prominent faculty covering important, timely issues and data related to the detection of autoimmune (AI) disorders. The emphasis is on the unique role primary care providers play in diagnosing and managing AI and maximizing patient care. Topics include:
- Overview of connective tissue diseases and ANA testing
- ANA IFA and ELISA
- New tests
- Subserologies with IFA
- Choosing wisely about ANA testing
- Diagnosis of RA, Sjögren’s, Lupus, and Systemic Sclerosis
- Titer Information
- Negative ANA testing
- When to refer
We’ll be discussing autoantibody testing for autoimmune diseases, or more precisely, connective tissue diseases. Our purpose here is to discuss how autoantibody testing, such as the ANA, may be used in the primary care setting to diagnose these disorders. Using the ANA test combined with a good medical exam and a good history, along with signs and symptoms of connective tissue diseases, will help to achieve greater benefits in diagnosing and treating patients.
Host: Jennifer Caudle, DO
Guest: Thomas C. Wright, Jr., MD
The Cervical Cancer Screening practice environment continues to change for both physicians and patients. Physicians are constantly tasked with evaluating analyses of new data on how best to approach cervical cancer screening for a particular patient demographic; and patients remain confused and unsure if the “new” approaches are better, or even less safe, than the “Pap” that has served as the bedrock for so many years.
This activity previously aired as a ReachMD Live Broadcast, where Dr. Thomas Wright, Jr., addressed these wide-ranging issues in a real-time, question and answer forum.
THIS ACTIVITY IS NO LONGER AVAILABLE FOR CME CREDIT.
Guest: David S. Friedman, MD, PhD, MPH
Guest: Steven J. Gedde, MD
Guest: W. Daniel Stamer, PhD
THIS ACTIVITY IS NO LONGER AVAILABLE FOR CREDIT.
Glaucoma is the leading cause of irreversible vision loss worldwide and it is expected that the number of people affected by glaucoma will increase dramatically in coming decades due to the aging of the world’s population. Despite advances in ocular imaging and visual field testing, a substantial proportion of patients with glaucoma remain undiagnosed and present late in the course of their disease. At the same time, while several classes of drugs are used to manage patients with glaucoma, significant unmet needs persist in glaucoma care.
In this CME/CE-certified enduring activity, glaucoma experts will discuss new pharmacologic and surgical advances in primary open-angle glaucoma (POAG) and ocular hypertension. Expert faculty will discuss the unmet clinical needs in glaucoma management and will review recently approved therapies together with those in the pipeline that may influence clinical decision-making, and may result in optimum outcomes for non-compliant patients or those refractory to medical therapy alone. Through discussion of creative clinical case scenarios, faculty will also highlight important treatment strategies for glaucoma that ophthalmologists can readily incorporate into clinical practice. These may include reduced complications with MIGS stents and ocular inserts vs. definitive, invasive trabeculectomy; ...
Guest: Sandro Esteves, MD, PhD
Recent studies have highlighted limitations of the existing definitions of poor ovarian response.
In this video, Dr. Sandro Esteves will review these limitations, explain the new POSEIDON criteria, discuss its new marker of success in Assisted Reproductive Technology, and provide innovative alternatives for clinical management.
Guest: Leonard H. Calabrese, DO
Guest: John R. Tesser, MD
This activity provides patient and practice-specific biosimilars content for clinicians in rheumatology practice.
Guest: David J. Portman, MD
Dr. David J. Portman demonstrates how clinicians can begin the conversation of dyspareunia with patients, as well as how to discuss the available treatment options for managing this condition in post-menopausal women.
Dr. Portman is Director Emeritus at Columbus Center for Women’s Health Research; and, Adjunct Instructor of Obstetrics and Gynecology at The Ohio State University, Columbus, OH.
Host: Shira Johnson, MD
Guest: Robert Vonderheide, MD
For years, the foundations of cancer treatment, surgery, chemotherapy, and radiation therapy were utilized with the objective of weakening cancer.
But over the past several years, immunotherapy – therapies that enlist and strengthen the power of a patient’s immune system to attack tumors - has emerged as a new tool for fighting cancer. In August 2017, one such treatment approach, called Chimeric Antigen Receptor or CAR T-cell Therapy, received FDA approval for the treatment of children and young adults with acute lymphoblastic leukemia (ALL). Additionally, research is continuing to look at CAR-T therapy’s effectiveness for treating solid tumors as well.
Host Dr. Shira Johnson sits down with Dr. Robert Vonderheide, Director of the Abramson Cancer Center of the University of Pennsylvania and the John H. Glick, MD, Abramson Cancer Center Director’s Professor, to talk about the potential of CAR-T therapy alongside other emerging immunotherapies in fighting cancer.
Host: Mimi Secor, DNP, FNP-BC, FAANP
Guest: Colleen T. LaBelle MSN, RN-BC, CARN
Participants are encouraged to consult the SAMSHA website, https://www.samsha.gov for additional and up to date information.
Nurses have always played a key role in the treatment of substance use disorders, and with the passage of the Comprehensive Addiction and Recovery Act of 2016 (which extends prescribing authority to NPs within the scope of state laws), their contributions have become even more critical. In today’s discussion, we’ll explore how nurses and nurse practitioners can help expand patient access to needed medications for the treatment of Opioid Use Disorder, or OUD. We’ll also highlight the benefits of employing a collaborative care approach to facilitate access to opioid therapy with buprenorphine in an office-based setting.
Host: Randall Wong, MD
Host: Russell Faust, MD
Want to speed up your site? Want to improve your SEO? These WordPress plugins can improve your website download speed, a crucial variable in the SEO equation. Making your website faster and improving your SEO will help you get the high rankings you want. And don’t let the technical jargon scare you. If Russ and Randy can use these plugins, so can you!
Drs. Russ Faust and Randy Wong share a few of their personal favorite plugins for making your website faster.
Host: Shira Johnson, MD
Guest: Jean Bennett, MD, PhD
There are 39 million people worldwide who are in total blindness and another 246 million with very low vision. The most frequent forms of visual impairment are caused by problems that can be corrected. Dr. Shira Johnson welcomes Dr. Jean Bennett, Professor of Ophthalmology and Cell and Developmental Biology at the University of Pennsylvania and researcher at the Children’s Hospital of Philadelphia. Dr. Bennett discusses her innovative work and research in curing blindness through gene therapy.
Microbial colonization and lung function in adolescents with cystic fibrosis. Hector A, Kirn T, Ralhan A, Graepler-Mainka U, Berenbrinker S, Riethmueller J, Hogardt M, Wagner M, Pfleger A, Autenrieth I, Kappler M, Griese M, Eber E, Martus P, Hartl D. J Cyst Fibros. 2016 May;15(3):340-9. doi: 10.1016/j.jcf.2016.01.004. Epub 2016 Feb 5.
Abstract With intensified antibiotic therapy and longer survival, patients with cystic fibrosis (CF) are colonized with a more complex pattern ofbacteria and fungi. However, the clinical relevance of these emerging pathogens for lung function remains poorly defined. The aim ofthis study was to assess the association of bacterial and fungal colonization patterns with lung function in adolescent patients with CF. Microbial colonization patterns and lung function parameters were assessed in 770 adolescent European (German/Austrian) CF patients in a retrospective study (median follow-up time: 10years). Colonization with Pseudomonas aeruginosa and MRSA were most strongly associated with loss of lung function, while mainly colonization with Haemophilus influenzae was associated with preservedlung function. Aspergillus fumigatus was the only species that was associated with an increased risk for infection with P. aeruginosa.Microbial interaction analysis revealed three distinct microbial clusters within the longitudinal course of CF lung disease. ...
A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR.
Tosco A, De Gregorio F, Esposito S, De Stefano D, Sana I, Ferrari E, Sepe A, Salvadori L, Buonpensiero P, Di Pasqua A, Grassia R, Leone CA,Guido S, De Rosa G, Lusa S, Bona G, Stoll G, Maiuri MC, Mehta A, Kroemer G, Maiuri L, Raia V.
Cell Death Differ. 2016 Aug;23(8):1380-93. doi: 10.1038/cdd.2016.22. Epub 2016 Apr 1.
Abstract
We previously reported that the combination of two safe proteostasis regulators, cysteamine andepigallocatechin gallate (EGCG), can be used to improve deficient expression of the cystic fibrosistransmembrane conductance regulator (CFTR) in patients homozygous for the CFTR Phe508del mutation. Here we provide the proof-of-concept that this combination treatment restored CFTR function and reduced lung inflammation (P<0.001) in Phe508del/Phe508del or Phe508del/null-Cftr (but not in Cftr-null mice), provided that such mice were autophagy-competent. Primary nasal cells from patients bearing different class II CFTR mutations, either in homozygous or compound heterozygous form, responded to the treatment in vitro. We assessed individual responses to cysteamine plus EGCG in a single-centre, open-label phase-2 trial. The combination treatment decreased sweat chloride from baseline, increased both ...
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, Kerem E, Fischer R, Smyth AR, Aaron SD, Conrad D, Geller DE,Elborn JS. J Cyst Fibros. 2016 Jul;15(4):495-502. doi: 10.1016/j.jcf.2015.12.004. Epub 2016 Feb 4.
Abstract RATIONALE:
For patients with cystic fibrosis (CF), the use of inhaled antibiotics has become standard of care to suppress chronic Pseudomonas airways infection. There are limited antibiotic options formulated and approved for inhaled use and antibiotic efficacies attenuate over time, making additional inhaled antibiotic classes desirable. APT-1026 (levofloxacin inhalation solution, LIS) is a fluoroquinolone in development for management of chronic P. aeruginosa airways infection in patients with CF.
OBJECTIVES:
To compare the safety and efficacy of a 28-day course of treatment with LIS 240mg or placebo BID in persons ≥12years old with CF and chronic P. aeruginosa infection.
METHODS:
A multinational, randomized (2:1), double-blinded study of LIS and placebo over 28days in CF patients ≥12years with chronic P. aeruginosa infection. Time to exacerbation was the primary endpoint. FEV1 (% predicted) and patient-reported ...
Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions. Cuzick J, Ho L, Terry G, Kleeman M, Giddings M, Austin J, Cadman L, Ashdown-Barr L, Costa MJ, Szarewski A. J Clin Virol. 2014 May;60(1):44-9. doi: 10.1016/j.jcv.2014.02.002. Epub 2014 Feb 14.
Abstract BACKGROUND:
HR HPV genotypes when assayed collectively, achieve high sensitivity but low specificity for the prediction of CIN2+. Knowledge of the specific genotypes in an infection may facilitate the use of HR HPV detection in routine clinical practice.
OBJECTIVES:
To compare the rate of HR HPV detection and the accuracy of CIN2+ prediction between PapType test (Genera Biosystems) and other commercially available HR HPV assays, and to examine the value of full HPV genotyping.
STUDY DESIGN:
PreservCyt samples from 1099 women referred for abnormal cervical cytology were used. CIN2+ was chosen as the primary end-point but CIN3+ was also evaluated. A hierarchy of HR HPV genotypes was created using PPV and this was used to create 3 groups of genotypes with potentially different ...
Host: Thomas C. Wright, Jr., MD
A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Schiffman M, Vaughan LM, Raine-Bennett TR, Castle PE, Katki HA, Gage JC, Fetterman B, Befano B, Wentzensen N. Gynecol Oncol. 2015 Sep;138(3):573-8. doi: 10.1016/j.ygyno.2015.06.040. Epub 2015 Jul 4.
Abstract BACKGROUND:
In US cervical screening, immediate colposcopy is recommended for women with HPV-positive ASC-US(equivocal) cytology. We evaluated whether partial typing by Onclarity™ (BD) might identify HPV-positive women with low enough CIN3+ risk to permit 1-year follow-up instead.
METHODS:
The NCI-Kaiser Permanente Northern California Persistence and Progression cohort includes a subset of 13,890 women aged 21+ with HC2 (Qiagen)-positive ASC-US at enrollment; current median ...
Host: Patrice L Basanta-Henry, MD, MHSc, FACOG
Egg freezing, or oocyte cryopreservation, can be a major relief for women who wish to preserve their fertility, allowing patients to wait for the “right time.” What are the latest advances in technology and protocol for this procedure, and who are the right patients? Host Dr. Patrice Basanta Henry welcomes guest expert Dr Kenan Omurtag to address these and other questions. Dr. Omurtag is Assistant Professor of the Division of Reproductive Endocrinology and Infertility at Washington University School of Medicine in St Louis, Missouri.
Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG
Host Dr. Renee Allen welcomes Dr. Victoria Green, renowned breast cancer researcher and OB/GYN clinician. Dr. Green is an Associate Professor in the Department of Gynecology & Obstetrics at Emory University School of Medicine. She will review USPSTF recommendations of biennial mammograms compared to ACOG's recommendations, as well as differences in how we define 'breast awareness' versus breast self-examination. Join the discussion!
Host: Jennifer Caudle, DO
Guest: Renée Simone Yolanda Allen, MD, MHSc., FACOG
Host Dr. Jennifer Caudle welcomes Dr. Renee S. Allen, Board certified OB/GYN and hospitalist, Fellow of ACOG, and Masters of Health Sciences from Atlanta, Georgia. Dr. Allen shares her expertise as an OB/GYN hospitalist, the growing support from ACOG in this new arena, and the goals of an emerging subspecialty.
Host: Matt Birnholz, MD
Studies in the field of anthropology have shown that having a healthy grandmother plays a critically positive role in family cohesion. But the wholistic, personalized health needs of women in their elder years are not always recognized. This care disparity is all the more prominent in general OB/GYN practice, but thanks to the work of a select few, the trends may be about to change.
Dr. Matt Birnholz speaks with Dr. Sarah Berga, Professor and Chair of OB/GYN at Wake Forest School of Medicine at ACOG’s annual meeting in San Francisco. They discuss maintaining grandmothers' health across both physiological and psychological spectra, and how this attention in care fundamentally changes larger family units for the better.
Host: Michael Krychman, MD
For women in their 40's and 50's, approximately one in four will develop a pelvic floor disorder such as urinary incontinence. By the age of 80, that prevalence rises to more than 50 percent. The struggle with a pelvic floor disorder has lasting effects on a woman's sexual health, leading to numerous psychosocial and physical consequences in turn. But of equal concern to many patients dealing with the symptoms of their disorder is the potential aftermath of reconstructive surgical treatments, such as mesh slings, due to their troubling complication rates. Are these concerns justified, and if so, how can the risks be mitigated by both physicians and patients?
Joining Dr. Michael Krychman to discuss the misconceptions versus realities of pelvic floor disorder treatments is Dr. Cheryl Iglesia, Professor in the departments of OB/GYN and Urology at the Georgetown University School of Medicine, and Drector of the Female Pelvic Medicine and Reconstructive Surgery section of Medstar Washington Hospital Center in Washington, DC.
Host: Michael Krychman, MD
Many clinicians think that one of the most dangerous things a woman will ever do in her life is to carry and conceive a child. Stemming from this belief, several misconceptions have risen within the medical community, and by extension the general public, concerning risks of sexual activity during pregnancy. Joining host Dr. Michael Krychman at ACOG's annual scientific meeting to clarify the facts versus myths on sexuality during and after this important life event is Dr. Haywood Brown, Professor and Chair of the Department of Obstetrics and Gynecology at Duke University Medical Center.
Host: Michael Krychman, MD
The market for sexual health products and accessories, from moisturizers to lubricants to self-stimulators, is very large, and this creates confusion among patients and physicians alike as to which types of products are most helpful for specific sexual health problems. To address ways to gauge the safety and efficacy of sexual health products on the market, particularly for perimenopausal patients with special needs, Dr. Michael Krychman welcomes Dr. Barb Depree, gynecologist, menopause care specialist, and founder of MiddlesexMD, a website providing information and recommended products for women's sexual health.
Host: Michael Krychman, MD
For years, women's sexual health matters have been relatively ignored in both clinical practice and the public eye despite consistently heavy media attention drawn towards men's sexual issues and associated therapeutic products. But there is recent evidence that the tide of public awareness is beginning to change, and that's women's sexual health is becoming more openly discussed across medical, public, and corporate entities. Joining Dr. Michael Krychman to qualify this new trend and examine ways to open communication about sexual health with women in clinical practice is Dr. Alyssa Dweck, assistant clinical professor of OB/GYN at the Mount Sanai School of Medicine and expert in women's sexual health and dysfunction.
Host: Michael Krychman, MD
Bladder leakage is one of many health-related issues that our female patients deal with. There are newly available treatment options, including non-surgical options, to help remedy the problem. Host Dr. Michael Krychman welcomes Dr. Holly Thacker to decipher the pros and cons of the various options available. Dr. Holly L. Thacker, nationally known for her leadership in women’s health, is the founder of the Cleveland Clinic Women’s Health Fellowship and is currently Professor and Director of the Center for Specialized Women’s Health at Cleveland Clinic and Lerner College of Medicine at Case Western Reserve University. She is also author of two books: Women’s Health: Your Body, Your Hormones, Your Choices and Cleveland Clinic Guide to Menopause.
Host: Prathima Setty, MD
Issues of vaginal health are commonly seen in post-menopausal women, breast cancer survivors and women who have had a hysterectomy. According to the US Census Bureau there are nearly 46M women between the ages of 50 and 80, and over 2.8M breast cancer survivors. Existing treatments for post-menopause vaginal health can be time intensive or messy, or contraindicated for health reasons. They also can have numerous side-effects and offer only marginal improvement -- according to a doctor associated with the study.
Host Dr. Prathima Setty welcomes Dr. Mickey Karram, Director of Fellowship Program on Female Pelvic Medicine & Reconstructive Surgery at The Christ Hospital, Cincinnati, OH. Dr. Karram will share preliminary findings from a trail evaluating laser treatment on post-menopausal women and breast cancer survivors experiencing vaginal health issues.
Supported by an Educational Grant from BD Diagnostics.
ReachMD retains full editorial control of the content for this program.
Host: Prathima Setty, MD
Fertility preservation technologies have become more advanced and more accessible over the past several years. Joining host Dr. Prathima Setty to discuss current options for women to protect their fertility is Dr. Naveed Khan, Reproductive Endocrinology and Infertility Specialist in Leesburg, VA. Dr. Khan practices with Shady Grove Fertility, the nation's largest fertility center, and is also a member of the American College of Obstetrics and Gynecology and the American Society of Reproductive Medicine.
Host: Lauren Streicher, MD
Guest: Michael Holick, PhD, MD
It seems these days patients know more about the benefits of Vitamin D than their physicians. Doctors are soaking up the information and making sure their patients are taking the proper levels of Vitamin D. Dr. Michael Holick, professor of medicine, physiology and biophysics and director of the Bone Health Care Clinic and the Heliotherapy, Light, and Skin Research Center at Boston University Medical Center, joins host Dr. Lauren Streicher to discuss the proper dosage, risk factors, geographical factors and benefits of Vitamin D.
Host: Lauren Streicher, MD
Guest: Jan Shifren, MD
Most research reveals 30 to 40 percent of women in the United States say they have sexual issues. A recent study examined how many women consider their sex issues to be a problem. With host Dr. Lauren Streicher, Dr. Jan Shifren, an associate professor of obstetrics, gynecology and reproductive biology at Harvard Medical School, looks at the findings of her research. The two review the impetus for the study, questions that were asked from 30,000 participants, and what has been gleaned from the results. The two also touch on whether testosterone and Viagra should be prescribed to help women who are distressed by their sexual issues.